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Unraveling Host-Gut Microbiota Dialogue and Its Impact on
Response to Immune Checkpoint Blockade
Alexandria Patricia Cogdill, B.Sc., M.Eng.
Advisory Professors: Jennifer A. Wargo, M.D., M.MSc., James P. Allison, Ph.D.
Cancer is a disease with only one degree of separation, affecting one in two men and one in
three women in their lifetimes; accounting for 1 of every 6 deaths. While cancer mortality rates
continue to improve, incidence rates are expected to rise and shift through 2050 due to
epidemiological and demographic transitions worldwide. As such, it is imperative to continue
to investigate and improve our understanding of both disease etiology and hallmarks of
response to treatment.
Currently, conventional therapies include, but are not limited to, surgery,
chemotherapy, and radiotherapy. However, within the past decade, major advances have
been made in cancer treatment using immunotherapy. Immunotherapy encompasses several
classes of therapeutics and is an exceptional type of precision medicine that leverages the
power of the human immune system to fight disease. In this way, it affords robust treatment
choices for patients thought to have intractable disease. One specific type of immunotherapy
shown to have a significant clinical benefit for cancer patients is monoclonal antibody immune
checkpoint blockade (ICB). ICB removes inhibitory signals of T cell activation which enables
tumor-reactive T cells to overcome regulatory mechanisms and mount an effective antitumor
response.
Despite significant clinical gains in the setting of ICB treatment, limitations to this
therapeutic strategy have inevitably surfaced as they have for prior generations of therapeutic
strategies. Efforts are underway to better understand the molecular and immune mechanisms
of therapeutic response and resistance in the context of ICB, and recent work has moved the
field forward in this regard. One area of medical research that aims to improve clinical
response of ICB is the gut microbiome. The microbiome is defined as the community of
commensal bacteria, fungi, and viruses, both good and bad, that co-habits the human body.
This dissertation is focused on the role of gut microbiome in shaping response and resistance
to cancer therapy. More specifically, this work follows up on preclinical studies that suggest
that the gut microbiome modulates tumor response to ICB. At the time, these studies had not
yet been well characterized in human cancer patients.
To address this gap in knowledge we prospectively collected gut microbiome and
immune samples from patients with metastatic melanoma starting treatment with anti–PD-1
therapy. Interesting, the clinical assessment of gut, tumor, and immune profiling suggested
gut microbiome composition and immunity correlated with patient response to ICB. To
understand this further, we designed preclinical murine studies to gain further insights into the
immune mechanisms through which the gut microbiome impacted response to ICB. Key
differences were found in responders and non-responders. Specifically, responders had
greater microbiome diversity and a significantly higher number of helper and killer T cells in
their tumor microenvironment; when compared to non-responders. Additionally, responders
were found to have higher systemic anti-cancer signaling molecules interferon-gamma and
interleukin-2. Together, these findings were the first of their kind, highlighting the impact of the
composition of the gut microbiome and the role of host immunity on patient response to anticancer immunotherapy.
In parallel to our work in evaluating how the gut microbiome modulates response to
checkpoint blockade, we also examined how external lifestyle factors influence the health of
the gut microbiome. To decipher these complexities, we assessed fecal microbiota profiles,
dietary habits, and over-the-counter (OTC) probiotic use in a cohort of melanoma patients.
x

Again, we observed substantial differences in gut microbiota between responders (R) and onresponders (NR); as well as distinct microbiome composition between patients with melanoma
and healthy donors. Notably, distinct patient dietary habits- low fiber intake and OTC probiotic
use- correlated with decreased response to ICB, decreased microbiome diversity, and
shortened progression-free survival (PFS). These findings were recapitulated in preclinical
mouse models designed to reflect patient fiber intake and probiotic use. Across these two
tumor models, we show that dietary and lifestyle factors can negatively affect ICB through a
coordinated suppression of CD8 and CD4+ IFNg T cells in the tumor microenvironment.
Taken together, this work evaluated factors within the wider immune milieu that
contribute, in collaboration with the gut microbiome, to the success of immune checkpoint
blockade. Additionally, we assessed the broader patient environment, intrinsic and extrinsic,
thought to shape the composition of the gut microbiome and thereby the patient’s anti-tumor
response. Collectively, we show how the gut microbiome influences local and systemic
immune response systems potentiating an anti-tumor response. These lines of research
have provided new insights as to how we might better target, track, and prevent cancer.
Moreover, given the ‘immune’ similarities cancer shares with a number of other chronic
maladaptive states this research looks to have a broader impact on chronic inflammatory
diseases such arthritis, type I diabetes, neurodegenerative disorders, and infectious
diseases such as COVID-19.

xi

TABLE OF CONTENTS
APPROVAL PAGE……………………………………………………………………….....i
TITLE PAGE…………………………………………………………………………………ii
COPYRIGHT………………………………………………………………………………..iii
DEDICATION……………………………………………………………………………….iv
ACKNOWLEDGEMENTS.…………………………………………………………………v
ABSTRACT……………….…………………………………………………………………x
TABLE OF CONTENTS ................................................................................................................ xii
LIST OF ILLUSTRATIONS ..........................................................................................................xiv
LIST OF TABLES ............................................................................................................................xvi
CHAPTER 1 BACKGROUND ........................................................................................................ 1

Cancer ............................................................................................................................................................................................. 1
Therapeutic targeting of immune checkpoints ........................................................................................................... 2
Hallmarks of Response to Immune Checkpoint Blockade ................................................................................... 6
Novel strategies to overcome resistance to immune checkpoint blockade ............................................. 14
Hypothesis and Research Questions........................................................................................................................... 15

CHAPTER 2 MATERIALS AND METHODS ......................................................................... 16
CHAPTER 3: UNRAVELING HOST-GUT MICROBIOTA DIALOGUE AND ITS
IMPACT ON RESPONSE ICB .................................................................................................... 57
Introduction ................................................................................................................................................................................ 57
The Gut Microbiome.............................................................................................................................................................. 57
The Microbiota and Carcinogenesis ............................................................................................................................. 60
The Influence of The Gut Microbiome on Anti-Cancer Therapy .................................................................... 66
Higher gut microbiome diversity is associated with improved response to anti-PD-1
immunotherapy in patients with melanoma .............................................................................................................. 67
Compositional Differences in The Gut Microbiome Are Associated with Responses to Anti-PD-1
Immunotherapy ........................................................................................................................................................................ 71
The Gut Microbiome Shapes Systemic and Antitumor Immunity .................................................................. 73
Summary ..................................................................................................................................................................................... 79

CHAPTER 4: EVALUATING THE IMPACT OF DIETARY HABITS AND
PROBIOTICS ON HOST IMMUNITY AND THE GUT MICROBIOME.......................... 80
Introduction ................................................................................................................................................................................ 80
Associations of Diet with Response to Melanoma Therapy ............................................................................. 80
Diet Influences Host Immunity and The Gut Microbiome .................................................................................. 85
Diet Influences Response To ICB .................................................................................................................................. 89
OTC Probiotics Limit Anti-Tumor Response ............................................................................................................ 90
Summary ..................................................................................................................................................................................... 96

CHAPTER 5: DISCUSSION......................................................................................................... 98
The Composition of the Gut Microbiome Shapes Host Immunity ................................................................. 98
Health Determinants Alter the Gut Microbiota .......................................................................................................100
The Composition of the Gut Microbiome Can Shape Patient Response to Immune Checkpoint
Blockade ....................................................................................................................................................................................102
Summary ...................................................................................................................................................................................103

xii

CHAPTER 6: FUTURE DIRECTIONS & OUTSTANDING QUESTIONS .................. 105

Future Directions...................................................................................................................................................................105
Outstanding Questions ......................................................................................................................................................105

GLOSSARY ..................................................................................................................................... 159
APPENDIX ....................................................................................................................................... 162
BIBLIOGRAPHY ............................................................................................................................ 173
VITA .................................................................................................................................................... 202

xiii

LIST OF ILLUSTRATIONS
CHAPTER 1
MAIN FIGURES
Figure 1 The Cellular Immune Response to Cancer.....................................................................3
Figure 2 Hallmarks of Immune Checkpoint Blockade.............................................................7

CHAPTER 3
MAIN FIGURES
Figure 3 Eubiosis and Dysbiosis in the Gut.................................................................................59
Figure 4 The Gut Microbiome and its Response to Cancer Therapy..........................................65
Figure 5 Notable bacteria associated with improved anti-cancer response................................66
Figure 6 Higher gut microbiome diversity is associated with improved response to anti–PD-1
immunotherapy in patients with metastatic melanoma.................................................................70
Figure 7 Compositional differences in the gut microbiome are associate with response to anti
pd-1 immunotherapy.....................................................................................................................71
Figure 8 A favorable gut microbiome is associated with enhanced systemic and antitumor
immunity. .....................................................................................................................................77
Figure 9 Composition of the microbiome shapes host immunity.................................................78

SUPPLEMENTAL FIGURES
Supplemental Figure S3.1 Microbiome sample acquisition schema...................................112
Supplemental Figure S3.3 Diversity of the fecal microbiome is increased in R to PD-1
blockade.....................................................................................................................................113
Supplemental Figure S3.4 (S18) Responders to anti PD-1 immunotherapy present an
enriched tumor immune infiltrate at baseline...........................................................................114
Supplemental Figure S3.5, (S19) Patients with a high abundance of Faecalibacterium
present a favorable antitumor immune infiltrate prior to anti PD-1
immunotherapy .........................................................................................................................115
Supplemental Figure S3.6 (S20) Faecalibacterium and Bacteroidales abundance in the
fecal microbiome have distinct associations with the tumor immune infiltrate prior to anti PD1 immunotherapy.......................................................................................................................116
Supplemental Figure S3.7 (S21) No association between CD8+ T cell density and alpha
diversity or crOTU community type..........................................................................................117
Supplemental Figure S3.8 (S22) Gating strategy for flow cytometric analysis of peripheral
blood in patients treated with anti PD-1 immunotherapy........................................................118
Supplemental Figure S3.9 (S23) Patients with high Faecalibacterium abundance display a
peripheral cytokine profile favorable for response to anti PD-1 immunotherapy at baseline
and enhanced cytokine responses over the course of therapy ............................................119
Supplemental Figure S3.10 (S24) Gating strategy for myeloid multiplex IHC in the tumors
of patients treated with anti PD-1 immunotherapy at baseline..............................................120
Supplemental Figure S3.11 (S25) High Faecalibacterium abundance at baseline is
associated with an increased immune infiltrate prior to anti PD-1 immunotherapy.............121
Supplemental Figure S3.12 (S26) A favorable gut microbiome is associated with systemic
anti-tumor immunity.................................................................................................................122
Supplemental Figure S3.13 (S27) 16S analysis of fecal samples from R and NR donors
and germ-free recipient mice...................................................................................................123
Supplemental Figure S3.14 (S28) Schematic representation of crOTUs compared to
traditional taxonomy.................................................................................................................124

xiv

CHAPTER 4
MAIN FIGURES
Figure 10 Characteristics of the gut microbiome in expanded melanoma patient cohort and
healthy individuals..................................................................................................................83
Figure 11 Associations of dietary fiber intake with features of the gut microbiome and
response to therapy in late-stage melanoma patients and murine models............................87
Figure 12 Associations of OTC probiotic use with features of the gut microbiome and
response to melanoma therapy..............................................................................................94

SUPPLEMENTAL FIGURES
Supplemental Figure S4.1 Differences in alpha diversity and response by Chao1, Shannon
in patients treated................................................................................................................125
Supplemental Figure S4.2 The gut microbiome and response to common systemic
therapies in metastatic melanoma. .....................................................................................126
Supplemental Figure S4.3 Abundance comparison of candidate taxa by response in antiPD1 treated melanoma patients..........................................................................................127
Supplemental Figure S4.4 The gut microbiome in late-stage melanoma patients by age,
sex, and body mass index (BMI) ....................................................................................... 128
Supplemental Figure S4.5 Differences in microbiome community structure between healthy
individuals from the American Gut Project (AGP) (n=194) and melanoma patients............129
Supplemental Figure S4.6 Differences in alpha diversity by Shannon, Chao1 between
healthy individuals from the American Gut Project (n=194) and melanoma patients..........130
Supplemental Figure S4.7 Differences in microbiome community structure by melanoma
stage....................................................................................................................................131
Supplemental Figure S4.8 Differences in alpha diversity by stage of melanoma.............132
Supplemental Figure S4.9 Differential taxonomic abundance by melanoma stage with
systemic therapy....... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ........133
Supplemental Figure S4.10 Distribution of estimated dietary fiber intake in the late-stage
melanoma lifestyle cohort....................................................................................................134
Supplemental Figure S4.11 Differences in microbiome community structure by dietary fiber
status in late stage melanoma patients...............................................................................135
Supplemental Figure S4.12 Differences in alpha diversity by dietary fiber status in the latestage melanoma lifestyle cohort..........................................................................................136
Supplemental Figure S4.13 Melanoma growth kinetics....................................................137
Supplemental Figure S4.14 Melanoma growth kinetics from additional mouse fiber
studies.................................................................................................................................138
Supplemental Figure S4.15 Effect of dietary fibers on response to anti-PD1 and
microbiome composition using mice from two different vendors.........................................139
Supplemental Figure S4.16 Abundance comparison of Akkermansia muciniphila and
Enterococcus hirae in mouse fiber experiments. ................................................................140
Supplemental Figure S4.17 The abundance of all genes encoding Hydroxylamine
reductase.............................................................................................................................141
Supplemental Figure S4.18 Metabolomic profiling of SCFAs...........................................142
Supplemental Figure S4.19 Flow cytometry and Transkingdom network analysis to identify
key players that mediate effect of dietary fibers on anti-PD1 response in mice..................143

Supplemental Figure S4.20 Antibiotics use among late-stage melanoma patients who did
and did not use OTC probiotics. ..........................................................................................144
Supplemental Figure. S4.21 Differences in alpha diversity and OTC probiotics use by
Chao1, Shannon among late-stage melanoma patients. ...................................................145
xv

Supplemental Figure S4.22 Differences in alpha diversity and OTC probiotics use by
Chao1, Shannon among healthy American Gut (AGP) cohort. .........................................146
Supplemental Figure S4.23 Differences in microbiome community structure by OTC
probiotic use among melanoma patients. ..........................................................................147
Supplemental Figure S4.24 Composition of OTC probiotics used in mouse experiments by
16S rRNA gene sequencing and culture............................................................................148
Supplemental Figure S4.25 Comparison of fold change (to control) of tumor sizes from
replicate probiotic experiments (1-4) .................................................................................149
Supplemental Figure S4.26 BP and MC38 growth kinetics from replicate probiotic
experiments........................................................................................................................150
Supplemental Figure S4.27 WGS of post-treatment fecal samples in humanized GF-mice
(FMT from complete responder) gavaged orally with either OTC probiotics or water followed
by tumor inoculation and treatment with anti-PDL1. ..........................................................151
Supplemental Figure S4.28 Correlative immune data from mice treated with
probiotics.............................................................................................................................152
Supplemental Figure S4.29 Comparison of results using VSEARCH-OTUs and denoising
with DADA2. .......................................................................................................................153
Supplemental Figure S4.30 Compositional differences in the microbiome validated using
DADA2 denoised ASV. .......................................................................................................154

LIST OF TABLES
Chapter 3
MAIN TABLES
Table 1 Targeting the Gut Microbiome.................................................................................60
Table 2 The Influence of Common Anti-Cancer Therapeutics in The Gut, Tumor, And
Blood.....................................................................................................................................63
Table 3 The Role of The Gut Microbiota in The Clinical Efficacy of Anticancer
Therapeutics.........................................................................................................................64

xvi

CHAPTER 1 BACKGROUND
•

Excerpts of this text were taken and used with permission from journal article
Cogdill, A.P., Andrews, M.C. and Wargo, J.A., 2017. Hallmarks of response to
immune checkpoint blockade. British journal of cancer, 117(1), pp.1-7.

Cancer
Cancer is now a disease of one degree of separation affecting one in two men and one in
three women in their lifetimes, representing 1 in every 6 deaths (1, 2). While cancer
responsiveness continues to improve, oncology incidence rates are expected to rise, and shift
through 2050 due to epidemiological and demographic transitions of the global burden
disease (2, 3). Cancer burden, morbidity, and mortality have a wide-reaching impact globally,
but recent advancements in precision medicine have given the field of oncology an opportunity
to greatly improve therapeutic strategies.
The treatment of cancer has been arduous, marked by just as much heterogeneity in
cancer treatment modality and outcome as is now known to exist at a cellular and molecular
level within tumors themselves. Recently declared the fourth pillar of cancer care,
immunotherapy differs from conventional chemotherapeutic agents in that its mechanism of
action employs, engages, or enhances a functional immune response to tumor cells, rather
than aiming principally to physically remove or destroy cancer cells through inherent radio- or
chemical toxicity. Importantly, although immunotherapy is commonly thought of as a new
treatment modality, the first immunotherapy approaches in fact predate the discovery and
development of cytotoxic agents for the treatment of cancer, or even the discovery of X-rays,
let alone the therapeutic use of non-ionizing radiation. Furthermore, immunotherapy
encompasses several subtypes of treatment modality, including vaccination strategies, cellbased therapies using the patient’s own immune cells with or without ex vivo modification, and
immunomodulatory agents, of which checkpoint inhibitor therapies have been the most
broadly successful to date.

1

Therapeutic targeting of immune checkpoints
Unopposed immune activation can be at least as damaging as an ineffective response,
necessitating a dynamic system of regulatory signals to integrate the prevailing immune
stimuli and direct immune responses appropriately. Initial immune activation requires
recognition of the target, which itself is a multistep process classically requiring antigen
expression by tumor cells, and its processing and presentation to helper T cells by specialized
antigen presenting cells (APCs, e.g., dendritic cells) in the context of class II human leukocyte
antigen (HLA; Figure 1). Whether a cognate HLA/antigen – T-cell receptor interaction results
in T-cell proliferation and activation is determined by the presence of additional co-stimulatory
signals, principally delivered by the engagement of CD28 on the T cell by CD80/86 on the
APC (Figure 1). Without this vital second signal, the interaction may be biologically interpreted
as representing recognition of a non-pathogenic (or ‘self’) antigenic stimulus to which
tolerance may develop. However, in the presence of appropriate co-stimulation, an active
immune response against the inciting antigen can proceed, with the generation of humoral
responses, recruitment of a cytotoxic T-cell response (HLA class I-restricted) and release of
numerous cytokines necessary for effector cell proliferation, survival, localization, and effector
function. Many other stimulatory signals are active throughout the immune response phase,
including inducible T-cell co-stimulator (ICOS), glucocorticoid-induced TNFR-related protein,
and tumor necrosis factor receptor superfamily members 4 (OX40 or CD134) and 9 (4-1BB or
CD137), which function in the amplification and maintenance of overall immune activation
(Figure 1).

2

Figure 1 The cellular immune response to cancer is complex and involves a diverse
repertoire of immunoregulatory interactions principally involving antigen presenting
cells (APC), T cells, and tumor cells. Presentation of distinct antigen epitopes to CD8+ and
CD4+ T cells in the context of major histocompatibility complex class I (on APC or tumor cells
directly) and class II (on APCs), respectively, facilitates tumor cell recognition, but numerous
other molecular interactions (inset boxes) and input from paracrine and humoral factors
(cytokines/chemokines, shown with arrowed lines) integrate to determine the ultimate
outcome of immune recognition. Elaboration of survival and inflammatory cytokines, such as
IL-2 and IFN-γ, can promote a cytotoxic (CD8+) T-cell response with consequent tumordirected lytic activity mediated by release of cytotoxic granule contents (e.g., perforin and
granzyme) as well as triggering of apoptotic pathways by tumoricidal cytokines (e.g., TNFα and IFN-γ) and death receptor ligation (e.g., FAS: FAS-L). Debris released from
apoptotic/necrotic tumor cells may be taken up by APC and presented in a cycle of
immunogenic cell death. However, prolonged immune activation is adaptively opposed by
upregulation of immunoinhibitory molecules (e.g., CTLA-4, PD-1, TIM3, TIGIT, and CTLA-4),
or their ligands, many of which may be subverted by tumor cells in order to escape immune
attack. Release of anti-inflammatory, immunoregulatory or Th2-skewed cytokines also
contributes to dampening of the cellular response.
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To achieve immune homeostasis, numerous negative feedback stimuli act to dampen
the immune response, including the well-described negative regulatory molecules cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4 or CD152) and programmed death 1 (PD-1 or
CD279). Cytotoxic T-lymphocyte-associated protein 4 is expressed on the T-cell surface and
competes with CD28 for binding to CD80/86, providing an inhibitory stimulus upon
engagement (Figure 1). It is thought that the action of CTLA-4 may be most relevant at the
T-cell priming stage in regional secondary lymphoid organs, thus ultimately acting to impair
T-cell help and the generation of an effector T-cell population and its egress back into the
tumor. Programmed death 1 is a T-cell surface receptor that delivers inhibitory signals upon
engagement with its ligands PD-L1/2, and these ligands may be upregulated in the setting of
high levels of IFN-γ (termed adaptive immune resistance), but may also be expressed in the
tumor microenvironment via oncogenic expression on tumor cells or expression on other
stromal elements (Figure 1) (4). Programmed death 1 expressing T cells are thought to
represent populations that have largely ‘seen’ their antigen in situ (i.e., within the tumor) and
are thus considered a more tumor-specific population than T cells arrested at the priming
stage by CTLA-4, however, high levels of PD-1 are also associated with an ‘exhausted’ T-cell
phenotype (5). Multiple other inhibitory ‘checkpoints’ have been identified, including
lymphocyte activation gene 3 (LAG3 or CD223), and T-cell immunoglobulin 3 (TIM3) and Tcell immunoglobulin and ITIM domain (TIGIT), for which ligands expressed on tumor or
stromal cells may act synchronously or sequentially to promote overall physiologic
suppression of immune responses (Figure 1).

Elucidation of the complex web of stimulatory and inhibitory signals that contribute to
the tug-of-war of immune regulation and their dysregulation in cancer presents clear
therapeutic opportunities targeting these to enhance anti-tumor immune responses. The
impressive proof-of-principle for this approach came with the report in 2010 of a phase III
4

clinical study of CTLA-4 blockade with the monoclonal antibody ipilimumab in patients with
metastatic melanoma, which demonstrated enhanced survival in treated patients(6). Although
objective responses were infrequent (<11%), checkpoint inhibitor therapies as a class have
been characterized by durability of responses in those patients who achieve an objective
response, contributing to a notable ‘tail’ in the survival curve of long-term survivors.
Importantly, while patient-level data are frequently limited, even summary data indicate that
objective responses are not an absolute requirement for a survival benefit from ipilimumab. In
the last six years, four engineered monoclonal antibody immune checkpoint inhibitor agents
have been approved in more than 50 global markets for six forms of cancer; ipilimumab (antiCTLA-4), pembrolizumab and nivolumab (anti-PD-1), and atezolizumab(anti-PD-L1), with
response rates of up to 40–50% with PD-1-based therapy. Combination strategies, including
immune checkpoint inhibitors, with different mechanisms of action have also been approved
(anti-CTLA-4 and anti-PD-1) and are associated with higher response rates (exceeding 60%)
though toxicity to therapy is a significant issue (7, 8). Although the greatest strength of
combination regimens may lie in converting a proportion of patients destined not to benefit
from single-agent checkpoint blockade into long-term survivors, reliable methods to identify
these patients before therapy remain elusive. In addition, matured outcome data will be
necessary to determine whether combination checkpoint blockade confers superior overall
survival outcomes relative to monotherapy approaches such as PD-1 blockade alone.

Despite significant clinical gains in the setting of treatment with immune checkpoint
blockade, limitations to this therapeutic strategy have inevitably surfaced as they have for prior
generations of novel therapeutic strategies. Treatment with current checkpoint inhibitor
monotherapy is not effective in all cancer types, as tumors with lower mutational burden and/or
lower immunogenicity may be inherently resistant to this form of therapy. Even in the setting
of initial responses in favorable tumor types, resistance may develop. This may be related to
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redundancy in the very web of activating and inhibitory molecules targeted by immune
checkpoint inhibitors (9), though other mechanisms of therapeutic resistance have also been
identified including adaptive loss of antigenicity, recognition machinery, and transience of the
inflamed tumor microenvironment. On top of this, strong predictive biomarkers of response to
immune checkpoint blockade are currently lacking, and toxicity can be a major issue,
particularly in combination strategies. All of these factors, as well as an appreciation of the
cost of these agents and issues with access to therapy, call for a more comprehensive
understanding of the hallmarks of response to immune checkpoint blockade in order to derive
more tailored strategies.

Hallmarks of Response to Immune Checkpoint Blockade
There is a growing appreciation of the key factors contributing to response and resistance to
immune checkpoint blockade, drawing upon features of the tumor itself (including the cancer
genome, epigenome, and microenvironment), components of host immunity (both systemic
and anti-tumor immunity), and external influences such as diet and the microbiome (Figure
2). The ‘hallmarks of cancer’ as previously described by Hanahan and Weinberg (10) are
tightly related to these responses, though current applications of the hallmarks are rather
tumor cell centric. In contrast, a description of the hallmarks of response to immune checkpoint
blockade must consider more global features, recognizing that tumors constitute a dynamic
milieu and integrate numerous reinforcing and antagonistic signals from both local and
systemic conditions. As such, we describe the four ‘pillars’ and associated hallmarks of
response to immune checkpoint blockade, with intimate interactions also noted between each
of the pillars (Figure 2).
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Figure 2 The core pillars and thematic hallmarks of anti-tumor immunity governing
response to immune checkpoint blockade. Extensive research has identified numerous tumorcentric domains (shown in blue), including both static (existing genomic aberrations) and dynamic
(epigenomic, metabolic and microenvironmental) features, which moderate anti-tumor immune
responses and have impact on the efficacy of immune checkpoint blockade. Relevant metrics of
overall immunocompetence, and systemic factors regulating the balance between immunotolerant
and inflammatory states (e.g., innate and adaptive cell abundance and composition, immune cell
circulation/sequestration, cytokine levels; shown in brown) are gradually being quantified.
Environmental factors previously not implicated in directly modulating the anti-tumor response are
now recognized to impact on immune checkpoint response (shown in green); principal among
these sources of immunomodulation is the gut microbiota, while environmental stresses (e.g.,
thermal stress) and other tumor-remote immune-pathogen interactions may produce humoral
factors that impact upon the specific anti-tumor response.
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Tumor genome and epigenome
We have gained a tremendous amount of information on cancer genomics over the past few
decades through the use of next-generation sequencing techniques, which has helped to
usher in the age of precision medicine, although how best to use this data in the clinic remains
unclear.
Genomic alterations in cancer may have divergent roles—potentially enhancing antitumor immunity in some instances and conferring resistance in others. A prime example of
how mutations may enhance responses comes from evidence that tumor types with higher
average mutational loads (such as melanoma and non-small cell lung cancer) have a much
higher response to treatment with immune checkpoint blockade than those with a lower
mutational burden, likely related to a proportionally higher burden of immunogenic cancerspecific ‘neoantigens’(11, 12). In addition to this, subtypes of cancer with specific genomic
alterations leading to increased mutational burden may also demonstrate enhanced
responses to immune checkpoint blockade, such as microsatellite unstable colorectal cancers
resulting from mutational loss or epigenetic silencing of DNA mismatch repair genes and
resultant genomic instability (13). Similarly, it has been noted that several mutagen exposures
– such as UV light in melanoma, and tobacco smoke in non-small cell lung cancer – display
strong co-associations with mutational burden and checkpoint blockade immunotherapy
response (14). However, simply harboring high mutational levels is not the complete story, as
neoantigen proteins must be expressed, processed, and of sufficient binding characteristics
in the context of HLA to be immunogenic although evidence suggests that the predictive value
of neoantigen load is not driven by the small proportion of neoantigens with high predicted
HLA-binding affinity (11). Detailed exomic analysis of a cohort of melanoma patients treated
with CTLA-4 blockade revealed a shared repertoire of tetrapeptide neoantigen sequences in
patients who derived clinical benefit; the immunogenicity of several neoantigen peptides was
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confirmed using patient-derived lymphocytes in vitro (15). Importantly, the association with
response was stronger for the neoantigen signature than for overall mutational burden,
consistent with the notion that overall mutational burden increases the likelihood that a tumor
is immunogenic, but that it may not be an absolute requirement for checkpoint blockade
response. Importantly, a number of other types of antigens exist in cancer (cancer germline
antigens, differentiation antigens, over-expressed antigens, and viral antigens), which can
help to elicit anti-tumor immune responses(16)
In contrast to the potentially pro-immunogenic impact of genomic alterations, there is
a growing body of evidence regarding other genomic and epigenomic alterations in tumors
that may impair immune responses and facilitate resistance to immune checkpoint blockade.
Constitutive mitogen-activated protein kinase (MAPK) activation by mutations in the BRAF
oncogene (and other MAPK pathway mutations) contributes to immune evasion by altering
expression of tumor-associated antigens and major histocompatibility complex expression
(17). Loss of expression of the tumor suppressor gene PTEN (either by mutations or copy
number alterations) is also associated with impaired response to immune checkpoint blockade
(18). Several studies have shown that immunotherapy resistance may originate in more than
one compartment of the tumor microenvironment, with signals derived from tumor cells
preventing immune infiltration (e.g., Wnt-β-catenin, PPAR-γ, FGFR3) while the dynamic
interplay of anti-tumor immune attack adaptively molds the landscape of immunomodulatory
elements present over time (19, 20). In line with evidence that interferon signatures play a
significant role in the response to immune checkpoint blockade and may potentially act as
clinical biomarkers (21), JAK1/2 mutations have been identified in patients resistant to PD-1
blockade, acting via disruption of tumor-inhibitory interferon signaling (22). Notably, the list of
genomic alterations demonstrated to modify response to immune checkpoint blockade grows
on a daily basis.

9

In addition to genomic alterations, epigenomic alterations in tumor cells may also have
a profound effect on anti-tumor immune responses. Epigenetic chromatin modifications
function physiologically to silence (or activate) genes in an orchestrated fashion during key
developmental processes, however aberrant epigenomic alterations often exist in cancer, and
can contribute to oncogenesis and also to immune evasion (23). Epigenetic downregulation
of antigen expression and silencing of immune-related genes may negatively impact
immunotherapy response (24) and early studies combining epigenetic modifiers, such as
hypomethylating agents and histone deacetylase inhibitors, with immune checkpoint inhibitors
have shown promising results (25).

Tumor microenvironment
The most extensively discussed component of the tumor microenvironment (TME) other than
cancer cells themselves is tumor infiltrating lymphocytes (TIL). The presence of TIL has long
been known to confer a favorable prognosis (26), and a greater appreciation of the complexity
of immune infiltrates with regard to phenotype and distribution of the infiltrating leukocytes is
mounting. Traditional metrics of TIL density and distribution (e.g., central vs peripheral) and
gross enumeration of the T-cell infiltrate by CD3 and CD8 markers can now be readily
supplemented with detailed characterization of numerous surface markers, expression of
immunomodulatory molecules, and quantification of T-cell clonotypes. Studies incorporating
these techniques have revealed a broad range of infiltrating lymphocytes far beyond the
dichotomous effector and regulatory T lymphocyte subsets, and have highlighted their
complex regulatory potential as well as potential plasticity (27). Additional information has
been gained by studying spatial relationships of TIL to tumor and stromal cells, yielding insight
into the physical limitations to intercellular functional interactions. This has been demonstrated
in the context of response to PD-1 blockade, in which not only density of CD8 T-cell infiltrate,
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but also location at the invasive margin and proximity of PD-1 expression to PD-L1 expression,
were important factors associated with treatment response (28).
Tumors not only contain cancer cells, but also harbor a rich microenvironment
composed of blood vessels, APCs, neutrophils, myeloid derived suppressor cells, tumorassociated macrophages and fibroblasts, components of the extracellular matrix, and soluble
factors (such as cytokines and growth factors), all of which may assist or hinder anti-tumor
immune responses. This is particularly evident when considering response to immune
checkpoint inhibitors where the ability to exclude infiltrating immune cells from the TME can
‘make or break’ an anti-tumor immune response. On the basis of this, tumors have been
classified into several cancer-immune phenotypes including ‘inflamed’ or ‘non-inflamed’ (29),
with more recent reports describing tumors as ‘immune-deserts’, ‘immune-excluded’, or
‘inflamed’ (30). This type of classification motivates extensive research to identify predictive
microenvironmental biomarkers that transcend existing markers such as PD-L1. Numerous
therapeutic approaches targeting non-tumor cell stromal elements and functions are currently
being tested in preclinical models and clinical trials, either as monotherapies or in combination
with immune checkpoint blockade. Key examples include molecules inhibiting generation of
the immunosuppressive metabolite indoleamine-2,3-dioxygenase (e.g., NCT02471846 and
NCT 02073123), antagonists of the tumor-associated macrophage stimulating CSF1R (e.g.,
NCT02713529, NCT02526017, and NCT02323191), and ongoing development of agonist
agents of the stimulator of interferon genes, aiming to favorably skew the TME towards an
inflamed phenotype. Early studies of combination immune checkpoint and angiogenesis
inhibition have showed promise from this multi-targeted approach in patients with advanced
melanoma and renal cell cancer(31, 32). Future advances in such strategies will be based on
a deeper unravelling of the microenvironmental interactions to identify targetable nodes in the
network.
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Host immunity
Central to the efficacy of immune checkpoint blockade is preserved host immunity, predicated
upon adequate number, availability, and activity of other innate and adaptive immune cell
types. Systemic immunity is dynamic, shaped by prior antigenic stimuli, and influenced by
interactions both within and outside the host, as diverse as invading microbial pathogens at
topologically ‘external’ body surfaces (e.g., skin and gut), and interactions with tumors
themselves. During the development and progression of cancer, components of dying tumor
cells are taken up by APCs, which present processed antigen in the context of HLA to helper
(CD4+) and cytotoxic (CD8+) T lymphocytes. This results in a cascade of events that leads
ultimately to activation and expansion or anergy, depending on numerous modulating factors,
principally the availability of appropriate co-stimulatory – or inhibitory – ligand-receptor
engagement. This forms the foundation of the cancer immunity cycle described by Chen and
Mellman (2013)(33), and involves contributions from numerous other cells of the innate (e.g.,
NK cells) and adaptive (e.g., B lymphocytes) immune system. That a quantitatively and
qualitatively intact overall immune system is important in cancer control is clear from the
generally higher rates of many cancer types, including several without known viral etiology, in
immunosuppressed patients (34). Although germline polymorphisms in immune-related genes
are known to impact cancer predisposition and immune function in other settings such as
hematopoietic transplantation outcomes (35), whether polymorphisms are predictive of
checkpoint inhibitor efficacy or toxicity, and can be identified, is currently unknown (though is
highly likely).
The host T-cell repertoire, within which a subset of potentially tumor-reactive T cells
resides, is largely shaped during development and early childhood while other components of
the immune system remain more malleable throughout adult life. Host immunity molds the
tumor landscape, exemplified by the concept of immune editing as described by Schreiber
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and colleagues, through which immune action shapes the tumor composition to arrive at the
parallel fates of equilibrium, elimination, or escape(36). However, it is becoming increasingly
clear that this relationship is bidirectional; tumors may themselves profoundly influence the
systemic environment through secretion of immunosuppressive cytokines and tumorassociated exosomes, which have been shown to be immunosuppressive (37) and prime
secondary locations for future metastasis (38).

Environment
Importantly, factors within the broader environment (both outside and inside the host) may
shape anti-tumor and overall immune responses. Perhaps the most poignant example of this
is the microbiome, with recent evidence demonstrating a critical link between the gut
microbiome and anti-tumor immunity. These interactions have significant implications in the
setting of immune checkpoint blockade, as there is evidence that modulating the gut
microbiome can enhance – or may even be a prerequisite for – therapeutic responses to these
agents in preclinical models (39, 40). This has recently been studied in patients, with data
suggesting that differential bacterial ‘signatures’ exist in responders vs non-responders to
immune checkpoint blockade (namely, anti-PD-1 therapy) in a cohort of patients with
metastatic melanoma (41-43). This finding needs to be validated in larger cohorts and across
cancer types, but provides formative evidence regarding the influence of environmental
factors on tumor and host immunity.
Indeed, other external pressures, such as diet and stress, can also impact the host
and anti-tumor immunity(44), with hints that these factors might also modulate responses to
immune checkpoint blockade although the complex mechanisms behind these influences are
still being elucidated. Nonetheless, it is clear that we are gaining a more holistic and
comprehensive view of the influences on anti-tumor immunity, which tightly relate to our
understanding of the factors affecting therapeutic immune checkpoint blockade.
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Novel strategies to overcome resistance to immune checkpoint blockade
On the basis of a deeper understanding of these pillars and hallmarks and the complex
interactions between them, we will ultimately be able to refine strategies to monitor and
enhance responses to immune checkpoint blockade. Importantly, the insights gained from the
study of checkpoint inhibitor agents in current clinical use will have direct relevance to other
forms of immunotherapy in active development, such as immunostimulatory checkpoint
agonists and adoptive cell therapy.
The pillars, and hallmarks, of response to immune checkpoint blockade should be
considered when designing immune monitoring strategies for these forms of therapy, and
must consider aspects of the tumor, the TME, overall immune competence, and environmental
influences. This is already being done in some regards, with interrogation of specific genomic
alterations and total mutational load as well as examination of the tumor for CD8 infiltrate
density and PD-L1 expression. Evidence is emerging that monitoring host immune responses
(e.g., via phenotypic markers, such as ICOS on T cells) (45), may help predict responses to
immune checkpoint blockade, and that the microbiome may serve as a predictive factor for
long-term benefit to other forms of immunotherapy (46-49). While standardized approaches
for each of these strategies have not yet fully been realized they represent an area of unmet
need in the field; additional intricacies will undoubtedly arise when monitoring combination
therapies pairing immune checkpoint blockade with immunostimulatory agents (e.g., agonistic
antibodies targeting 4-1BB or OX40), cell-based therapies, or molecular-targeted agents.
In addition to implications for monitoring responses, an understanding of these pillars
and hallmarks also provides a framework for understanding and overcoming mechanisms of
therapeutic

resistance

to

immune

checkpoint

inhibitors.

Numerous

(epi)genomic,

microenvironmental, and immune mechanisms of resistance to immune checkpoint blockade
have been identified (50), spurring the development of even more numerous multi-drug
14

strategies targeting them. There is growing interest in better understanding the role of chronic
inflammation, diet, and stress on general and tumor-specific immunity but much work is
required to extract actionable elements from this knowledge.
These proposed pillars and hallmarks provide a foundation on which to build as we
gain volumes of information from preclinical studies, clinical trials, and biomarker assessment
in patients on standard-of-care therapy. Ultimately, integration of such data sets will inform
optimal therapeutic strategies incorporating immune checkpoint blockade (and other forms of
immunotherapy) in this age of cancer precision medicine.

Hypothesis and Research Questions
To that end, herein we explore the influence and impact of the various pillars and
hallmarks of response to immune checkpoint blockade. Specifically, we first examine more
closely the role of the gut microbiome in patient response or resistance to immune checkpoint
blockade. We then evaluate factors within the wider immune milieu that contribute, perhaps
in collaboration with the gut microbiome, to the success or failure of immune checkpoint
blockade. Lastly, we assess the broader patient environment, both outside and inside the
host, which are thought to shape the composition of the gut microbiome and thereby the
patient’s anti-tumor response when treated with immunotherapy. Taken together, we
hypothesize that the gut microbiome influences local and systemic immune response systems
potentiating a positive or negative anti-tumor response. Collectively we believe these lines of
research will provide new insights on how we might better target, track, and prevent cancer.
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CHAPTER 2 MATERIALS AND METHODS
Excerpts of this text were taken and used with permission from journal articles:
• Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets,
T.V., Prieto, P.A., Vicente, D., Hoffman, K., Wei, S.C. and Cogdill, A.P., 2018. Gut
microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients.
Science, 359(6371), pp.97-103.
•

Excerpts of this text were taken and used with permission from journal articles (Wei,
S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N. A. A., Andrews, M. C., ... &
Allison, J. P. (2017). Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1
checkpoint blockade. Cell, 170(6), 1120-1133.

•

Excerpts of this text were taken and used with permission from journal article Wei,
S.C., Anang, N.A.A., Sharma, R., Andrews, M.C., Reuben, A., Levine, J.H., Cogdill,
A.P., Mancuso, J.J., Wargo, J.A., Pe’er, D. and Allison, J.P., 2019. Combination anti–
CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially
distinct from monotherapies. Proceedings of the National Academy of Sciences,
116(45), pp.22699-22709.

Patient cohort
An initial cohort of 112 patients with metastatic melanoma were included in this study. All
patients were treated with anti-PD-1 immune checkpoint blockade therapy at The University
of Texas (UT) MD Anderson Cancer Center between April 2015 and May 2016 and signed
voluntary informed consent for collection and analysis of tumor, blood and microbiome
samples under Institutional Review Board (IRB)–approved protocols (IRB LAB00-063, 20120846, PA13-0291, PA15-0232, and PA12-0305). Patients who were diagnosed with uveal
melanoma (n=10), or who received anti-PD-1 in combination with targeted agents or with
adoptive T cell transfer therapy (n=7), or in whom response could not be determined (n=6)
were excluded from this analysis. Electronic medical charts were reviewed independently by
three investigators to assign a clinical response group and document other clinical
parameters. The primary outcome of clinical response (responder, R) was defined by
radiographic evidence of complete response, partial response or stable disease per RECIST
1.1 criteria for at least 6 months. Lack of a clinical response (non-responder, NR) was
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defined by disease progression (PD) on serial CT scans or stable disease lasting less than 6
months.

Microbiome sample collection
Buccal samples were collected during routine pre-treatment clinic visits using the Catch-All
Sample Collection Swab (Epicentre, Madison, WI). All patients were also provided an
OMNIgene GUT kit (OMR-200) (DNA Genotek, Ottawa, Canada) for outpatient fecal sample
collection. Importantly, this kit maintains microbial DNA stability at room temperature for up
to 60 days. All samples were frozen at -80°C prior to DNA extraction and analysis. Our final
analysis cohort consisted of buccal samples collected from 86 patients, of whom 52 were R
and 34 were NR, and fecal samples collected from 43 patients, of whom 30 were R and 13
were NR. All but 2 buccal and 2 fecal samples were collected at baseline. We included
these as a baseline surrogate as a subset analysis on longitudinal samples showed no
significant change after treatment intervention in this cohort.

Tumor and blood sample collection
Available tumor samples (n=21) at matched pre-treatment time points were obtained from
the MD Anderson Cancer Center Department of Pathology archive and Institutional Tissue
Bank. After samples underwent quality control checks for percent tumor viability by an MD
Anderson pathologist, we included 15 samples from R and 6 from NR. Blood samples
collected and stored for research (protocols previously listed) (n=11) were also queried for
study inclusion yielding samples from 8R and 3NR.

DNA extraction and bacterial 16S rRNA sequencing
Sample preparation and sequencing was performed in collaboration with the Alkek Center
for Metagenomics and Microbiome Research (CMMR) at Baylor College of Medicine. 16S
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rRNA gene sequencing methods were adapted from the methods developed for the NIHHuman Microbiome Project. Briefly, bacterial genomic DNA was extracted using MO BIO
PowerSoil DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA). The 16S rDNA V4 region
was amplified by PCR and sequenced on the MiSeq platform (Illumina, Inc, San Diego, CA)
using the 2x250 bp paired-end protocol yielding paired-end reads with near-complete
overlap. The primers used for amplification contain adapters for MiSeq sequencing and
single-end barcodes allowing pooling and direct sequencing of PCR products.
Quality filtered sequences with >97% identity were clustered into bins known as Operational
Taxonomic Units (OTUs), using open-reference OTU picking, and classified at the species
level against the NCBI 16S ribosomal RNA sequence database (release date February 11,
2017) using ncbi-blast+ package 2.5.0. Phylogenetic classification was obtained from the
NCBI taxonomy database (release date February 16, 2017). The relative abundance of each
OTU was determined for all samples. A step-by-step description of our analysis pipeline is
included below:

Analysis pipeline
Demultiplexing of fastq files from paired-end reads and barcodes was done by using the
command split.libraries.fastq.py from QIIME. Merging of paired-end reads to create
consensus sequences was done with the VSEARCH command fastq_mergepairs. A
maximum of 10 mismatches were allowed in the alignment. Quality filtering and conversion
of the .fastq file to .fasta format was done using the fastq_filter command in VSEARCH. The
merged fasta file was then dereplicated in VSEARCH by full-length matching using the
derep_fulllength command. All sequences were then sorted by decreasing length using the
sort by length command in VSEARCH. The minimum and maximum limits for this step were
set at 200 and 350 base pairs respectively. Next the sort by size command was used to sort
sequences by decreasing cluster size of representative sequences. The minimum cluster
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size allowed was 2, which resulted in the removal of singleton sequences. The cluster_otus
command within USEARCH was then used to perform 97% OTU clustering using the
UPARSE algorithm. The UPARSE algorithm allows for the construction of OTU sequences
from pre-processed paired reads using greedy clustering, where input sequences are
ordered by decreasing abundances such that the centroid of each OTU is selected from the
most abundant reads. Further post-processing is still needed to map reads to OTUs in order
to construct an OTU table. This step also allows for selection and exclusion of chimeras.
Next the USEARCH algorithm was used (usearch_global command) to search the database
of merged reads for high identity hits and generate a uc. file. It exploits the fact that similar
sequences have several short words in common. If there is a tie, the tie is broken by
choosing the first OTU in database file order. The reference database for this step is the
previously generated representative OTU sequences. The identity threshold used for this
step was 0.97. The mapped OTUs were converted into an OTU table using a series of
python scripts summarized in uc2otutab.py. The OTU table is a delimited text file that can be
conveniently imported into a spreadsheet or parsed by a script. Representative OTU
sequences were then classified at the species level from the NCBI 16S database using
BLAST (Basic Local Alignment Search Tool). This step was done in R using the blastn UNIX
executable and served as the database against which the original merged reads were
mapped. Taxonomic assignment was validated using the mothur method with Greengenes,
RDP, and SILVA. In order to estimate beta diversity, sequences were first aligned by the
PyNAST method using the align_seqs.py command in QIIME. filter_alignment.py was then
used to filter the sequence alignment by removing the highly variable regions. The
make_phylogeny.py script in QIIME was used to create the phylogenetic tree from multiple
sequence alignment. Finally, the beta_diversity.py script was used to generate beta diversity
distance matrices. In order to estimate alpha diversity the OTU table was first rarefied using
the single_rarefaction.py command in QIIME. The rarefaction cutoff used was the total read
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count for the sample with the least number of reads. The alpha_diversity.py script in QIIME
was then used to estimate alpha diversity. Additionally, we performed validation of taxonomy
assignment by classifying all identified OTUs within our fecal analysis cohort, using the
mothur method, with the Greengenes, SILVA, and RDP databases, observing a high degree
of concordance with NCBI taxonomies. A phylogenetic tree was empirically constructed
using the FastTree algorithm in the QIIME software package, as described previously.
Briefly, all nodes of the tree were considered as clusters of related OTU (crOTU), where the
abundance of each crOTU was the sum of abundances of its member OTUs. The trees were
constructed from a sequence alignment of all observed OTUs within both oral 1152 (97.5%
of 1182 OTUs) and gut 1434 (98.6% of 1455 OTUs) microbiome samples. The resultant oral
and gut microbiome crOTU trees contained 1152 and 1434 nodes respectively. We then
performed simple hierarchical clustering of samples using Euclidean distances based on
abundances of crOTUs within samples. This approach assumes that bacteria more closely
related by evolutionary proximity, as determined by 16S sequence similarity, may share
phenotypic traits, including traits that may be associated with clinical responses to cancer
immunotherapy. It is analogous to examining effects at different phylogenetic levels
(phylum, class, order, family, genus, species), but allows for a more comprehensive
examination of possible bacterial groupings, including for example, subgenera, or
subfamilies. The success of the clustering can be visualized with notable taxonomic
differences between patients in crOTU community type 1 vs crOTU community type 2.
Furthermore, a distinct clustering effect was seen upon performing principal coordinate
analysis on weighted UniFrac distances by crOTU community type. Alpha diversity was
estimated using the Inverse Simpson Index (D), which captures the variance of taxonomic
abundance as D=1/∑ pi2 S k=1, where pi is the proportion of the total species S that is
comprised by the species i. Rarefaction limits were set based on the least number of reads
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in all oral (13,000) and fecal samples (8,000) that were analyzed. Results were also
validated using other indices such as Chao1, Simpson and Shannon.

Bipartite network to compare and contrast the oral and gut microbiota
The bipartite network was constructed using make_bipartite_network.py script in QIIME
using default parameters and then visualized in Cytoscape using an edge-weighted springembedded layout. We generated 2 networks, using both aggregate and paired samples.
Enrichment Index to visualize differences in oral and gut microbiota between R and NR
To generate the heatmap we introduced a new parameter, the OTU enrichment index, “ei.”
The parameter is important to evaluate the enrichment when most OTUs in the dataset are
rare, which is typical of sparse, compositional microbiome data. To calculate the index we
first determined the representation of each OTU in each outcome (response) group. We
refer to this value as the OTU representation index (“ri”) and calculate it for each group, R
(riR) and NR (riNR), as the proportion of samples that have non-zero abundance of the
OTU. The values of ri range from 0 (OTU not found in any sample within a group) to 1 (OTU
found in all samples within a group). The OTU enrichment index (ei) is then calculated from
the ri values as: ei = (riR – riNR) / (riR + riNR) The ei index takes values from -1 to +1. An
OTU found in all R samples but no NR sample takes ei=+1. Conversely, an OTU found in all
NR samples but no R sample takes ei=-1.
We further used the ei to visualize differences between R and NR as a heatmap of
OTU abundances where samples are shown in columns and OTUs in rows. We grouped
samples according to response (R and NR), sorting within each group by alpha diversity,
from high to low. OTUs (rows) were grouped into 3 sets according to their ei using
thresholds determined from the overall ei distribution (fig. S9); Set 1 was comprised of OTUs
enriched in R (ei>0.3 for oral microbiome, ei>0.5 for fecal microbiome), Set 2 included OTUs
that were not differentially enriched in either response category (-0.3≤ei≤0.3 for oral
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microbiome and -0.5≤ei≤0.5 for fecal microbiome), and Set 3 was comprised of OTUs
enriched in NR (ei<-0.3 for oral microbiome, ei<-0.5 for fecal microbiome). Within each set,
OTUs were then sorted by average abundance prior to plotting. OTU abundance in each
sample was designated by mapping abundance (low, medium, high) to color (green, yellow,
red), using thresholds derived from the overall abundance distribution for all OTUs. We then
explored the taxonomy of OTUs grouped together within each ei- 5 derived set by
summarizing taxa at the order level as shown in accompanying pie charts. A major utility of
the enrichment index is that it allows visualization of both rare and common OTUs, and
therefore allows for the appreciation of biologically-relevant, community-level effects (both
cooperative and antagonistic).

Statistical assessment of biomarkers using LEfSe
The LEfSe method of analysis first compares abundances of all bacterial clades (in this case
between R and NR), using the Kruskal-Wallis test at a predefined α of 0.05. Significantly
different vectors resulting from the comparison of abundances (e.g., Faecalibacterium
relative abundance) between groups are used as input for linear discriminant analysis
(LDA), which produces an effect size. The primary advantage of LEfSe over traditional
statistical tests is that an effect size is produced in addition to a p-value. This allows sorting
of results of multiple tests by the magnitude of the difference between groups. In the case of
hierarchically-organized bacterial clades, there may be a lack of correlation between pvalues and effect sizes due to differences in the number of hypotheses considered at
different levels since a greater number of comparisons would need to be made at the genus
and species levels when compared to the phylum and class levels.

Metagenomic whole genome shotgun (WGS) sequencing
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Metagenomic sequencing provides species-level resolution of bacteria, and depending on
sequence depth can quantify the near-complete genomic content of the collection of
microbes in a particular sample, referred to as the sample’s metagenome.
Whole genome shotgun (WGS) sequencing utilized the same extracted bacterial genomic
DNA used for 16S rRNA gene compositional analysis and was done in collaboration with the
CMMR and Metagenopolis (MGP). Briefly, individual libraries were constructed from each
sample and loaded into the HiSeq platform (Illumina) and sequenced using the 2x100 bp
paired-end read protocol. The process of quality filtering, trimming, and demultiplexing was
carried out by an in-house pipeline developed by assembling publicly available tools such as
Casava v1.8.3 (Illumina) for the generation of fastq files, bbduk for adapter and quality
trimming, and PRINSEQ for sample demultiplexing.
Gut microbiota analysis was performed using the quantitative metagenomics pipeline
developed at MGP. This approach allows the analysis of the microbiota at the gene and
species level. High quality reads were selected and cleaned to eliminate possible
contaminants such as human reads. These were mapped and counted using the 9.9M gene
integrated reference catalog of the human microbiome. Filtered high-quality reads were
mapped to the 9.9 million-gene catalogue using Bowtie 2 included in METEOR software
using a >95% identity threshold to account for gene variability and for the non-redundant
nature of the catalogue. The gene abundance profiling table was generated using a two-step
procedure: first, the unique mapped reads (reads mapped to a unique gene in the
catalogue) were attributed to their corresponding genes, then, the shared reads (reads that
mapped with the same alignment score to multiple genes in the catalogue) were attributed
according to the ratio of their unique mapping counts.
After a rarefaction step at 14M reads (to correct for the different sequencing depth) and
normalization (RPKM), a gene frequency profile matrix was obtained which was used as the
reference to perform the analyses using MetaOMineR, a suite of R packages developed at
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MGP and dedicated to the analysis of large quantitative metagenomic datasets. The 9
million gene catalogue has been clustered into 1436 MGS (Metagenomic Species), groups
of >500 genes that co-vary in abundance among hundreds of samples and thus belong to
the same microbial species. The taxonomic annotation of the MGS was performed using the
homology of its genes with previously sequenced organisms (using blastN against nt and
wgs databanks, NCBI, November 2016 version). MGS signal among samples was
calculated as the mean signal of the 50 genes defining a robust centroid of the cluster. A
MGS frequency profile matrix was constructed using the MGS mean signals after
normalization (sum of the MGS frequency of a sample =1).
Reads whose genomic coordinates overlap with known KEGG orthologs were tabulated,
and KEGG modules were calculated step-wise and determined to be complete if 65% of the
reaction steps were present per detected species and for the metagenome. Pathways were
constructed for each taxa and metagenome by calculating the minimum set through MinPath
resulting from the gene orthologs present.

Pathway Metagenome Databases (PGDB)
Databases were generated for each WGS sample using the PathoLogic program from the
Pathway Tools software. Inputs for the program were produced using predicted gene
functions based on KEGG orthology and their taxonomy assignment in the metagenomes.
Thus, if the same function (KO group) had several taxonomic annotations, each annotation
was considered as a separate gene. The definition of the KO group in KEGG was used as
the gene function and the first name of the KO group, if available, was used as the gene
name. EC numbers were assigned to the gene according to annotations of the KO group by
the numbers in KEGG. The metabolic reconstructions were made in the automatic mode as
described in the Pathway Tools manual with the option –tip to automatically predict transport
reactions. We used the DOMAIN value ‘TAX-2 (Bacteria)’ as the organism class for the
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PGDB and the CODON-TABLE value to be equal to 1. The generated PGDB were
summarized and compared using Pathway Tools.

Whole exome sequencing
Genomic DNA was extracted from 10 tumor samples and matched peripheral blood as
germline controls. Exome capture was performed on 500ng of DNA per sample based on
the Kapa Hyper Prep using the Agilent Human All Exon baits V3 kit according to the
manufacturer’s instructions. Whole exome sequencing was performed on the Illumina HiSeq
2500 sequencing platform. The average coverage for whole exome sequencing data was
247× in tumor samples and 111× in germline samples. Paired-end sequencing reads in
fastq format were generated from BCL raw data using Illumina CASAVA (Consensus
Assessment of Sequence and Variation) software. The reads were aligned to the hg19
human reference genome using BWA. Duplicate reads were removed using Picard tools
(unpublished, http://broadinstitute.github.io/picard/), and local realignments were performed
using GATK. The average mapping ratio was 95.8% in tumor samples and 96.8% in
germline samples. The BAM files were then used for downstream analysis.

Mutation calling
MuTect was used to identify somatic point mutations, and Pindel was used to identify
somatic insertions and deletions. A series of post-calling filters were applied including: (a)
total read count in tumor sample ≥20, (b) total read count in germline sample ≥10, (c) VAF
(Variant Allele Frequency) ≥0.02 in tumor sample and ≤0.02 in matched normal sample, (d)
a population frequency threshold of 1% was used to filter out common variants in the
databases of dbSNP129, 1000 Genome Projects, Exome Aggregation Consortium and
ESP6500. Driver mutations were identified by reference to a published list of driver genes
and mutations of cutaneous melanoma from Zhang et al.
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Immunohistochemistry
Immunohistochemistry was performed as described previously. Briefly, sections (4µm
thickness) were prepared from formalin-fixed paraffin-embedded (FFPE) tissues. The
presence of the tumor was confirmed by a pathologist on hematoxylin & eosin-stained slides
(H&E). Slides were then stained using a Leica Bond RX automated slide stainer (Leica
Biosystems, Buffalo Grove, IL) for CD3 (n=17)(1:100, DAKO, Santa Clara, CA), CD8
(n=21)(1:100, Thermo Scientific, Waltham, MA), PD-1 (n=16)(1:250, Abcam, Cambridge,
UK), PD-L1 (n=15)(1:100, Cell Signaling, Danvers, MA), GzmB (n=17; ready-to-use, Leica),
RORγT (n=14)(1:800, EMD Millipore, Billerica, MA), FoxP3 (n=16)(1:50, BioLegend, San
Diego, CA) and counter-stained with hematoxylin. Stained slides were then scanned using
an automated Aperio Slide Scanner (Leica), and the density of the immune infiltrate was
quantified in tumor regions using a modified version of the default “Nuclear v9” algorithm
and expressed as positive counts/mm2 for CD3, CD8, PD-1, FoxP3, GzmB and RORγT and
as an H-score for PD-L1 which takes into account a percentage of positive cells multiplied
by their intensity on a scale of 1 to 3 for a score between 1-300.

Flow cytometry
Flow cytometry was performed as described previously. In short, peripheral blood
mononuclear cells (PBMC) were stained with CD3 (UCHT1, BioLegend), CD4 (SK3,
eBioscience, Thermo Scientific), CD8 (RPA- T8, BD Biosciences, Mississauga, Canada),
FoxP3 (PCH101, eBioscience), CD127 (HIL-7R-M21, BD Biosciences), CD19 (HIB-19,
BioLegend), CD14 (61D3, eBioscience), HLA-DR (L243, BD Biosciences), CD33 (WM53,
BD Biosciences), CD56 (NCAM1, BD Biosciences), and CD11b (ICRF44, BD Biosciences)
and acquisition was carried out on a Fortessa Flow Cytometer (BD Biosciences). Analysis
was performed with FlowJo version 10 (Tree Star Inc., Ashland, OR).
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Multiplex immunohistochemistry
Sequential 12-marker myeloid multiplex immunohistochemistry was performed as described
previously. Briefly, FFPE sections underwent sequential staining, scanning and destaining
cycles using AEC as chromagen and scanned with an Aperio Slide Scanner (Leica
Biosystems). Staining was performed with hematoxylin (DAKO), CD68 (1:50, Abcam),
Tryptase (1:20000, Abcam) CSF1R (1:150, Abcam), DC-SIGN (Santa Cruz, Dallas, TX,
1:100), CD66b (1:600, eBioscience), CD83 (1:40, Abcam), CD163 (Thermo Scientific,
1:100), HLA- DR (1:100, Novus Biological, Littleton, CO), PD-L1 (1:100, Cell Signaling),
CD3 (1:150, Thermo Scientific), CD20 (1:1000, Santa Cruz), CD56 (1:25, Santa Cruz), and
CD45 (1:100, Thermo Scientific). CD45-positive regions of all images were then extracted
using ImageScope (Leica Biosystems), aligned, overlayed and segmented using CellProfiler
(Cambridge, MA) and layers were pseudo-colored for analysis and quantification using FCS
Express 6.0 Plus Research Edition (De Novo Software, Glendale, CA).

Cytokine multiplexing
41 plasma cytokine levels were assessed using multiplex bead assay (Bio-Rad, Hercules,
CA). Cytokines, chemokines and soluble mediators quantified included IL-1β, IL-1Rα, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL10, IL-12(p70), IL-13, IL-15, IL-17, Eotaxin, FGF basic, GCSF, GM-CSF, IFN-γ, IP-10, MIP-1α, PDGF-bb, MIP1β, RANTES, TNF-α, VEGF, IL-2Rα,
HGF, TRAIL, IL-17A, IL-17F, IL-23, SDF1/CXCL12, CCL22, MCP1/CCL2, Gro-α/CXCL1,
ENA78/CXCL5, EGF, TGF-β1, TGF-β2, and TGF-β3.

Statistical analyses
Alpha diversity was compared between R and NR using the Wilcoxon rank-sum or MannWhitney (MW) test. All patients were classified into high, intermediate or low diversity groups
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based on quartiles of distribution. Time to progression was defined as the interval (in days)
from the date of microbiome sample collection to the date of progression. Patients who did
not progress were censored at their date of last contact. Kaplan-Meier estimates of
progression-free survival (PFS) were estimated for each group, and compared using the logrank test. Hazard ratios and 95% confidence intervals were calculated using univariate and
multivariate Cox proportional hazards models to assess associations between time to
progression and features of the fecal microbiomes along with several clinical factors. Final
models were selected using forward stepwise selection methods. All assumptions for the
Cox models were met. The ability of clinical and significant bacterial variables in predicting
PFS was assessed by computing receiver operating characteristic (ROC) curves using the
“timeROC” package (74) in R. Area under the curve (AUC) values were calculated at t=50
days for these variables alone and in combinations with the “Cox” weighting option.
Pairwise comparisons of taxonomic abundances by both response and cluster were also
conducted using the MW test. Within each level (phylum: n=3, class: n=3, order: n=3, family:
n=7, genus: n=8, and species: n=9), we excluded the low abundance (<0.1%) and low
variance taxa (<0.01). Adjustments for multiple comparisons were done using the falsediscovery rate (FDR) method at an α level of 0.05. An effect size was estimated for each
taxon as U/√n, where U is the test statistic for the MW test, and n is the total sample size for
fecal samples (n=43). Volcano plots were generated for log10(FDR-adjusted p-values) on
the y-axis and median-adjusted effect sizes on the x-axis. In addition, patients were also
classified as having high or low abundance of Faecalibacterium or Bacteroidales based on
the median relative abundance of these taxa in the gut microbiome sample.
In general, the MW test was used for comparisons between binary outcome variables (R vs
NR), and the Spearman 8 rank correlation test was used to compare continuous variables.
Additionally, the Fisher’s exact test was used when proportions were compared between
binary variables. Hypothesis testing was done using both one-sided and two- sided tests as
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appropriate at a 95% significance level. All analyses were conducted in R, GraphPad Prism
(La Jolla, CA) and SAS version 9.4 (Cary, NC).

Fecal microbiota transplantation (FMT)
All animal studies were approved by the Animal Care and Use Committee at The UT MD
Anderson Cancer Center, in compliance with the Guide for the Care and Use of Laboratory
Animals. B6 germ-free mice for murine studies were provided by the gnotobiotic facility of
Baylor College of Medicine (Houston, TX). Mice were transported in specialized autoclaved
shipping cages, and were housed at the MD Anderson Cancer Center mouse facility. All
cages, bottles with stoppers and animal drinking water were autoclaved before being used.
Food and bedding were double irradiated and tested to ensure sterility prior to being used in
the experiment. Within each treatment category, a control group of mice received only prereduced PBS. All other mice from experimental groups received FMT from either R or NR
donors, with each donor sample delivered to 3 mice. 200µl cleared supernatant from 0.1 g/μl
human fecal suspension was obtained using a 100 μm strainer and gavaged into mice for 3
doses over 1 week, followed by a break of 1 week to allow microbiome establishment. Mice
were then injected with the BRAFV600E/PTEN-/- (BP) syngeneic tumor cell line (Day 14),
and animals were treated with anti-PDL1 monoclonal antibody (purified low endotoxin,
functional formulation, Leinco Technologies Inc., Fenton, MO) once tumors reached ~250500 mm3. Tumor growth and survival were assessed and fecal specimens, blood and
tumors were harvested and processed for further analysis.

Immunofluorescence and immunohistochemistry on FFPE samples
Xenograft tumors, mouse gut and spleens were harvested, fixed in buffered 10% formalin (4
hours at room temperature), then switched to 70% ethanol and stored at 4°C. Tissues were
embedded in paraffin and 5 μm sections were mounted on positively charged slides. Next,
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tissues were deparaffinized and antigen retrieval was performed in pH 6.0 Citrate buffer
(Dako) using a microwave. Sections were then blocked in blocking buffer (5% Goat
Serum/0.3% BSA/0.01%Triton in PBS) followed by primary antibody incubation overnight at
4°C. Finally, sections were washed and then incubated with Alexa-conjugated secondary
antibody (1:500, Molecular Probes) for 1 hour at room temperature. Coverslips were washed
3 times in PBS/0.01% Triton and then incubated for 15 minutes at room temperature in
Hoechst stain (1:5000, Invitrogen) then mounted in ProLog Diamond mounting media
(Molecular Probes). Images where captured using a Nikon A1R+ confocal microscope
equipped with a four solid state laser system and a 20 objective. IHC for FoxP3+ (FJK-16s,
eBioscience) Treg and and RORγT+ (Q31- 378, BD Pharmingen) Th17 cells was quantified
by counting positive cells in five random 1 mm2 areas. The average total number of cells
positive for each marker was expressed as density per mm2.

Cytometry by Time-Of-Flight (CyTOF)/Mass cytometry
Tumors were manually dissociated, digested using liberase TL (Roche) and DNase I for 30
minutes at 37°C, and passed through a 70 μm mesh filter. Samples were then centrifuged
using a discontinuous gradient of Histopaque 1119 (Sigma-Aldrich) and RMPI media. Single
cell suspensions of up to 2.5 x 106 cells per sample were Fc Receptor blocked and stained
with a surface antibody mixture for 30 minutes at 4°C. Metal-conjugated antibodies were
purchased from Fluidigm or conjugated using X8 polymer antibody labeling kits according to
the manufacturer’s protocol (Fluidigm). Samples were stained using 2.5 μM 194Pt-cisplatin
(Fluidigm) for 1 minute and washed twice with 2% FCS PBS. Cells were barcoded using a
palladium mass tag barcoding approach according to the manufacturer’s protocol (Fluidigm)
and combined after two washes with 2% FCS PBS. Cells were then fixed and permeabilized
using FoxP3 transcription factor staining kit according to the manufacturer’s protocol
(eBioscience). Samples were then stained using a mixture of antibodies against intracellular
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targets for 30 minutes at room temperature. Samples were washed twice with 2% FCS PBS
and then incubated overnight in a 1.6% PFA/100 nM iridium/PBS solution prior to acquisition
using a Helios mass cytometer (Fluidigm). 9 Mass cytometry data were bead normalized
and debarcoded using Fluidigm software. Total live and CD45+ cells were manually gated
using FlowJo. Dimension reduction (t-SNE) analyses were performed on total live and
CD45+ cells using the Cyt package in Matlab. Data were arcsinh transformed using a
coefficient of 4 and randomly down-sampled to 50,000 events per sample prior to t-SNE
analysis. t-SNE plots for each experimental group were then generated by merging samples
from each group and displaying an equal number of randomly down-sampled events
(50,000) from each treatment group.

CyTOF panel
Target Clone Metal Tag Stain Source
CD45 30-F11 89Y Surface Fluidigm
c-MYC 9E10 115In Intracellular eBioscience
MHC-II M5/114.15.2 139La Surface Biolegend
NK1.1 PK136 141Pr Surface Biolegend
CD11c N418 142Nd Surface Biolegend
CD80 16-10A1 143Nd Surface Biolegend
MHC-I 28-14-8 144Nd Surface Fluidigm
CD4 RM4-5 145Nd Surface Fluidigm
CD8a 53-6.7 146Nd Surface Fluidigm
CD86 GL-1 147Sm Surface Biolegend
CD27 LG.3A10 148Nd Surface Biolegend
OX40 OX-86 149Sm Surface eBioscience
CD25 3C7 150Nd Surface Fluidigm
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TIGIT 1G9 151Eu Surface Biolegend
CD3 145-2C11 152Sm Intracellular Fluidigm
PD-L1 10F.9G2 153Eu Surface Fluidigm
BATF D7C5 154Sm Intracellular Fluidigm
ICOS 7E.17G9 155Gd Surface eBioscience
CD69 H1.2F3 156Gd Surface Biolegend
CXCR5 2G8 158Gd Surface BD
PD-1 29F.1A12 159Tb Surface Fluidigm
CD62L MEL-14 160Gd Surface Fluidigm
CXCR3 CXCR3-173 161Dy Surface Biolegend
TIM3 RMT3-23 162Dy Surface Fluidigm
LAG3 C9B7W 163Dy Surface Biolegend
LAP-TGFβ TW7-16B4 164Dy Surface Fluidigm
FoxP3 FJK-16s 165Ho Intracellular Fluidigm
BCL2 BCL/10C4 166Er Intracellular Biolegend
GATA3 L50-823 167Er Intracellular BD
BCL6 K112-91 168Er Intracellular BD
CD117 2B8 169Tm Surface Biolegend
CD127 A7R34 170Er Surface Biolegend
CTLA-4 UC10-4B9 171Yb Intracellular Biolegend
CD11b M1/70 172Yb Surface Fluidigm
TBET 4B10 173Yb Intracellular Biolegend
RORγT Q31-378 174Yb Intracellular BD
CD28 37.51 175Lu Surface Biolegend
EOMES Dan11mag 176Yb Intracellular eBioscience
Live/Dead N/A 194Pt Surface Fluidigm
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CD19 6D5 195Pt Surface Biolegend
TCRγδ GL3 196Pt Surface Biolegend
KLRG1 2F1 198Pt Surface BD
CD44 IM7 209Bi Surface Fluidigm

Flow cytometry of mouse tumor and blood
Tumors were isolated and minced into small pieces and digested for 1 hour in RPMI
containing collagenase A (2 mg/mL; Roche) and DNase I (40 units/mL; Sigma-Aldrich) with
agitation at 37°C. Cell suspensions were passed through a 70μm cell strainer, washed in
2% RPMI supplemented with 2 mmol/L EDTA and resuspended in FACS buffer (PBS
containing 2% heat-inactivated FBS with 2 mM EDTA supplementation). For analysis of cell
surface markers, the following antibodies were used: CD45 (30-F11, BD Biosciences),
CD11b (M1/70, eBioscience), CD11c (HL3, BD Pharmigen), Ly6G (RB6-8C5, eBioscience),
Ly6C (AL-21, BD Bioscience), and F4/80 (BM8, eBioscience). Cells were labeled with
LIVE/DEAD viability stain (Life Technologies) and samples were acquired on a LSR
Fortessa X20 flow cytometry (BD Biosciences). Doublets were distinguished and excluded
by plotting FSC area versus FSC height. All data were analyzed using FlowJo software
(Tree Star).

Chapter 4 Materials and Methods
•

Excerpts of this text were taken and used with permission from journal article, C.N.
Spencer,* V. Gopalakrishnan,* J.L. McQuade,* M. Vetizou,* A.P. Cogdill,* M.A.W.
Khan,* J.A. McCulloch,* et al Diet and probiotics impact the gut microbiome and
melanoma immunotherapy response Science

Study Design
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Examined differences in the microbiome across the spectrum of healthy, early- and latestage melanoma patients and expand upon our prior findings of the gut microbiome in
immunotherapy responses. We provide novel data on the role of dietary fiber and probiotic
use during systemic immunotherapy for advanced melanoma. This is examined within a well
characterized clinical cohort of melanoma patients treated at a single, large cancer center,
with confirmatory studies in mice (both conventional and gnotobiotic).
Human study subjects
In total, data from 506 study subjects were included in this study. The overall cohort
included fecal samples from 312 melanoma patients and 194 healthy individuals. All
melanoma patients were treated at the University of Texas MD Anderson Cancer Center
(UTMDACC) in Houston, TX and had fecal samples collected between April 2015 and May
2018 following signed voluntary informed consent under Institutional Review Board (IRB)–
approved protocols (IRB LAB00-063, 2012-0846).

Healthy cohort
A comparable cohort of healthy U.S. adults (age ≥18 with no history of cancer by self-report)
were selected from the American Gut Project (AGP).

Melanoma stage and treatment cohorts
Melanoma patients treated at UTMDACC were further categorized as early-stage (Stage I
and II, n=39) vs. late-stage (Stage III and IV, n=273) melanoma. Within the late-stage
cohort, we examined analytic subsets of the melanoma patient cohort by treatment type and
by availability of complete dietary and probiotic use data. For assessments of the
microbiome and treatment response, the primary analysis was restricted to 202 non-uveal
melanoma patients treated with any systemic therapy. Subgroup analyses were conducted
in various treatment subgroups to account for the differences in response rates of various
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therapies. Patients in our cohort were most frequently treated with immune checkpoint
inhibitor (ICI) therapy, and the most common therapy was anti PD-1 inhibitor and the most
frequent combination was anti-CTLA4 + anti-PD1. We focused on these two subsets
throughout this analysis, as they provided the greatest sample size to explore associations
with variables of interest and clinical outcomes.

Melanoma lifestyle cohort
Of the 105 late-stage patients who attempted the lifestyle survey at the time of the data cut,
all responded to the OTC probiotics and antibiotics queries and 80% completed the dietary
assessment module. Stage and treatment response were similarly distributed among
patients who did (n=84) versus did not (n=21) adequately complete the 26-item dietary
assessment module to calculate estimated intake of key dietary variables. To evaluate
associations of probiotics use (n=105) and diet (n=84) with the microbiome in late-stage
melanoma patients, independent of treatment or outcome, we excluded patients who
reported recent antibiotic use; leaving 72 patients for the primary analysis of the microbiome
with OTC probiotics use and 64 patients for the primary analysis of the microbiome with
dietary fiber. Functional attributes of the microbial metagenome were characterized in a
subset of 26 patients 3 treated with anti-PD-1 therapy (and compared to murine models)
with available whole metagenomic sequencing and dietary data. By treatment cohort, 62
and 51 of the anti-PD1 +/- CTLA4 treated patients had complete data on probiotic use and
dietary fiber intake and evaluable therapeutic response. Of these, 46 were treated with antiPD-1 without anti-CTLA 4 and 46 had complete data on probiotic use and 38 had complete
data on dietary fiber intake.

Fecal sample collection
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Fecal (gut) microbiome samples (one per patient) were collected prior to initiation of new
systemic therapy or at time of diagnosis for early stage melanoma. Following informed
consent during their clinic visit at UTMDACC, melanoma patients were asked to provide an
OMNIgene GUT kit (OMR-200) (DNA Genotek, Ottawa, Canada) for outpatient fecal sample
collection. Patients provided these samples during the time of their clinic visit (if possible) or
returned the sample via mail. Importantly, this kit maintains microbial DNA stability at room
temperature for up to 60 days. All samples were stored at -80C prior to DNA extraction and
analysis.

TMB estimation in late-stage melanoma patients
Tumor mutational burden (TMB) was derived from targeted whole genome sequencing data
as previously described. In brief, predicted total mutation burden in individual tumors was
determined using a set of genes routinely evaluated as a part of clinical care at MD
Anderson Cancer Center. The algorithm calculates the predicted TMB using these weighted
scores of specific genes mutated in a given tumor

PD-L1 staining in late-stage melanoma patients
Tumor PD-L1 was quantified via immunohistochemical studies performed using the FDA
approved Dako pharmDx PD-L1 (clone 28-8, Dako/Agilent Technologies, Carpinteria, CA)
on Dako Autostainer Link 48 autostainer (Dako/Agilent Technologies, Carpinteria, CA) and
antigen retrieval with PT Link with Target Retrieval Solution, low pH (Dako/Agilent
Technologies, Carpinteria, CA) as specified by the manufacturer.

Assessment of dietary fiber intake and OTC probiotics use in the melanoma lifestyle cohort
Patient-reported survey information on dietary habits and probiotic supplement use
was collected as a part of an ongoing study at UTMDACC to characterize lifestyle factors in
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melanoma patients with planned initiation of systemic therapy. Following notification of
treatment initiation and voluntary informed consent on UTMDACC IRB protocol PA16-0336,
lifestyle surveys were administered to patients being treated at UTMDACC via web-based
format or by paper copy, according to the patient’s preference. This survey contained short
modules, including queries assessing whether the patient had taken OTC probiotics or
antibiotics in the last month leading up to the start of treatment and the 26-item NCI Dietary
Screener Questionnaire (NCI-DSQ) asking patients to recall “the different kinds of foods you
ate or drank during the past month, that is, the past 30 days. When answering, please
include meals and snacks eaten at home, at work or school, in restaurants, and anyplace
else.” Responses were converted to daily frequencies, missing and/or improbable
frequencies were identified, and specific hot and cold cereal types/brands were coded
according to standard procedures. Using the DSQ responses and What We Eat in America
24-hour dietary recall data from a national survey, we estimated each individual’s dietary
intake of fiber (g), fruits, vegetables, and legumes (cup equivalents), and whole grains
(ounce equivalents). The dietary fiber threshold of 20 grams per day was selected based on
the statistical distribution within our cohort. Use of OTC probiotics and antibiotics within the
month prior to starting therapy was coded as yes if patients reported any frequency of use
and coded as no if the frequency was reported as zero or none.

Clinical outcomes assessment in melanoma patients
Electronic medical records were reviewed independently by two trained medical oncologists
to assign systemic treatment and clinical response groups. Response (R) was defined by
radiographic evidence of complete response, partial response or stable disease per RECIST
1.1 criteria for at least 6 months. Lack of a clinical response (non-responder, NR) was
defined by disease progression (PD) on serial CT scans or stable disease lasting less than 6
months. Progression-free survival (PFS) was defined as the interval of time from treatment
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start to treatment progression (via scans or clinically determined) or the date of death.
Patients were censored at the time of their last visit to the clinic.

Microbiome extraction and sequencing methods
Bacterial DNA extraction and 16S rRNA gene sequencing for human studies and mouse
probiotics experiments: Sample preparation and sequencing was performed in collaboration
with the Alkek Center for Metagenomics and Microbiome Research (CMMR) at Baylor
College of Medicine across the entire melanoma patient cohort (n=312) and for all samples
derived from the mouse probiotics experiment. The 16S V4 amplification protocol was
adapted from those described in Earth Microbiome Project i.e; primers 515f/806r. Briefly,
genomic DNA was extracted using Qiagen/MO BIO PowerMicrobiome DNA isolation kit on
automated liquid handlers (Hamilton STARlet instruments). The 16S rDNA V4 region was
amplified by PCR and sequenced on the MiSeq platform (Illumina, Inc, San Diego, CA)
using the 2x250 bp paired-end protocol yielding paired-end reads with near-complete
overlap. The primers used for amplification contain adapters for MiSeq sequencing and
single-end barcodes allowing pooling and direct sequencing of PCR products.

16S analysis pipeline
Details of our analytical pipeline have been described previously. Briefly, quality filtered
sequences with >97% identity were clustered into bins known as Operational Taxonomic
Units (OTUs), and classified phylogenetically against the NCBI 16S ribosomal RNA
sequence database (release date September 1, 2018) using the NCBI-BLAST+package
2.8.1. 2018). A step-by-step description is also provided below: Merging of paired-end
reads, with a maximum of 10 mismatches to create consensus sequences was done with
the VSEARCH command fastq_mergepairs. This was followed by dereplication by full length
matching using the derep_fulllength command, sorting by decreasing length (sort by length
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command; 200 to 350 bp), and sorting by decreasing cluster size of representative
sequences (sort by size command, minimum 2). OTU clustering (97%) was done using the
cluster_otus command within USEARCH (34) using the UPARSE algorithm. This step also
allows for selection and exclusion of chimeras. Next, using the usearch_global command we
searched the database of merged reads for high identity hits and to generate a uc. file. The
reference database for this step is the previously generated representative OTU sequences.
The identity threshold used for this step was 0.97. The mapped OTUs were converted into
an OTU table using a series of python scripts summarized in uc2otutab.py. Representative
OTU sequences were then classified at the species level from the NCBI 16S database using
BLAST (Basic Local Alignment Search Tool). This step was done in R using the blastn UNIX
executable and served as the database against which the original merged reads were
mapped. Microbiome indices representative of alpha and beta diversity were calculated
using QIIME. In order to estimate the phylogenetic distances among OTUs, sequences were
first aligned by the PyNAST method using the align_seqs.py command. Filter_alignment.py
was then used to filter the sequence alignment by removing the highly variable regions.
Next, the make_phylogeny.py script was used to create the phylogenetic tree from multiple
sequence alignment and the beta_diversity.py script was used to estimate beta diversity
using Bray-Curtis dissimilarity, Weighted and Unweighted UniFrac distance matrices. In
order to estimate alpha diversity, the OTU table was first rarefied using the
single_rarefaction.py command in QIIME. The rarefaction cutoff used was the total read
count for the sample with the least number of reads. The alpha_diversity.py script in QIIME
was then used to estimate alpha diversity. Alpha diversity was primarily estimated using the
Inverse Simpson Index (D), which captures the variance of taxonomic abundance as D=1/
ΣS k=1 pi2, where pi is the proportion of the total species S that is composed by the species
and results were confirmed using other indices such as Chao1, and Shannon. All
microbiome readouts were validated using the DADA2 methodology (a pipeline that
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denoises amplicon data and corrects sequenced amplicon errors thereby offering a higher
resolution of results through a very stringent filter and SILVA v132 reference database. A
strong correlation between the pipelines was observed for both alpha diversity scores and
Ruminococcaceae abundances. Additionally, we ran Procrustes analysis using the nearest
neighbor model to test the degree of relationship between taxonomic datasets in both
pipelines and observed a goodness of fit value (m2) of 0.327, and p-value of 0.001. This
indicated that the two datasets displayed greater concordance than expected by chance
alone. This was also confirmed by Mantel test results comparing Bray-Curtis dissimilarity
matrices which also revealed a strong degree of correlation between the two pipelines.
Lastly, a pairwise comparison of relative abundances of bacterial taxa (generated using
DADA2 denoised ASVs) in the same subset of patients characterized (i.e., all patients on
systemic therapy; n=202) revealed highly similar bacterial candidates associated with
response.

Human Type 1 and Type 2 microbiome (response) signature
The microbiome signature was derived as described previously in the original published
cohort. Briefly, based on a cohort specific threshold level of candidate response bacteria,
the Type 1 signature was defined at or above 11% relative abundance of Ruminococcaceae
and Type 2 signature was defined below 11% relative abundance of Ruminococcaceae.

Metagenomic data generation for mouse and human studies
Mouse (probiotic studies) samples and a subset of the anti-PD1 treated human samples
with available fiber data were submitted to the Alkek Center for Metagenomic and
Microbiome Research (CMMR) for microbiome profiling via 16S (described above) were
selected for metagenomic shotgun sequencing. The same DNA extracts used for 16S were
used for metagenomic shotgun sequencing to minimize biases introduced in the extraction
40

process. For the human samples, individual sequencing libraries were constructed from
each sample then pooled and loaded onto the Illumina HiSeq2000 platform. Sequencing
reads were derived from raw BCL files which were retrieved from the sequencer and called
into fastqs by Casava v1.8.3 (Illumina). Paired-end raw sequence reads in fastq format were
processed further to quality trim the sequences, filter for Illumina phix sequences and trim
the Illumina adapters using bbduk (BBMap version 37.58). The trimmed fastqs were then
mapped to a hg38 reference database (GCA_000001405.28, in this case human) using
bowtie2 v.2.3.4.3 end-to-end and very-sensitive parameters in order to remove host
contamination reads. For mouse samples, extracted DNA (CMMR) was submitted to
CosmosID for sequencing. The change in data generation facilities was a result of halted
research activities at the CMMR due to COVID19. At CosmosID, DNA samples were
quantified using Qubit4 and individual sequencing libraries were prepared following
CosmosID’s proprietary methods. DNA libraries were sequenced on the Illumina NextSeq
550 platform in two separate 300 cycle runs. Raw FASTQ files were made available through
the CosmosID client portal. Metagenomic data generation for the mouse fiber studies was
carried out at the National Institutes of Health Microbiome Core facility. Fecal DNA
extraction was carried out using the Mobio PowerMag Microbiome DNA/RNA isolation kit
(cat#27500-4-EP). DNA extraction from samples was automated using an epMotion5073
robot instrument (Eppendorf). Individual sequencing libraries were constructed with Nextera
Flex and sequenced on the Illumina NextSeq500 platform. All metagenomic data for both
human and mouse studies were analyzed following the same parameters using the JAMS
package as described in the next section below.

Metagenomic analysis pipeline for all human and mouse samples
All bioinformatic analyses of whole shotgun metagenomic data were conducted using the
JAMS package (https://github.com/johnmcculloch/JAMS_BW). Briefly, for each sample,
41

Illumina reads that did not align to the Mus musculus genome or the human genome (hg38)
using Bowtie2 were assembled into contigs using Megahit version v1.1.3. Contigs were
taxonomically classified using kraken v2.08 with a custom-built k-mer database containing
all complete and draft bacterial, archaeal, fungal, viral and protozoan genomes plus the Mus
musculus and human genomes included as secondary filters. Contigs were annotated using
Prokka v1.14 and the predicted proteome was functionally annotated using Interproscan
(https://www.ebi.ac.uk/interpro/about/interproscan/). Reads used as input for assembly were
aligned back to contigs to gauge sequencing depth and compute base pair coverage for
each feature. Taxonomic information for each sequence (contig or unaligned reads) was
expressed as Last Known Taxon (LKT), which was defined as being the lowest taxonomic
level unambiguously classified by kraken2. Taxonomic relative abundances for each LKT
were computed as the sum of bases of covering contigs classified as belonging to that LKT
plus the number of unassembled bases of that LKT divided by the total number of base
pairs used for assembly for that sample, expressed in Parts per Million (PPM). To obtain
Gene Ontology (GO) term relative abundances, base counts of Interproscan annotated
genes attributed to a given GO terms were aggregated by summing and divided by the total
number of base pairs used for assembly for that sample, expressed in Parts per Million
(PPM). Where applicable, the stratification of the contribution of each taxon to each
individual GO term aggregation was determined using the retrieve_features_by_taxa
function in the JAMS package. Briefly, the taxonomic origin of each single gene having a
particular GO term was obtained by looking up the taxonomy of which assembly it came
from and adding up the relative abundances for these genes within each taxon.

Murine studies
Cell culture and reagents: B2905 (M4) and HMel (M3) melanoma cell lines were provided by
Dr. Glenn Merlino (NCI, Bethesda, MD). The HMel melanoma model (M3) was induced in
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Cdk4R24C/R24C; Hgftg mice by topic administration of 7,12-Dimethylbenz(a)anthracene
(DMBA) at day. The B2905 melanoma model B2905 (M4) was generated in Hgftg mice by
UV radiation at day 3. Both were cultured in RPMI1640 containing 10% fetal bovine serum,
L-glutamine, sodium pyruvate, and non-essential amino acids (Lonza, Walkersville, MD)
BRAFV600E/PTEN-/- (BP) murine melanoma cells and MC38 murine colon carcinoma cells
were cultured in DMEM containing 10% fetal bovine serum.
Mice
Studies were conducted at the Trincheri lab at the National Cancer Institute. C57BL/6J or
C57BL/6NCr females were obtained from different vendors and maintained in a specific
pathogen-free environment, and generally used between 7 and 14 weeks of age. Animal
studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the
National Cancer Institute (Frederick, Maryland) and were conducted in accordance with the
IACUC guidelines and the National Institutes of Health Guide for the Care and Use of
Laboratory. Germ-free C57BL/6 mice were bred and maintained at the gnotobiotic Facility
(Frederick, Maryland) in accordance with the procedures outlined in the Guide for the Care
and Use of Laboratory Animals under an animal study proposal approved by the NCI Animal
Care and Use Committee. Mice received a standard fiber-rich chow diet until tumor
implantation and for mice on low fiber diet, the diet was changed the day of the tumor
implantation. Fecal samples were collected just prior to the diet oscillation and at interval
time points and were immediately stored at -80C until further use. Fiber-free diet was
sterilized by gamma irradiation and the Fiber-rich diet (NIH-31; autoclavable rodent diet) was
sterilized by autoclaving. The Fiber Free diet was manufactured by Teklad/Envigo (WI, USA)
and, as previously described (TD.130343)(25) consisted of a modified version of Harlan
TD.08810 in which starch and maldodextrin were replaced with glucose. Mice were injected
in the flank subcutaneously with 1 × 106 cells (B2905 and HMEL) or 8 × 105 cells (BP and
MC38). When tumor sizes reached approximately 40mm3 (HMel, B2905, MC38) or 100mm3
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(BP), mice were injected intraperitoneally (i.p) with 250μg of anti-PD-1 antibody (clone
RMP1-14) or isotype control (clone 2A3) or for experiments using BP, with 200μg of antiPD- L1 monoclonal antibody (clone 10F.9G2, BioXcell, NH, USA) as this model is more
responsive to anti-PDL1 than anti-PD-1. Mice were injected 4 times at 3-day intervals, and
the tumor size was routinely monitored by means of a caliper. Tumor volume was calculated
using the following formula: Volume (mm3) = (longest diameter) × (shortest diameter)2/2.
Mice were euthanized when tumor volume reached ~4000 mm3 or when they became
moribund.

Immune profiling by marker analysis and flow cytometry from fiber experiments
For ex vivo intracellular cytokine staining (ICS) tumors were harvested 16 days after
beginning the therapy in mice that had not yet reached the endpoint (n=6 and 7 mice). After
mechanical disruption, tumors were digested with 50μg/ml Liberase (Roche) and 0.5mg/ml
DNase1 (Roche) for 20 minutes at 37°C under agitation. The mixture was subsequently
passed through a 100μm cell strainer and counted. Dead cells were excluded using
LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen). Tumor cells were preincubated with
purified anti-mouse CD16/CD32 (clone 93; eBioscience) for 5 minutes at 4°C, before
membrane staining. For intracellular staining, the FoxP3 staining kit (eBioscience) was used.
PDL-1 (MIH5), CD4 (GK1.5), ICOS (7E.17G9), CD25 (7D4), CD3 (145-2C11), CD19 (1D3),
IL-17, FoxP3 (MF23), NK1.1 (PK136) and isotype controls rat IgG2a (clone R35-95) and rat
IgG2b (clone R35-38) were purchased from BD Biosciences. TCR (GL3) and CD8 (53-6.7)
were purchased from BioLegend (San Diego, CA). PD-1 (J43), CD45 (104), IFNᵧ (XMG1.2),
and isotype control Armenian Hamster IgG (eBio299Arm) was purchased from eBioscience.
All cells were analyzed on a FACS LSR FORTESSA (BD) and data was analyzed by FlowJo
(Tree Star, Ashland, OR).
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RNA sequencing of CD45+ tumor infiltrating leukocytes from mouse fiber studies
CD45+ cells were isolated from the tumor by magnetic sorting (Miltenyi) and RNA
was extracted from lysed cells using the RNeasy Microkit (Qiagen). Efficiency of the CD45+
magnetic enrichment was verified by flow cytometry and was superior to 97%. RNA seq
libraries were prepared using Lexogen technology. The libraries were multiplexed, clustered,
and sequenced on an Illumina NextSeq. Heatmap was designed comparing 435 genes
significantly different (p<0.05, FoldChange < or > 1.5 ) between anti-PD-1 treated groups
using Partek flow software (Align Reads to mouse genome mm10 using Star Aligner Version
2.4.1d index). SCFAs quantification from mouse fiber experiments: Samples were
homogenized and extracted with 50% acetonitrile at a concentration of 100 mg/ml with a
Bead Ruptor (Omni). After centrifugation, the supernatant was diluted 3 times with 50%
acetonitrile before use. SCFAs were derivatized with 3-Nitrophenylhydrazine (3-NPH, Santa
Cruz Biotechnology). In a 500 μL plastic vial, 20 μL each of diluted extract (or standard),
isotopic internal standards (obtained from Cambridge Isotope Laboratories, Sigma, or CDN
Isotopes), EDC at 120mM 5(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
from Thermo Fisher Scientific) 120 mM solution was prepared in 50% acetonitrile containing
6% pyridine), and 3-NPH solutions (prepared as 200 mM solution in 50% acetonitrile) were
mixed. After heating at 50°C for 30 min, the vials were cooled on ice. After centrifugation,
the supernatant was transferred to sample injection vials. Liquid chromatography-tandem
mass spectrometry LC was performed with a Shimadzu 20ACXR system. Separation was
achieved at 60°C with a 2.1 x 100 mm, 2.7 μm Cortex C18 column (Waters). Mobile phase A
was 0.01% formic acid in water and mobile phase B was 0.01% formic acid in acetonitrile.
The injection volume was 2 μl. The flow rate was 300 μL/min and the SCFAs were
separated with a gradient (0-0.2min/5%B; 15min/50%B; 15.1-16min/95%B; 16.118min/5%B). Liquid chromatography-tandem mass spectrometry MS/MS was performed
with a TSQ Quantiva triple quadrupole mass spectrometer (Thermo Fisher Scientific)
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operating in selected reaction monitoring (SRM) mode with negative electrospray ionization.
The precursor and product ions for the 3-NPH derivatives are listed in Table 1. The
concentration of the diluted supernatant of the extracts were determined by calibration
curves generated by the Thermo Xcalibur software. Calibration curves, constructed by
plotting the peak area ratios versus standard concentrations, were fitted by linear
regressions with 1/x weighting. The peak area ratios were calculated by dividing the peak
areas of the target compounds by the peak areas of the corresponding isotopic internal
standards.

Murine probiotics studies
Fecal microbiota transplantation (FMT): All animal studies were conducted in the Wargo lab
at MD Anderson Cancer Center and approved by the Animal Care and Use Committee at
The UT MD Anderson Cancer Center, in compliance with the Guide for the Care and Use of
Laboratory Animals. All mice were female, aged 6-8 weeks. C57BL/6J mice were obtained
from Jackson laboratories and maintained in a specific-pathogen-free environment. B6
germ-free mice for murine studies were provided by the gnotobiotic facility of Baylor College
of Medicine (Houston, TX). Germ-free mice were transported in specialized autoclaved
shipping cages, and were housed at the MD Anderson Cancer Center mouse facility. All
cages, bottles with stoppers and animal drinking water were autoclaved before being used.
Food and bedding were double irradiated and tested to ensure sterility prior to being used in
the experiment. All mice received FMT from either R or NR human donors, with each donor
sample delivered to 6 mice. 200μl cleared supernatant from 0.1 g/μl human fecal
suspension was obtained using a 100 μm strainer and gavaged into mice for 3 doses over 1
week, followed by a break of 1 week to allow microbiome establishment.

Culturing Lactobacillus GG and Bifidobacterium longum 35624, density, and sequencing
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Commercial OTC probiotics were acquired. Per the labels, Probiotic 1 contained 1
billion CFU (4 mg) of Bifidobacterium longum strain 35624 per capsule, and Probiotic 2
contained 10 billion CFU of Lactobacillus GG per capsule. Lactobacillus GG was prepared
by mixing 6 capsules in 8 ml UltraPure distilled water then filtered through a 100 um filter.
Lactobacillus was diluted up to 10-9 in PBS. 50 uL of 10-1 then 10-5 through 10-9 were
plated on Lactobacilli MRS plates supplemented with cysteine and grew at 37C in anaerobic
chamber for 24 hours. Colonies were counted and six were isolated for identification using
the Bruker MALDI Biotyper System. All six colonies were identified as Lactobacillus
rhamnosus. Total CFUs per mL was 24.3 billion. Bifidobacterium longum 35624 was
prepared by mixing 8 capsules in 10 ml UltraPure distilled water then filtered through a 100
um filter. Bifidobacterium was diluted up to 10-6 in PBS. 50 uL of 10-1 through 10-6 were
plated on Bifidus Selective Medium agar plates supplemented with BSM supplement and
Modified Reinforced Clostridial plates and grew at 37C in anaerobic chamber for 48 hours.
Colonies were counted and 3 from each set of plates for a total of 6 were isolated for
identification using the Bruker MALDI Biotyper System. Colonies were identified as
Bifidobacterium longum. Total CFUs per mL was 680 million.

Treatment with probiotics and checkpoint inhibitors
The contents of probiotics capsules were emptied into purified water and stirred for one hour
with a stir bar and then filtered through a 100μM filter. 8 capsules of probiotic 1 were
dissolved in 10 mL of sterile water. 6 capsules of probiotic 2 were dissolved in 8 mL of sterile
water. Mice were gavaged with 200 ul of purified water or purified water and probiotics
solution for 5 doses over 1 week. At each gavage of probiotic, mice received ~1.5x109
CFUs Lactobacillus or 1.6 x 108 CFUs Bifidobacterium. One-week break was then provided
to allow microbiome establishment. Mice were injected in the flank subcutaneously with 2.58 × 105 BRAFV600E/PTEN-/- (BP) or MC38 cells. When tumor sizes reached approximately
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250-500mm3, mice were injected intraperitoneally (i.p) with 200μg of anti-PD- L1
monoclonal antibody (purified low endotoxin, functional formulation, Leinco Technologies
Inc., Fenton, MO). Mice were injected 3 times at 2-day intervals, and the tumor size was
routinely monitored by means of a caliper. Tumor volume was calculated using the following
formula: Volume (mm3) = (longest diameter) × (shortest diameter)2/2. Mice were euthanized
when tumor volume reached 2000 mm3 or when they became moribund. For immune
profiling studies, mice were euthanized 4 days (Experiment 6) and 6 days (Experiment 7)
after the final dose of anti-PD-L1.

Immune cell isolation from lamina propria
Dissected intestines were placed in PBS on ice immediately; mesenteric material, fat, and
Peyer’s patches were removed. Intestines were cut open, feces removed, and intestinal
tissue was cut into 2 cm pieces. Intestinal tissue pieces were placed in 8 mL ice-cold PBS
and shaken vigorously by hand at room temperature for 2 min. Tissue pieces were
transferred to 20 mL PBS containing 1 mM DTT, 30 mM EDTA (Sigma, St. Louis, MO,
USA), and 10 mM HEPES (Sigma) at room temperature. The samples were placed in a
bacterial shaker incubator for 10 min at 37 ℃ while rotating at 200rpm, and then shaken by
hand at room temperature for 1 min. Tissue pieces were transferred to new tubes containing
a fresh solution of 20 mL PBS, 30 mM EDTA, and 10 mM HEPES, and were shaken for a
second time as indicated. The tissue pieces were rinsed gently with RPMI medium
containing 2% heat-inactivated fetal bovine serum (FBS) (RPMI/2%FBS) at room
temperature. Tissue pieces were transferred to tubes containing 5 mL of RPMI medium,
10% FBS, 200 U/ml collagenase VIII (Sigma), and 150 μg/ml DNaseI (Sigma). Tissues were
digested by shaking in a bacterial shaker incubator at 100 rpm at 37 ℃ for 1 h, and then
shaken by hand at room temperature for 1 min. The digested tissues were placed on a 100
μm cell strainer; single cells in the flow through were collected. Cells were centrifuged at 600
48

g for 5 min at 4 ℃ and resuspended in 4 mL 40% Percoll (Sigma) in RPMI/2% FBS. The
Percoll-cell solution was layered on top of 4 mL 80% Percoll in RPMI/2% FBS, and
centrifuged at 1300 g at room temperature for 20 min; spins were concluded without using
the centrifuge brake. The cells at the interface of the 40% and 80% Percoll solutions were
collected; cells were washed once with ice-cold PBS prior to antibody incubations.
Immune cell isolation from spleen, mesenteric lymph nodes (mLNs), and tumors
Single cell suspensions were generated from tumors, spleen, and mLNs by smashing
tissues with a syringe plunger onto a 100 μm cell strainer; cells were rinsed through the
strainer with RPMI/2%FBS at room temperature. Cells were centrifuged at 600 g for 5 min at
4 ℃ prior to antibody incubations.

Immune profiling by marker analysis and flow cytometry
Cells were incubated with rat anti-mouse CD16/32 antibody (Tonbo Bioscience, San Diego,
CA, USA) for 15 min at 4 °C to block surface Fc receptors, followed by incubation with
fluorescently-conjugated antibodies for surface makers for 30 min at 4 °C. For analysis of T
cell subsets, cells were stimulated with 0.5 μg/mL ionomycin (Sigma) and 50 ng/mL phorbol
12-myristate 13-acetate (PMA, Sigma) for 4-6 h in the presence of GolgiStop (BD
Biosciences, Palo Alto, CA, USA); subsequently, T cells were fixed and permeabilized using
commercial reagents (Intracellular Fixation and Permeabilization Buffer Set, eBioscience,
San Diego, CA, USA), and stained with antibodies against intracellular proteins for 30 min at
4 °C. Dead cells were distinguished by staining with Ghost Dye Violet 510 according to the
manufacturer (Tonbo Biosciences, San Diego, CA, USA). Cells were enumerated with the
use of Precision Count Beads (BioLegend, San Diego, CA, USA) according to the
manufacturer’s instructions.

Flow Panel- Mouse probiotics studies
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Antibody name/ Company/ Catalog number/ Clone Panel
CD8a-BV711 Biolegend 100748 53-6.7 Lymphoid
CD19-PE-Cy7 eBioscience 25-0193-82 1D3 Lymphoid
FOXP3-PerCP-Cy5.5 Invitrogen 45-5773-82 FJK-16s Lymphoid
CD3-BV605 BD Biosciences 564009 17A2 Lymphoid
IL-17A-AF647 BD Biosciences 560184 TC11-18H10 Lymphoid
IFN-γ-PE Invitrogen 12-7311-82 XMG1.2 Lymphoid
IL-4-BV421 BD Biosciences 562915 11B11 Lymphoid
CD4-APC-Cy7 Tonbo 25-0041-U100 GK1.5 Lymphoid
CD90-FITC Invitrogen 11-0909-42 eBio5E10 (5E10) Lymphoid
CD11b-PerCP-Cy5.5 BD Biosciences 550993 M1/70 Myeloid
Ly6G-FITC BD Biosciences 551460 1A8 Myeloid
Ly6C-APC-Cy7 Biolegend 128026 HK1.4 Myeloid
CD45-BUV395 BD Biosciences BDB564279 30-F11 Myeloid
PD-L1-BUV737 BD Biosciences 741877 MIH5 Myeloid
CD11c-PE-Cy7 Biolegend 117318 N418 Myeloid
MHC II-eF450 eBioscience 48-5321-82 M5/114.15.2 Myeloid
CD62L-Alexa 700 Invitrogen 56-0621-80 MEL-14 Myeloid
CX3CR1-PE Biolegend 149005 SA011F11 Myeloid
CD64-BV711 Biolegend 139311 X54-5/7.1 Myeloid
CD86-BV785 Biolegend 105043 GL-1 Myeloid
CD206-BV650 Biolegend 141723 C068C2 Myeloid
CD103-BV605 Biolegend 121433 2E7 Myeloid
CXCR4-APC Invitrogen 50-153-72 2B11 Myeloid

Human Studies
50

Diversity and taxonomic abundance comparison of the gut microbiota in the human studies:
Alpha diversity was compared between groups (by cohort, stage, response, diet and
probiotic groups) using the Wilcoxon rank-sum/Mann-Whitney U test or Wilcoxon signedrank test, as appropriate. The Kruskal-Wallis (KW) test was used when comparing more
than 2 groups. Beta diversity among groups was ordinated using Principal Coordinate
Analysis (PCoA) and centroids were compared using analysis of similarities (ANOSIM) with
999 permutations. Spearman rank correlation was used to assess associations of
continuous variables, e.g. dietary fiber intake and taxonomic abundance.
Multivariable-adjusted comparisons of alpha diversity between groups were performed using
linear regression models (R function ‘lm’) setting alpha diversity (by Inverse Simpson scale,
log transformed) as the outcome variable and reporting p-values of primary comparisons of
interest by t statistic. Adjusted community-level (beta diversity) associations according to
subgroups of interest were performed using semi-parametric kernel machine regression
framework MiRKAT (https://cran.r-project.org/web/packages/MiRKAT/MiRKAT.pdf). This
method allows for covariate adjustment using a variance-component score statistic to test
for the association with analytical p-value calculation. Confirmation of previously identified
pro-response bacterial candidates in anti-PD-1 treated patients– Firmicutes, Clostridiales,
Ruminococcaceae, and Faecalibacterium was performed by contrasting their relative
abundances between R and NR using the Wilcoxon rank sum test. Further taxonomic
discovery and adjustment was done as follows: Differential enrichment of bacterial taxa was
initially conducted between R and NR within each treatment subset using LEfSe. Pairwise
comparisons of taxonomic abundances between R versus NR across all systemic therapies
and early versus late-stage melanoma patients was done using the Wilcoxon rank sum test
followed by 1000 bootstraps. Adjusted p-values were estimated using FDR. Fold change
was estimated as the ratio of mean relative abundance of a feature within each group.
Volcano plots were generated using log2fold change on the x-axis and -log10unadjustedp51

value on the y – axis. The ‘DAtest package’ in R was used to perform differential abundance
comparisons within treatment subsets with adjustments for multiple hypothesis testing. It
ranks commonly used differential abundance tests based on their suitability for the input
dataset. The input used for these analyses were compositional count tables at all taxonomic
levels taken together except species. The workflow includes random shuffling of predictor
variables followed by spiking in of randomly chosen features that are associated with the
shuffled predictor. Scores for each test per comparison are provided in the supplemental
tables. These analyses further generate crude and adjusted p-values, effect size (log2fold
change), directionality, and test-used for every feature. For all strategies above, we only
considered those features that were present in at least 40% of all samples included in each
analysis.

Associations of dietary fiber and OTC probiotic use with clinical outcomes in the late-stage
melanoma cohort
Modeling of clinical outcome by lifestyle, clinical and demographic variables was
performed using univariate and multivariable-adjusted logistic regression and Cox
proportional hazards regression. Odds ratios and 95% CIs and p-values were computed by
R package ‘glm’ (https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/glm)
for binomial families and cross-checked with SAS command “proc logistic.” Statistical
significance was assessed by the Wald test or exact methods, as appropriate. Kaplan-Meier
curves were constructed using the R ‘survminer’ package
(https://cran.rproject.org/web/packages/survminer/survminer.pdf) and Hazard Ratios, along
with 95% CIs were generated using R package ‘Survival’
(https://cran.rproject.org/web/packages/survival/survival.pdf). Hypothesis testing was done
using both one sided and two-sided tests as appropriate at a 95% significance level.
Potential confounders or model covariables evaluated in our analysis included biological
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variables (age, sex, and BMI) and known clinicopathologic indicators of response or PFS in
melanoma patients treated with ICI. For classifications of TMB and PD-L1 categorical
covariables, missing data were retained as a separate category. Given sparse data in some
cells within our ICI treatment cohorts, each covariable was evaluated with respect to fiber
status and OTC probiotic use and then assessed one at a time in the model of response or
PFS. We additionally conducted statistical model selection using the best subset model
selection procedure (R package ‘bestglm’https://cran.rproject.org/web/packages/bestglm/bestglm.pdf) that uses an algorithm to select the best
model (or models) based on the model fit parameter Akaike Information Criteria. This
package has an option to set the limit of covariates the model can include, which we set to
two variables (again due to sample size and event rate concerns). Final models, odds ratios,
95% CIs and p-values were reported per methods above. Multivariable-adjusted models of
response and PFS, adjusted for factors associated with our exposures of interest and
clinically relevant to immunotherapy outcomes (BMI, prior ICI, TMB, and PD-L1) were also
constructed. To assess model fit and the statistical significance of the associations
observed, AIC, Wald P-value, and 95% CI were considered, as appropriate. The CochranArmitage test for trend (R “Cochran Armitage Test” function) was used assess the presence
of trend in the context of clinical response (R/NR) and the joint or combined variables (4level categorical score) of the microbiome signature (type 1/type 2) with dietary fiber intake
(sufficient/low) and with probiotic use (yes/no) according to the hypothesized order.

Software
Statistical analysis and computations were conducted in R (v3.6.1). GraphPad Prism (La
Jolla, CA) or SAS version 9.4 (Cary, NC). Heatmaps of features significantly different
between groups were created using the ‘ComplexHeatmap’ package.
Statistical analysis of tumor volume and immune from mouse experiments
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Tumor growth kinetics was compared between groups using the linear mixed-effects models
(random intercept); R package ‘lme4’. Statistical significance testing was done using the
Satterthwaite's degrees of freedom method – lmerTest package. Log2(tumor volume) was
used as the dependent variable, and assumptions of homoscedasticity and normality of
residuals were checked Data plots of tumor growth are expressed as mean or mean ± SD.
Refer to figure legends for the specific statistical tests used in each experiment. Sample
sizes were determined based on previous experience with similar experiments. Immune
populations from mouse experiments were compared by Wilcoxon rank sum for pairwise
comparisons, and KW test when comparing more than 2 groups.

Statistical analysis of RNA sequencing of CD45+ tumor infiltrating immunocytes from fiber
experiments
Genes significantly modified (FDR adjusted p value<0.05, FC < or > 2) between anti-PD1
and Isotype control groups were also determined using Partek Flow and the Enriched
Ontology Clusters were identified from the 603 genes upregulated only in mice receiving
anti-PD1 versus Isotype control and fed with high-fiber diet using Metascape software.
Dimension reduction and clustering analysis of flow cytometry data
Dimension reduction was performed using the tSNE algorithm in FlowJo version 10.6 from
clusters of interest identified using median fluorescence intensities (MFI).

Network reconstruction
The host gene expression, as well as the bacterial taxonomic (16S rDNA and shotgun) and
its functional (gene and family level) abundances from the shotgun data were relativized and
quantile normalized. In order to make a statistical model of interaction between diet,
microbiota, host genes and tumor under treatment with checkpoint inhibitor (anti-PD1), we
created a transkingdom network. First, elements (bacteria, host genes, FACS and tumor
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measurements) that differentially changed upon anti-PD1 treatment in the high-fiber diet
were selected. Next, spearman rank correlations were calculated between all pairs of
elements. To keep robust relationships interactions were selected if they had the same sign
of correlation in (i) samples on high fiber diet (ii) samples on fiber free diet (iii) samples
receiving anti-PD1 treatment (iv) samples on isotype control (not receiving anti-PD1), and (v)
samples receiving anti-PD1 treatment in the high-fiber diet. Finally, pairs were included in
the network if they satisfied principles of causality [i.e., satisfied fold change relationship
between the two partners in the anti-PD1 vs isotype comparison in high-fiber diet] and
passed FDR cutoffs (10% for within-host edges and 20% for all other edges) when metaanalysis was performed over diet [(i) and (ii)] or over treatment [(iii) and (iv)].

Inferring critical causal players
Network interrogation using bipartite betweenness centrality (BiBC) analysis was used to
identify “bottleneck” elements connecting the microbial and host gene networks to changes
in tumor. FACS measurements, host genes, and bacteria with high BiBC are more likely key
regulators of host outcomes (e.g., changes in tumor weight).
Detecting gene expression subnetworks and pathway enrichment
The networks were visualized in the Cytoscape Software 2.6.3. To identify subnetworks in
the host gene expression subnetwork, we used the MCODE v1.2 (Molecular Complex
Detection) plug-in for Cytoscape to identify clusters (subnetworks) of correlated genes. The
largest two subnetworks were selected for further functional enrichment analysis, as all other
subnetworks were representing parts of them. Pathway enrichment analysis of clusters was
performed using Metascape.

Data and materials availability
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All individual and mouse-level data and metadata necessary to reproduce the results of this
report have been deposited in dbGaP under accession numbers phs0020.
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Introduction
The human microbiome is a complex aggregate of microorganisms, and their genomes exert
a number of influences crucial to the metabolic, immunologic, hormonal, and homeostatic
function of the host. Recent work, both in preclinical mouse models and human studies, has
shed light on the impact of gut and tumor microbiota on responses to systemic anticancer
therapeutics(39, 40, 42, 43, 51-54). In light of this, strategies to target the microbiome, and
factors which influence in the microbiome upstream, to improve cancer responsiveness are
underway.
Here, we discuss and reveal key mechanisms by which microbiota may impact
treatment with immune checkpoint blockade. This work is critical to clinical medicine and
scientific research as we devise putative strategies to target the microbiome to improve cancer
responsiveness and general health.

The Gut Microbiome
The human body has coevolved with complex microbial communities (55-57) and early
environmental exposures help to shape microbial ecology during the months and years
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following birth (55, 58). These microbiota, including bacteria, viruses, fungi, and protozoa and
their collective genomes (termed the microbiome) influence overall immune function, and
thereby our general health, via a number of different mechanisms; resulting in a wide array of
responses ranging from tolerance to immune activation (59). As a result, there continues to
be a growing appreciation of the impact of microbiota at different anatomic sites on immunity,
and for different pathologic conditions, including cancer, neurodegeneration, autoimmunity,
type II diabetes and malnutrition. This area of study has been greatly facilitated by the use of
next-generation sequencing techniques, which have expanded our understanding of the
breadth and function of the microbiota beyond conventional culturing techniques.
The microbiota, within a niche, are in a constant state of flux, and homeostasis is
maintained by an ongoing and dynamic crosstalk with different arms of the immune system.
The balance is delicate, as evidenced by the fact that its disruption, termed ‘dysbiosis’, can
contribute to several chronic pathologies, including cancer (60) (Figure 3). Recently,
compelling preclinical data and translational studies in human cohorts have indicated that
aspects of the tumor as well as the gut microbiota, holistically (via overall microbial diversity
and through differential abundance of specific taxa) can modulate therapeutic efficacy and
tolerability of anticancer therapies (40, 41, 43, 61-63). While the emergence of data has been
truly eye-opening, there is also acknowledgment of the limited overlap of bacterial signatures
across cohorts, with extensive ongoing research dedicated towards delineating unifying
mechanisms. Nevertheless, there is universal acceptance of the fact that the microbiome is
accessible, resilient, and amenable to targeting, making it a highly attractive target for
therapeutic manipulation through the use of modulators such as fecal microbiota transplants,
designer bacterial consortia, and dietary supplements(64) (Table 1) .
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Figure 3 Eubiosis and Dysbiosis in the Gut. Distinct features distinguish a eubiotic, or healthy gut, from
that of a dysbiotic or unhealthy gut. (A) A eubiotic gut maintains an intact intestinal epithelium, key to absorbing
nutrients and protecting the mucous membrane against pathogenic bacteria. (B) In a dysbiotic state
(inflammation or infection) there is an increase in proinflammatory cytokines driving dendritic cells (DCs) and
T helper cells to a Th17 and Th1 silo. Additionally, dysbiosis leads to increased reactive oxygen species (ROS)
production, causing increased tissue damage, unlike in a healthy gut where tissue protection is regulated
tightly by mucosal immunity between innate and adaptive immune mechanisms. Antigen presentation by DCs
and first responder cells, such as mast cells and macrophages, drive cell-mediated immunity via Th1 cells and
immune tolerance via T regulatory cells and through the release of key cytokines such as IL-12. (C) Eubiosis
and dysbiosis are often influenced by a number of complex multifactorial components, such as environmental
factors, immune dysregulation, genetics, epigenetics, the microbiota, and general health. APC, antigen
presenting cell; DC, dendritic cell; TGF-b, transforming growth factor b; LPS, lipopolysaccharide.
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Table 1: Targeting the Gut Microbiome
Type of therapy

Target

Refs

Fecal microbiota
transplantation (FMT)

Colorectal carcinogenesis (preclinical)

[157]

Acute myeloid leukemia (clinical)

NCT02928523

Melanoma (clinical)

NCT03353402

Nondigestible
polysaccharides

SCFAs

[158]
NCT02843425
NCT02079662

Elimination of animal fats

Bacteroidales

[159]

Nonabsorbable
procyanidins

Firmicutes, Bacteroidetes,
and Akkermansia muciniphila

[160]

Caloric restriction

Firmicutes, Bacteroidetes, and A.
muciniphila

[161]
[162]

Vancomycin

Bacteroidales

[11]

Prohep

Prevention of hepatocellular
carcinomas

[163]

Designer probiotics

Microbial manipulation in cancer
patients

[164]
[165]
NCT03358511

Bacteriophages

E. coli

[166]

S. typhimurium

[167]

Diet

The Microbiota and Carcinogenesis
In order to understand the influence of the microbiota in response to cancer therapy, we must
first consider its impact on cancer development as a whole. Carcinogenesis is influenced by
a number of internal and external factors ultimately leading to uncontrolled growth of
transformed cells, and there is now clear evidence that immunoediting can modulate a prohost versus pro-tumor balance in the immune system (65). Accordingly, there is a growing
body of literature on the influence of the microbiota on cancer immunosurveillance,
demonstrating an influence on carcinogenesis at multiple putative steps and for different
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cancer types (66). The intensity as well as signatures of immune responses may be dictated
by the cross reactivity between tumor and microbial antigens, or by the stimulation of pattern
recognition receptors (PRRs) via microbe-associated molecular patterns. Furthermore,
microbes have been shown to influence carcinogenesis for different cancer types, affecting
various host factors, dictating cancer hallmarks, modulating inflammation, influencing the
genomic stability of host cells, and producing metabolites that can epigenetically regulate host
gene expression (66). A full discussion of the role of the microbiota in carcinogenesis is
admittedly beyond the scope of this thesis however, some basic knowledge can provide a
better understanding of the role of the microbiota in influencing therapeutic responses.
Numerous bacteria have been implicated in the process of carcinogenesis, including
Helicobacter pylori in the case of gastric carcinoma (67) and Fusobacterium nucleatum in the
case of colon cancer (68-72). Mechanisms through which these bacteria can induce
carcinogenesis continue to remain incompletely understood. However, several hypotheses
have been put forward regarding potential mechanisms, including a bacterial driver–
passenger model for carcinogenesis, wherein indigenous ‘driver bacteria’ can drive genomic
instability and potentiate carcinogenesis. As in the case of group B2 Escherichia coli strains,
which can induce single-stranded DNA breaks and increase mutation rates, as well as
anchorage-independent colony formation in infected cells. This can occur through the
production of colibactin (73), or enterotoxigenic Bacteroides fragilis, which can also promote
tumorigenesis through the induction of a persistent Th-17 like chronic inflammatory
response(74). Subsequently, this type of driver-passenger model can progressively diminish
in abundance leading to its replacement by opportunistic ‘passenger bacteria,’ ultimately
leading to cancer progression (75). Staphylococcus gallolyticus is another potential passenger
that is frequently encountered in the colonic tumor microenvironment (TME). Interestingly it
has the unique ability to cross differentiated epithelia leading to the formation of biofilms on
the basement membrane collagen fibers found in distorted colon wall structures (76).
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Similarly, viral pathogens such as human papillomavirus (HPV), hepatitis B virus
(HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), Kaposi sarcoma-associated
herpesvirus (KSHV), and human T cell leukemia-lymphoma virus (HTLV-1) have long been
known to be associated with human tumors (77). More recently, cytomegalovirus (CMV) was
identified in glioblastoma multiforme and Merkel cell polyomavirus (MCPyV) has been
associated with Merkel cell carcinoma (78). Together viruses can contribute to carcinogenesis
by expressing transforming proteins or noncoding RNAs that can act on cellular targets, thus
activating or repressing signaling pathways and altering cellular gene expression. Moreover,
integration of the virus DNA into the host’s genome is a hallmark of tumorigenesis for many
viruses(79).
As technology improves additional candidate ‘driver’ microbes in carcinogenesis are
likely to be identified with the use of metagenomic sequencing of premalignant lesions across
cancer types (Table 2).
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Table 2 The Influence of Common Anti-Cancer Therapeutics in The Gut, Tumor, And
Blood

Treatment type

Gut

Tumor

Systemic response

Treatment naïve

Activation of macrophage and
Normal enteric peptide granulocytes, increased DC
presentation
priming
and
CD4+ and
CD8+ infiltration

Chemotherapy

Gut dysbiosis caused
Bacterial
translocation
to
by altered ratio of gut Antitumor apoptosis effect by
lymphoid organs; increase of Th1
microbiota;
barrier Th1 and Th17 effector cells
and Th17 subset increased
disruption

Hypofractionated
radiation therapy

Strong tumor killing response
Bacterial translocation
aggregate by cytotoxic CD8+ T
caused by increased
cells
and
radiotherapy;
cell death
increased DC population seen

Molecular
targeted therapy

Increased
chloride
secretion due to crypt Tumor infiltrating myeloid cells Global inflammatory response,
damage,
barrier activate to induce CD8+ and increased
cytotoxic
killing,
disruption,
and NK+ antitumor immunity
augmented DC priming
mucositis observed

Cytokine therapy

Therapy
causes
increased
intestinal
toxicity
and
gut
shortening.
Sodium
uptake and increases in
LPS
cause
a
pathogenic
inflammatory response

Innate targeting

Bacteria
initiates
Tumor infiltrating myeloid cells
priming
of
innate
activated to induce CD8+ and
myeloid cells through
NK cells for antitumor immunity
TLR4

Increase
in
FOXP3
Treg
population, downregulation in
NFkB activation, decrease in
Th17 subsets

Systemic expansion of Treg
population in response to
increased tissue inflammation
observed

Systemic inflammatory response
Alters immune homeostasis in
leads
to
proinflammatory
the tumor increases TNFα,
cytokine response and an
apoptosis, neutrophil infiltrate.
increase in a complement
Th1 and IL-17 increase
cascade activation
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CpG activates monocyte and
macrophages to release Th1
cytokines leading to activation of
T and NK cells

Table 3 The Role of The Gut Microbiota in The Clinical Efficacy of Anticancer
Therapeutics
Cancer

Study

HCC

Zheng et al., Journal for ImmunoTherapy of
Cancer, 2019

MM

Frankel et al., Neoplasia, 2017

N =¬†

Tech.

Diversity

Results (good)

Results (bad)

aPD-1

8

MGN

Increased in R

Akkermansia muciniphila
Ruminococcaceae spp.
Bifidobacterium dentium
Dialister invisus
Coprococcus comes

Bacteroides nordii
Fusobacterium varium

aCTLA-4±aPD-1

39

MGN

No difference

Bacteroides caccae

Coriobacteriaceae

Streptococcus parasanguinis
Faecalibacterium prausnitzi

Atopobium parvulum
Acidaminococcaceae

ICI

Country

Sample

China

Stool

Texas, USA

Stool

Bacteroides

France

Stool

Texas, USA

Stool

Chicago, USA

Stool

France

Stool

Netherlands

Stool

Japan

Stool

Bacteroides thetaiotamicron
Holdemania filiformis
Dorea formicogenerans
MM

Chaput et al., Ann. Oncol., 2017

MM

MM

MM
MM

aCTLA-4

26

16S rRNA

Not adressed

Gopalakrishnan et al., Science, 2018

aPD-1

43

16S rRNA

Increased in R

Clostridiales
Ruminococcaceae
Faecalibacterium

Bacteroidales

Matson et al., Science, 2018

aPD-1

42

16S rRNA

Not adressed

Bifidobacterium longum
Roseburia intestinalis

Ruminococcus obeum
Collinsella aerofaciens
Enterococcus faecium

38

MGN

Not adressed

Faecalibacterium
Gemminger

aCTLA-4±aPD-1

25

MGN

No difference

Streptococcus parasanguinis
Bacteroides massiliensis
Akkermansia muciniphila

Coutzac et al., Nature Communications, 2020 aCTLA-4
Wind et al., Melanoma Research, 2020

Faecalibacterium prausnitzii
Unclassified
Ruminococcaceae
Clostridium XIVa
Blautia

Peptostreptococcaceae

NSCLC/gastric

Fukuoka et al., ASCO, 2018

aPD-1

38

16S rRNA

Increased in R

Clostridiales

NSCLC/RCC

Routy et al., Science, 2018

aPD-1

100

MGN

NA

Firmicutes
Akkermansia muciniphila
Alistipes indistinctus

Parabacteroides distasonis
Bacteroides nordi

France

Stool

NSCLC

Jin et al., Journal of Thoracic Oncology, 2019 aPD-1

37

16S rRNA

Increased in R

Alistipes putredinis
Bifidobacterium longum
Prevotella copri

Ruminococcus unclassified

China

Stool

NSCLC

Katayama et al., Transl Lung Cancer Research
2019
aPD-1

17

16S rRNA

NA

Lactobacillus
Clostridium
Syntrophococcus

Bilophila
Sutterella

Japan

Stool

aPD-(L)1
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16S rRNA

Increased in R

Clostridiales

Ruminococcaceae UCG 13

Japan

Stool

NSCLC

Hakozaki et al., ASCO, 2020

NSCLC

Song et al., Thorac Cancer., 2020

aPD-1
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MGN

Increased in R

Parabacteroides
Methanobacteriaceae

Veillonella
Selenomonadales
Negativicutes

China

Stool

NSCLC

Botticelli J Transl Med. 2020

a-PD-1

11

NA

NA

Propionate
Butyrate
Lysine
Nicotinic acid

2-Pentanone
Tridecane

Italy

Stool

Riquelme et al., Cell, 2019

Surgery

43

16S rRNA

Increased in R

Pseudoxanthomonas
Saccharopolyspora
Streptomyces

n/a

Jang et al., International Journal of Radiation
Oncology ‚ Biology ‚Physics (2020)
Preoperative Chemoradiation
45
16S rRNA

Increased in R

Duodenibacillus massiliensis

Bacteroidales
Erysipelotrichaceae
bacterium_2_2_44A
Clostridium hathewayi
Clostridium clostridioforme

PC

Rectal cancer
RCC

RCC

Derosa et al., European Urology, 2020

aPD-1

58

MGN

Increased in R

Akkermansia muciniphila
Bacteroides salyersiae
Eubacterium siraeum

Agarwal et al., JCO, 2020

aPD-1
aPD-1

22
52

16S rRNA
NA

Increased in R
NA

Akkermansia muciniphila
Acetic acid
Propionic acid
Butyric acid
Valeric acid

Chemotherapy/
immunotherapy

26

MGN

Increased in R

Bacteroides xylanisolvens
Bacteroides ovatus
Prevotella copri
Alistipes spp.

Solid Cancers

Nomura et al., JAMA Netw Open. 2020

Solid Cancers

Heshiki et al., Microbiome, 2020
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Clostridium symbiosum
Ruminococcus gnavus

Tumor

Korea

Stool

France

Stool

USA
Japan

Stool
Stool

NA

Stool
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Figure 4 The Gut Microbiome and its Response to Cancer Therapy is Multidimensional and Complex in its Makeup. There are several mechanisms which influence response
to anticancer therapeutics. This key figure demonstrates this intricate relationship at the level of the gut (brown), the tumor (orange), and systemically in the blood (red) across
multiple treatments: chemotherapy, radiation, molecularly targeted therapy, cytokine-based therapy, checkpoint inhibitors, adoptive cell therapy, and agents that target innate
immunity. CAR, chimeric antigen receptor engineered cell; DC, dendritic cells; ECM, extracellular matrix; mAB, monoclonal antibodies; mAPC, mature antigen presenting cells;
MDSC, myeloid-derived suppressor cells; NK, natural killer cells; TCR, T cell receptor engineered cell; TIL, tumor infiltrating cells; TLR, toll-like receptors; Treg, T regulatory cells.

The Influence of The Gut Microbiome on Anti-Cancer Therapy
While we have begun to appreciate the role of gut microbiome in driving carcinogenesis, we
also have a deeper understanding surrounding how the gut microbiome may influence cancer
responsiveness. Moreover, there are several mechanisms thought to control how the gut
microbiome may influence such responses (40, 51, 53, 74, 80, 81). Additionally, it is becoming
increasingly clear that there is a complex bidirectional relationship between the gut
microbiome and anticancer therapies; including, but not limited to, chemotherapy, radiation,
molecularly targeted therapy, cytokine-based therapy, checkpoint inhibitors, adoptive cell
therapy (ACT), and agents that target innate immunity (Table 3, Figure 4).

Figure 5. Notable bacteria associated with improved anti-cancer response. Discoveries made in the last
decade that demonstrated that the composition of the intestinal microbiota influences the effectiveness of
anticancer agents and regulates tumor immunosurveillance. Key regulatory bacteria associated with tumor control
during treatment with immunotherapy are noted in this figure.
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Notwithstanding, the reproducibility seen in the studies discussed above are not
universal across tumor types and the reason remains elusive. While numerous studies have
exposed the robust ability of the microbiome to regulate the anti-tumor response of the
immune system in the context of immune checkpoint blockade (43, 46). The ability to
potentiate this response from the level of the gut to the periphery in humans has not been well
studied. To better understand how the distinct composition of the gut microbiome works with
host immunity in the context of treatment with immune checkpoint blockade we prospectively
collected microbiome and immune data from metastatic melanoma patients treated with
immune checkpoint blockade anti-PD-1.
While this work does not undertake a deep exploration of the distinct cellular
mechanisms which drive ICB, it is an important piece of this story. A more comprehensive
understanding of immune checkpoint inhibitors in mouse and human studies are likely to
provide further insights not just on how to improve response to response to immunotherapy
but how we might better leverage host immunity through the gut microbiota (82-85).

Higher gut microbiome diversity is associated with improved response to
anti-PD-1 immunotherapy in patients with melanoma
To better understand the role of the microbiome in response to immune checkpoint blockade,
we prospectively collected microbiome samples from patients with metastatic melanoma
starting treatment with anti–PD-1 therapy (n = 112 patients) (Supplemental Figure S3.1,
Supplemental Table S1). Oral (buccal) and gut (fecal) microbiome samples were collected
at treatment initiation, and tumor biopsies and blood samples were collected at matched
pretreatment time points when possible, to assess for genomic alterations as well as the
density and phenotype of tumor-infiltrating and circulating immune cell subsets (Figure 6).
Taxonomic profiling using 16S ribosomal RNA (rRNA) gene sequencing was performed on all
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available oral and gut samples, with metagenomic whole-genome shotgun (WGS) sequencing
performed on a subset (n = 25). Eligible patients (n = 89) were classified as responders (R, n =
54) or non-responders (NR, n = 35) on the basis of radiographic assessment using the
response evaluation criteria in solid tumors (RECIST 1.1)(86) at 6 months after treatment
initiation. Patients were classified as R if they achieved an objective response (complete or
partial response or stable disease lasting at least 6 months) or NR (progressive disease or
stable disease lasting less than 6 months). This classification accounts for the subset of
patients who may derive long-term disease benefit despite not achieving a bona fide RECIST
response and has been used in numerous published studies of patients on checkpoint
blockade (11, 15, 30, 50). Of note, patients in R and NR groups were similar with respect to
age, gender, primary type, prior therapy, concurrent systemic therapy, and serum lactate
dehydrogenase (Supplemental Table S3.2). Prior genomic analyses have demonstrated that
patients with tumors that have a higher mutational load are more likely to respond to anti–
CTLA-4 (12, 15) or anti–PD-1 therapy (12, 14, 21); however, a high mutational load alone
appears neither sufficient nor essential for response.
We first assessed the landscape of the oral and gut microbiome in all available
samples in patients with metastatic melanoma using 16S sequencing (n = 112), noting that
both communities were relatively diverse with a high abundance of bacteria of the order
Lactobacillales in the oral microbiome and Bacteroidales in the fecal microbiome (Fig 6B).
Data analysis suggested that a clear separation of community structure between the oral and
fecal microbiomes suggesting that these communities are distinct in terms of their
compositional structure. Loss of microbial diversity (dysbiosis) is associated with chronic
health conditions (46, 87, 88) and cancer (89-91) and is also associated with poor outcomes
of certain forms of cancer therapy, including allogeneic stem cell transplant (46). Based on
these data, we examined the diversity of the oral and gut microbiomes in eligible patients on
anti–PD-1 therapy and found that alpha diversity, or within-sample diversity, of the gut
68

microbiome was significantly higher in R (n = 30) compared to NR (n = 13) using several
indices (P < 0.01; Fig. 6C and Fig. S3.3). We then tested the relationship of diversity and
progression-free survival (PFS) in our cohort by stratifying patients based on tertiles of inverse
Simpson scores, demonstrating that patients in the highest tertile of fecal alpha diversity had
significantly prolonged PFS compared to those with intermediate or low diversity (P = 0.02
and 0.04, respectively; Fig. 6D, E).
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Figure 6 Higher gut microbiome diversity is associated with improved response to anti–PD-1
immunotherapy in patients with metastatic melanoma (A) Schema of sample collection and analyses. (B)
Stacked bar plot of phylogenetic composition of common bacterial taxa (>0.1% abundance) at the order level
in oral (n = 109, top) and fecal (n = 53, bottom) samples by 16S rRNA sequencing. (C) Inverse Simpson
diversity scores of the gut microbiome in R (n = 30) and NR (n = 13) to anti–PD-1 immunotherapy by MannWhitney U rank sum (MW) test. Error bars represent the distribution of diversity scores. (D) Phylogenetic
composition of fecal samples (n = 39) at the family level (>0.1% abundance) at baseline. High [blue, >11.63
(inverse Simpson score), n = 13], intermediate (gold, 7.46 to 11.63, n = 13), and low (red, <7.46, n = 13)
diversity groups were determined using tertiles of inverse Simpson scores. (E) Kaplan-Meier (KM) plot of PFS
by fecal diversity: high (median PFS undefined), intermediate (median PFS = 232 days), and low (median PFS
= 188 days). High versus intermediate diversity (HR 3.60, 95% CI 1.02 to 12.74) and high versus low (HR 3.57,
95% CI 1.02 to 12.52) by univariate Cox model. (F) Principal coordinate analysis of fecal samples (n = 43) by
response using weighted UniFrac distances. *P < 0.05; **P < 0.01.
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Compositional Differences in The Gut Microbiome Are Associated with
Responses to Anti-PD-1 Immunotherapy
Because compositional differences in the microbiome
may also influence cancer development and response
to therapy (39, 51, 92, 93), we sought to determine if
differences existed in the gut microbiomes of R and NR
to anti–PD-1 therapy. To test this, we first compared an
enrichment of operational taxonomic units (OTUs) in R
versus NR, demonstrating that distinct sets of rare low
abundance OTUs were associated with response to
anti–PD-1 therapy, with enrichment of orders
Clostridiales in R and Bacteroidales in NR in the gut
microbiome (P < 0.01; Fig. 7A).
To further explore these findings, we performed high-

Figure 7A) Taxonomic cladogram from LEfSe
showing differences in fecal taxa. Dot size is
proportional to the abundance of the taxon.
Letters correspond to the following taxa: (a)
Gardnerella vaginalis, (b) Gardnerella, (c)
Rothia, (d) Micrococcaceae, (e) Collinsella
stercoris, (f) Bacteroides mediterraneensis, (g)
Porphyromonas pasteri, (h) Prevotella
histicola, (i) Faecalibacterium prausnitzii, (j)
Faecalibacterium, (k) Clostridium hungatei, (l)
Ruminococcus bromii, (m) Ruminococcaceae,
(n) Phascolarctobacterium faecium, (o)
Phascolarctobacterium, (p) Veilonellaceae, (q)
Peptoniphilus, and (r) Desulfovibrio alaskensis

dimensional class comparisons using linear
discriminant analysis of effect size (LEfSe) (31), which
again demonstrated differentially abundant bacteria in
the fecal microbiome of R versus NR in response to
anti–PD-1 therapy; with Clostridiales order and
Ruminococcaceae family enriched in R and
Bacteroidales order enriched in NR (Fig. 7B).
We next asked whether bacterial composition
and abundances within the gut microbiomes of patients
were associated with a specific treatment outcome to
anti–PD-1 therapy. We found that patients
segregated into two distinct community types. Type 1
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Figure 7B) Linear discriminant analysis
(LDA) scores computed for differentially
abundant taxa in the fecal microbiomes of R
(blue) and NR (red). Length indicates effect
size associated with a taxon. P = 0.05 for the
Kruskal-Wallis H statistic; LDA score > 3.

was composed entirely of R and was enriched for Clostridiales, whereas type 2 comprised a
mixture of R and NR (P = 0.02) and was enriched for Bacteroidales (Fig. 7C).
To explore how specific bacterial taxa affect patient treatment response, we
compared PFS following anti–PD-1 therapy as it related to the “top hits” that were
consistently observed across our analyses. From the Ruminococcaceae family of the
Clostridiales order, we focused on the Faecalibacterium genus in R and Bacteroidales order
in NR and stratified patients into high versus low categories on the basis of the median
relative abundance of these taxa in the gut microbiome. Patients with high Faecalibacterium
abundance had a significantly prolonged PFS versus those with a low abundance (P =
0.03). Conversely, patients with a high abundance of Bacteroidales had a shortened PFS

Figure 7C Unsupervised hierarchical clustering by complete linkage of Euclidean distances by crOTU abundances in 43 fecal
samples. Bottom: Stacked bar plot of relative abundances at the order level by crOTU community type. Fig 2D Comparison
KM plot PFS curves by log-rank test in patients with high abundance (dark blue, n = 19, median PFS = undefined) or low
abundance (light blue, n = 20, median PFS = 242 days) of Faecalibacterium (top PFS curve) or with high abundance (dark
red, n = 20, median PFS = 188 days) or low abundance (light red, n = 19, median PFS = 393 days) of Bacteroidales (bottom
PFS curve).
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compared to that of those with a low abundance (P = 0.05, Fig. 7D). This is in line with
published data on anti-CTLA-4 blockade, where patients with a higher abundance of
Faecalibacterium had a prolonged PFS compared to those with a higher abundance of
Bacteroidales in the gut microbiome(94).

The Gut Microbiome Shapes Systemic and Antitumor Immunity
Next, we sought to gain insight into the mechanism through which the gut microbiome may
influence response to anti–PD-1 therapy. There is clear evidence in preclinical models that
differential composition of the gut microbiome may influence therapeutic responses to anti–
PD-1 therapy at the level of the tumor microenvironment (39); thus, we next examined the
relationship between the gut microbiota and systemic and antitumor immune responses in our
cohort of patients on anti–PD-1 therapy. We compared the tumor-associated immune
infiltrates using multiparameter immunohistochemistry (IHC) and observed a higher density of
CD8+ T cells in baseline samples of R versus NR (P = 0.04), consistent with prior reports (Fig.
8A and Fig. S3.4) (28, 30).
Pairwise comparisons using Spearman rank correlations were then performed
between specific bacterial taxa enriched in the gut microbiome of R and NR and immune
markers in the tumor microenvironment, demonstrating a statistically significant positive
correlation between the CD8+ T cell infiltrate in the tumor and abundance of the
Faecalibacterium genus, the Ruminococcaceae family, and the Clostridiales order in the gut
and a nonsignificant but negative correlation with Bacteroidales (Fig. 8B,C, and Figs.
S3.5,S3.6). No associations were seen between CD8+ T cell density and diversity or crOTU
community type membership (Fig. S3.7). Analysis of systemic immune responses using flow
cytometry and cytokine assays revealed that patients with a high abundance of Clostridiales,
Ruminococcaceae, or Faecalibacterium in the gut had higher frequencies of effector CD4+
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and CD8+ T cells in the systemic circulation with a preserved cytokine response to anti–PD1 therapy, whereas patients with a higher abundance of Bacteroidales in the gut microbiome
had higher frequencies of regulatory T cells (Tregs) and myeloid-derived suppressor cells
(MDSCs) in the systemic circulation, with a blunted cytokine response (Fig. 8D and Figs.
S3.8,S3.9).
To better understand the influence of compositional differences in the gut microbiome
on antigen processing and presentation within the tumor microenvironment, we next
performed multiplex IHC targeting the myeloid compartment(95). In these studies, patients
with a high abundance of Faecalibacterium in the gut microbiome had a higher density of
immune cells and markers of antigen processing and presentation compared to that of
patients with a high abundance of Bacteroidales (Fig. 8E,F and Figs. S3.10, S3.11),
suggesting a possible mechanism through which the gut microbiome may modulate antitumor
immune responses (12), though this must be validated in a larger cohort.
To investigate a causal link between a “favorable” gut microbiome and response to
immune checkpoint blockade, we performed fecal microbiota transplantation (FMT)
experiments in germ-free recipient mice (Fig. 8G). In these studies, mice that were
transplanted with stool from responders to anti–PD-1 therapy (R-FMT) had significantly
reduced tumor size (P = 0.04; Fig. 8H and Fig. S3.12.A) by day 14 compared to those
transplanted with stool from NR (NR-FMT). Importantly, mice transplanted with R-FMT stool
also exhibited improved responses to anti–PD-L1 (PD-1 ligand 1) therapy (Fig. 8I) in contrast
to mice that were transplanted with stool from NR (NR-FMT).
Next, we performed 16S sequencing on fecal samples collected from mice treated with
FMT, demonstrating that mice transplanted with R-FMT stool also had significantly higher
abundance of Faecalibacterium in their gut microbiome (P < 0.01) (Fig. S3.14). We also
wanted to better understand the mechanism through which the gut microbiome may influence
systemic and antitumor immune responses, and so we performed correlative studies on
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tumors, peripheral blood, and spleens from these mice. These studies demonstrated that
tumors of mice receiving R-FMT stool had a higher density of CD8+ T cells than mice receiving
NR-FMT, consistent with human data (Fig. 8J and Fig. S3.12.B). Analysis of CD45+ myeloid
and lymphoid tumor-infiltrating cells by flow cytometry confirmed this result (Fig. S3.12.C).
Moreover, FMT from R locally increased the number of CD45+ immune and CD8+ T cells in
the gut compared to FMT from NR (Fig. 8K and Fig. S3.12.B).
Mass cytometry analysis using t-distributed stochastic neighbor embedding dimension
reduction was performed on tumors from mice and demonstrated up-regulation of PD-L1 in
the tumor microenvironment of mice receiving R-FMT versus NR-FMT stool (Fig. S3.12.D),
suggesting the development of a “hot” tumor microenvironment. Further phenotypic studies of
tumor immune infiltrates revealed a significant enrichment of innate effector cells (expressing
CD45+CD11b+Ly6G+) in mice receiving R-FMT stool (Fig. S3.12.E). A lower frequency of
suppressive myeloid cells (expressing CD11b+CD11c+) was observed in mice receiving RFMT stool compared to that of mice receiving NR-FMT (Fig. S3.12.F). Finally, an increase in
the frequency of RORγT+ T helper 17 cells in the tumor was also detected in mice
transplanted with NR-FMT stool (Fig. S3.12.G), in line with what we observed in tumors from
patients who failed to respond to anti–PD-1 therapy. Mice receiving NR-FMT stool also had
higher frequencies of regulatory CD4+FoxP3+ T cells (Fig. S3.12.H) and CD4+IL-17+ T cells
(Fig. S3.12.I) in the spleen, suggesting impaired host immune responses.
Given that this primary data suggested that a more “favorable” gut microbiome is
associated with a higher density of CD8+ T cells in the tumor, and more effector T cells in the
periphery, we sought to better understand how various compositions of the gut microbiome
influenced host immunity. To do this we utilized mass cytometry to comprehensively profile
changes in tumor immune infiltrates, across two distinct microbiome composition types,
following treatment with immune checkpoint blockade in patients with melanoma. The
resulting CyTOF data were analyzed using t-SNE dimension reduction and clustering
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approaches identified unique immune cell populations in responder and non-responder
classified patients. Preliminary data showed that responders to anti-PD-1 who have a more
favorable microbiome also had an increased frequency of tumor infiltrating B-cell and CD4+
T-cell populations versus non-responders. In contrast, non-responders who had an
unfavorable microbiome phenotype were found to have a higher frequency of myeloid
suppressive and T regulatory immune cell population. These respective cell types are in line
with previous research that suggests increased B cells and CD4+ T cell population are
associated with tumor regression, where tumor growth was often associated with increased T
regulatory cells and myeloid populations (Fig 9A, B) (41, 50, 96-99).
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Figure 8 A favorable gut microbiome is associated with enhanced systemic and antitumor immunity. (A)
Quantification by IHC of the CD8+ T cell infiltrate at pretreatment in tumors in R (n = 15, blue) and NR (n = 6, red) by onesided MW test. Error bars represent the distribution of CD8+ T cell densities. (B) Pairwise Spearman rank correlation
heatmap of significantly different taxa in fecal samples (n = 15) at baseline and CD3, CD8, PD-1, FoxP3, Granzyme B, PDL1, and RORγT density in matched tumors. (C) Univariate linear regression between CD8+ T cell density in counts per
mm2 in the tumor versus Faecalibacterium [blue, coefficient of determination (R2) = 0.42, P < 0.01] and Bacteroidales
(red, R2 = 0.06, P = 0.38) abundance in the gut. (D) Pairwise Spearman rank correlation heatmap between significantly
different fecal taxa and frequency of indicated cell types by flow cytometry in peripheral blood at baseline. mDC, myeloid
dendritic cell. (E) Representative multiplex IHC images and (F) frequency of various immune cell types in patients having
high Faecalibacterium (n = 2) or Bacteroidales (n = 2) in the gut. In (E), rectangles identify magnified region. MHC II, major
histocompatibility complex II. (G) Experimental design of studies in germ-free (GF) mice. Time in days (indicated as D)
relative to tumor injection (2.5 × 105 to 8 × 105 tumor cells). PO, per os (orally); BP, BRAFV600E/PTEN–/–; s.c., subcutaneous;
IP, intraperitoneal. (H) Difference in size by MW test of tumors at day 14, implanted in R-FMT (blue) and NR-FMT mice
(red), expressed as fold change (FC) relative to average tumor volume of control GF mice. Data from two independent FMT
experiments (R-FMT, n = 5, median FC = 0.18; NR-FMT, n = 6, median FC = 1.52). (I) Representative tumor growth curves
for each GF mouse from anti–PD-L1 treated R-FMT (blue, n = 2, median tumor volume = 403.7 mm3), NR-FMT (red, n = 3,
median tumor volume = 2301 mm3), and control (black, n = 2, median tumor volume = 771.35 mm3) mice. Statistics are as
follows: P = 0.20 (R-FMT versus NR-FMT) and P = 0.33 (NR-FMT versus control) by MW test. Dotted black line marks
tumor-size cutoff for anti–PD-L1 treatment (500mm3). (J) Quantification of CD8+ density in tumor of R-FMT [n = 2, median =
433.5 cells/high-power field (HPF) across 12 regions], NR-FMT (n = 2, median = 325 cells/HPF across 12 regions), and
control mice (n = 2, median = 412 cells/HPF across 9 regions). MW test P = 0.30 (R-FMT versus control). (K) Quantification
of CD8+ density in gut R-FMT (n = 2, median = 67 cells/HPF across 7 regions), NR-FMT (n = 2, median = 24 cells/HPF
across 5 regions), and control (n = 2, median = 47 cells/HPF across 10 regions). MW test P = 0.17 (R-FMT versus control).
*P < 0.05; **P < 0.01; ****P < 0.0001.
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Figure 9 Composition of the microbiome
A)
profiling of tumor infiltrating T cell
populations following checkpoint blockade. t-SNE plot of mass cytometry analyses of patient tumor samples treated with
anti-PD1, infiltrates overlaid PhenoGraph identified clusters. B-C) Cluster frequency of human melanoma in B) tumor
infiltrating C) peripheral blood. D) Respective color coding of human samples (Red, Blue, Green) E) Phylogenic
composition of OTUs within each set at the order level, enriched in R (favorable)-blue, NR (unfavorable)-red, NR
(favorable)-green
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Summary
Our results indicate that the gut microbiome may modulate responses to anti–PD-1
immunotherapy in melanoma patients. We propose that patients with a favorable gut
microbiome

(for

example,

high

diversity

and

abundance

of

Ruminococcaceae

and Faecalibacterium) have enhanced systemic and antitumor immune responses mediated
by increased antigen presentation and improved effector T cell function in the periphery and
the tumor microenvironment. By contrast, patients with an unfavorable gut microbiome (for
example, low diversity and high relative abundance of Bacteroidales) have impaired systemic
and antitumor immune responses mediated by limited intratumoral lymphoid and myeloid
infiltration and weakened antigen presentation capacity. These findings highlight the
therapeutic potential of modulating the gut microbiome in patients receiving checkpoint
blockade immunotherapy and warrant prompt evaluation in cancer patients through clinical
trials.
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CHAPTER 4: EVALUATING THE IMPACT OF
DIETARY HABITS AND PROBIOTICS ON HOST
IMMUNITY AND THE GUT MICROBIOME
Introduction
Treatment with immune checkpoint blockade has revolutionized cancer therapy (100) and the
impact of the gut microbiome on therapeutic response has now been demonstrated in
numerous human cohorts and in preclinical models (41-43, 101). Several environmental
factors have been known to shape features of the microbiome in large studies of cancer-free
populations including diet (102, 103) and medication use (104, 105), with heritability
accounting for <10% of variation (106). However, the impact of these factors on
immunotherapy response in cancer patients, and in general health, remains unclear
(Appendix A1).

Associations of Diet with Response to Melanoma Therapy
To address this, we profiled the gut (fecal) microbiome in a large cohort of melanoma patients
(n=312) including early-stage melanoma patients (Stage I and II, n=39) as well as late-stage
melanoma patients (Stage III and IV, n=273) (Figures 10A and 10B). A subset of patients
completed assessments of dietary habits and OTC probiotic use at start of systemic therapy
(n=105), and we examined associations of these factors with microbiome characteristics and
therapeutic response (86). Patients who received systemic therapy for advanced melanoma
underwent radiographic assessment and were classified as responders (complete or partial
response or stable disease ≥6 months, R; n=128) versus non-responders (stable disease < 6
months or progressive disease, NR; n=74) using Response Evaluation Criteria in Solid
Tumors (RECIST 1.1) (86). Patient demographic, clinical, and treatment characteristics, as
well as self-reported dietary habits, antibiotic and probiotic use were assessed (107).
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Given the established and strong links between antibiotic use and both the gut
microbiome and immunotherapy outcomes (42, 108, 109), we carefully considered antibiotics
use in our analyses of diet and OTC probiotics. In addition, gut microbiome profiles from the
melanoma patient cohort (n=312) were broadly compared to those of a cohort of healthy
individuals (103) [n=194, American Gut Project (AGP); Figure 10A]. We first examined the
diversity and composition of the gut microbiome between R and NR in our expanded cohort
of patients with late-stage melanoma treated with immune checkpoint blockade (PD-1 +/CTLA-4 blockade based) and/or targeted/other therapy (Figure 10B). Consistent with our
previously published findings in anti-PD-1 treated patients (41), higher alpha diversity of the
gut microbiome was associated with response to therapy when all the patients were pooled
across all treatment types (p=0.04; NR=74, R=128; Figure 10C, S4.1), as well as the subsets
of patients treated with anti-PD-1 (p=0.02; NR=42, R=66) or all immunotherapies (anti-PD1
and/or anti_CTLA4) (p=0.01; NR=64, R=106; Fig S2) were analyzed separately.
Taxonomic differences were also observed between R vs. NR across multiple
treatment types (Figure 10D). Additionally, we confirmed candidate response-associated
bacterial taxa from our prior report, including Firmicutes (p=0.02), Clostridiales (p=0.007),
Ruminococcaceae (p=0.004), and Faecalibacterium (p=0.005) for anti-PD-1 treated patients
(NR=42, R=66; Fig S4.3). New candidate taxa associated with response were also detected
in the anti-CTLA4, anti-PD-1, and targeted-therapy subsets (Fig S4.2).
Next, we compared the diversity and composition of the gut microbiome in melanoma
patients with early- versus late-stage disease to a cohort of healthy individuals (41). Notably,
age, sex and body mass index (BMI) were similarly distributed between the melanoma and
healthy cohorts, and neither the diversity nor community structure of the gut microbiome
significantly differed by these potential confounders in the melanoma cohort (Fig S4.4). In
these analyses, significant differences in the community structure of the gut microbiome were
noted between melanoma patients (n=312) and healthy individuals (n=194), with distinct
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clustering upon ordination of Bray-Curtis beta-diversity (p=0.001; Figure 10E, Fig S4.5), a
difference that remained consistent following adjustment for potential confounders (p=0.003).
No significant differences in alpha diversity were observed between the cohorts (p=0.31;
Figure 10F, Fig S4.6; age, sex, and BMI- adjusted p=0.08).
When comparing the community structure of patients with early- versus late-stage
melanoma, no differences were observed in Bray-Curtis beta-diversity (p=0.53; earlystage=39, late-stage=273; Figure 10G, Fig S4.7). However significant differences were noted
with regard to alpha diversity, with patients with early-stage melanoma demonstrating a higher
diversity of the gut microbiome when compared to patients with late-stage melanoma (p=0.02;
Figure 10H, Fig S4.8; age, sex, and BMI-adjusted p=0.03). Taxonomic differences in the gut
microbiota were also noted between patients with early- vs. late-stage melanoma (Fig S4.9).
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Figure 10. Characteristics of the gut microbiome in expanded melanoma patient cohort
and healthy individuals.
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Figure 10. Characteristics of the gut microbiome in expanded melanoma patient cohort and
healthy individuals. (A) Schema of human study design. (B) Pie chart of systemic therapy types in
late-stage melanoma patients (n=262). (C) Differences in alpha diversity between NR (n=74) and R
(n=128) by Inverse Simpson index (p=0.04 [above] by Wilcoxon rank sum test; age, sex and BMIadjusted p=0.16 by linear regression). (D) 670 Volcano plot depicting pair wise comparisons of relative
abundances of bacterial taxa by Wilcoxon rank sum test between NR (n=74) and R (n=128) to systemic
therapy. (E) Beta diversity plot comparing melanoma patients (n=312) and AGP healthy controls
(n=194). Ordination of Bray-Curtis beta-diversity dissimilarity [Analysis of similarity (ANOSIM) p=0.001
[above]; age, sex, and BMI-adjusted p=0.003 by MiRKAT) and (F) Alpha diversity by Inverse Simpson
index between healthy AGP subjects (n=194) and melanoma patients (n=312) (p=0.31 [above] by
Wilcoxon rank sum test; age, sex, and BMI-adjusted p=0.08 by linear regression). (G) Beta-diversity
plot comparing early (n=39) and late-stage (n=273) melanoma patients. Ordination of Bray-Curtis betadiversity dissimilarity (ANOSIM p=0.53 [above]; age, sex, and BMI-adjusted p=0.26 by MirKAT). (H)
680 Alpha diversity by Inverse Simpson index between early (n=39) and late-stage (n=273) melanoma
patients (p=0.02 [above] by Wilcoxon rank sum test; age, sex, and BMI-adjusted p=0.14 by linear
regression).
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Diet Influences Host Immunity and The Gut Microbiome
We then interrogated the relationship between the gut microbiome and patients’ self-reported
dietary habits with a particular focus on dietary fiber intake given the critical impact of diet on
the gut microbiome (102, 110-112), as well as the known association of previously identified
bacteria in responders with fiber fermentation(113-115). Patients completed the National
Cancer Institute Dietary Screener Questionnaire (NCI-DSQ)(107), and responses were
scored according to standard procedures to derive the total estimated intake of dietary fiber
and the major contributing food groups (fruit, vegetables and legumes, and whole grains).
Dietary fiber intake was categorized according to the distribution of reported intake within our
cohort (Fig S4.10) with low or insufficient fiber intake defined at a threshold of less than 20
g/day and sufficiently high fiber intake at or above 20 g/day. We assessed whether patient
characteristics (including key clinicopathologic factors) varied by dietary fiber intake, and
noted that low fiber consumers had slightly higher BMI but were otherwise similar with regard
to other variables, including age, sex, stage, melanoma subtype, serum lactate
dehydrogenase (LDH), antibiotics use, prior checkpoint therapy, tumor mutational burden
(TMB), and PD-L1 expression.
In these studies, we observed significant differences in the community structure of
patients with low vs. sufficient dietary fiber intake as measured by Bray-Curtis beta diversity
(p=0.03; low=50, sufficiently high=14; Figure 11A, Fig S4.11; BMI-adjusted p=0.06). No
differences in alpha diversity were observed between low vs. sufficient fiber groups (Fig
S4.12), which is consistent with findings from other human studies (116). We then analyzed
associations of dietary fiber intake with the relative abundance of candidate response and onresponse associate bacteria based on our prior published studies (41). Positive correlations
were noted between intake of fiber, whole grains, fruits and vegetables and responseassociated commensals such as Firmicutes, primarily driven by Ruminococcaceae, and
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negative correlations were noted with Bacteroidales, Bacteroides, and Proteobacteria (n=64;
Figure 11B), which have been inversely associated with immunotherapy response (41).
Following this, we examined dietary fiber intake in relation to therapeutic response,
demonstrating a lower proportion of responders to anti-PD-1 therapy in low (n=25; 32% R)
versus sufficient (n=13; 69% R) fiber consumers (p=0.04; Figure 11C). Notably, the odds of
responding to anti-PD- 1 therapy in patients who reported consuming a low fiber diet relative
to a sufficiently high fiber diet were nearly 1 to 5 (n=38; OR=0.21, 95% CI=0.05-0.84; Table
S4.11). Importantly, the magnitude and direction of the effect remained consistent with
adjustment for other clinicopathologic and patient factors, including TMB and PD-L1, among
other factors known to impact immunotherapy response (TMB and PD-L1 adjusted OR=0.15,
95% CI=0.02-0.80). We then probed the relationship between low versus sufficient dietary
fiber intake in the setting of the microbiome signature, as previously defined by a cohortspecific threshold abundance of response-related candidate taxa (41). In looking at the trend
of response across fiber status and the type 1 (above the threshold/favorable) or type 2 (below
the threshold/unfavorable) signature, we noted the proportion of responders was highest in
individuals with both sufficient dietary fiber intake and the Type-1 signature (75% R), and
lowest among those with a Type-2 signature and low fiber intake (20% R) (Cochran-Armitage
Ptrend=0.007; n=38; Figure 11D).
To expand upon this, we also assessed the relationship between fiber intake and
progression-free survival (PFS), which was consistent with the response findings, revealing
patients with low fiber diets had a greater risk of progression on anti-PD-1 (p=0.05; Figure
11E) even after adjustment for other important clinicopathologic factors (TMB and PD-L1
adjusted HR = 3.29, 95% CI= 1.03-10.40).
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Figure 11. Associations of dietary fiber intake with features of the gut microbiome and
response to therapy in late-stage melanoma patients and murine models.
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Figure 11. Associations of dietary fiber intake with features of the gut microbiome and response
to therapy in late-stage melanoma patients and murine models. (A) Ordination of Bray-Curtis betadiversity dissimilarity comparing low (n=50) vs. sufficiently high (n=14) dietary fiber status among latestate patients going on to systemic therapy, excluding recent antibiotic users (ANOSIM p=0.03 [above];
BMI-adjusted p= 0.06 by MirKAT). (B) Heatmap representing Spearman correlations of dietary fiber
and fiber-rich food groups with bacterial taxa in late-stage patients on systemic therapy, excluding
recent antibiotic users (n=64). (C) Stacked bar plot showing proportions of late-stage patients who
responded to PD-1 therapy by low (n=25, 32% R) versus sufficiently high (n=13, 69% R) dietary fiber
intake with corresponding Fisher’s exact test p-value (p=0.04 [above]; n=38). Low versus sufficiently
high dietary fiber intake associated with lower odds of response to anti-PD1 therapy (OR=0.15,
95%CI=0.02-0.80; TMB and PD-L1-adjusted OR=0.21, 95%CI=0.05-0.84). (D) Stacked bar plot
showing proportions of patients who responded to PD1 by fiber and microbiome signature group - Type
2 low fiber (n=10, 20% R), Type 2 sufficiently high fiber (n=5, 60% R), Type 1 low fiber (n=15, 40% R),
type 1 sufficiently high fiber (n=8, 75% R) (p=0.007 by Cochran-Armitage test for trend). (E)KaplanMeier plot comparing progression-free survival intervals of anti-PD-1 cohort by fiber status (n=38,
p=0.05 [above] by Log-Rank test). Low versus sufficiently high dietary fiber intake associated with lower
PFS in PD1 patients (n=38; HR=2.80, 95%CI=0.94-8.50; TMB and PDL1- adjusted HR=3.29,
95%CI=1.03-10.40). (F) Experimental design of studies in SPF C57BL/6) mice that received either a
high fiber or low fiber diet at inoculation of M3 (HCmel1274) melanoma cells (1 × 106 tumor cells) and
then treated with anti-PD-1 or isotype control. Time in days relative to tumor injection. (G) M3 melanoma
growth kinetics of control (high fiber) diet (circles) or low fiber (fiber free) diet (squares) treated four
times with intraperitoneal injection of anti-PD-1 antibody (dark green) or the isotype control left
untreated (light green). Data are means +/- SEM tumor volume from one representative experiment
(n=5/group). All p-values from likelihood ratio test in linear mixed model (p=0.69 Isotype-Ctrl and High
fiber, p=0.02 Anti-PD-1 and High fiber, p=0.08 Anti-PD-1 and Low fiber vs. Isotype-Ctrl and Low fiber);
*p<0.05. (H) PCoA plot comparing shotgun metagenomics of fecal microbiomes of mice treatment and
diet group from 2 experiments (n=4-5/group) using Bray-Curtis dissimilarity (ANOSIM p=0.001) at
experimental Day 16 (I) Heat map of gene expression of flow sorted CD45+ tumor infiltrating
immunocytes in mice fed high vs. low fiber diet and treated with anti-PD1 or isotype control J) Gene set
enrichment analysis depicting pathways enriched in high fiber diet mice treated with anti-PD1 vs.
isotype control which were not differentially expressed by treatment in low fiber diet mice.
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Diet Influences Response To ICB
Next, we examined whether dietary fiber modulation could enhance therapeutic response to
immune checkpoint blockade in pre-clinical mouse models. In these studies, C57BL/6 SPF
mice were provided with a standard fiber-rich whole grain diet (17.6% fiber) versus a fiberpoor diet (2% fiber) (25), and challenged with murine melanoma tumors (26) and treated with
anti-PD-1 therapy versus isotype control (Figure 11F). In these studies, mice receiving a fiberrich diet had delayed tumor growth on treatment with anti-PD-1 compared to mice who
received a fiber-poor diet (p=0.02; Figure 11G).
Notably, findings were recapitulated in additional tumor models (Fig S4.13, S4.14). In
contrast, there was no effect of fiber-rich vs. fiber-poor diet on response to anti-PD- 1 therapy
in a germ-free mouse model, supporting the hypothesis that the effect of diet on treatment
efficacy is microbiota-dependent (Fig S4.13). Profiling of the gut microbiome in these models
revealed significant differences in the community structure of mice fed fiber-rich versus fiberpoor diets (p=0.0001; Figure 11H) and differences in the phylogeny of gut microbiota between
the groups (Fig S4.15, S4.16). Linking functional pathways in these murine models to a subset
of patients with WGS data available (n=26) revealed that genes encoding hydroxylamine
reductase activity, an enzyme implicated in autoimmune diseases and SCFA production (27,
28), are upregulated by fiber consumption in both species and may possibly underlie the
effects of dietary fiber on anti- tumor immunity (Fig S4.17). Stool metabolomic profiling
revealed significantly higher levels of the short chain fatty acid (SCFA) propionate in mice
receiving a fiber-rich diet (p=0.02), though no significant differences were noted in SCFA
levels as a whole (Fig S4.18).
Immune profiling by flow cytometry of tumors in treated mice revealed a significantly
higher frequency of CD4+ T cells overall (and those expressing PD-1) in tumors of mice on
high- versus low fiber diet (p=0.03 and p=0.04, respectively; Fig S4.19 A, B). We next
conducted RNA sequencing of CD45+ tumor infiltrating lymphocytes (TIL) and observed
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significantly higher expression of genes related to T- cell activation and interferon response
in mice receiving a high- versus low-fiber diet in the setting of treatment with anti-PD-1 (Figure
11I-J).

Further, network analysis of murine data suggested that the fiber fermenting

Ruminococcaceae family of bacteria may strongly contribute to the effects of fiber on antitumor immunity by affecting different pathways of T cell activation as well as accumulation of
T cells in the tumor including ICOS expressing CD8 and CD4 T cells (Fig S4.19 C-H).
Given the growing evidence that gut microbes facilitate anti-cancer immune
responses, there is intense interest in developing strategies to modulate the gut microbiome
with the hopes of enhancing anti-tumor immunity. Clinical trials incorporating microbiome
modulation approaches are currently underway, including administration of fecal microbiota
transplant from patients with a strong and durable response to immune checkpoint blockade
into non-responding patients (NCT03341143, NCT03353402, NCT03772899, NCT03772899,
NCT03819296), as well as administration of defined microbial consortia (NCT03817125,
NCT03595683, NCT03934827).

OTC Probiotics Limit Anti-Tumor Response
In addition to these well-controlled studies, individual patients have expressed interest in
modulating their gut flora via commercially available over-the-counter (OTC) probiotics. We
assessed the use of OTC probiotics in our patient population via data collection from surveys
(n=105 patients with evaluable data) and observed that a substantial proportion (42%)
reported recent use of OTC probiotics (Figure 12A).
We next assessed whether patient characteristics, including key clinicopathologic
factors, varied by OTC probiotic use, and noted no clear associations with regard to age, sex,
BMI, stage, LDH, TMB, and PD-L1 expression, however a higher proportion of patients with
acral or mucosal melanoma subtypes and lower proportion of ICI-naive patients reported use
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of OTC probiotics. Importantly, we also looked at concurrent antibiotic and probiotic use in our
cohort, with similar proportions of patients reporting antibiotic use among the yes vs. no OTC
probiotic use groups (Fig S4.20). We then evaluated gut microbiome profiles in patients who
reported recent OTC probiotic use versus those who did not, excluding patients with
concurrent antibiotic use given the known impact of antibiotics on the gut microbiome and
immunotherapy response (2, 15, 16). Patients who reported OTC probiotic use had lower
alpha diversity in the gut microbiota compared to those who did not (p=0.05; yes=34, no=44;
Figure 12B), a difference that was somewhat attenuated after adjustment for age, sex, and
BMI (p=0.14). Intrigued by these results, we then assessed the frequency of reported OTC
probiotic use in “healthy” individuals in the American Gut Project cohort (7), and found a
similarly high proportion (56%) of healthy individuals reporting recent use of OTC probiotics
(Figure 12C). Notably, alpha diversity was also significantly lower in healthy individuals who
reported taking OTC probiotics versus those who did not (p=0.002; yes=94, no=79; Figure
12D, Fig S4.22; age, sex, and BMI-adjusted p=0.008). No clear differences in community
structure or function were noted between those who reported taking OTC probiotics versus
those who did not in our melanoma cohort (Fig S4.23), which may reflect heterogeneity with
regard to the type and frequency of OTC probiotic use.
Next, we queried the association of OTC probiotic use with therapeutic response to
anti-PD-1 immunotherapy, demonstrating a lower proportion of responders among patients
who reported OTC probiotic use (n=15; 33% R) versus those who did not (n=31; 58% R)
(p=0.05; Figure 12E). Similarly, the odds of responding to anti-PD-1 therapy was nearly 1 in
3 among OTC probiotic users compared to those who did not (n=46; OR=0.36, 95% CI=0.101.27). Notably the magnitude and direction of the association remained consistent when
considering important clinicopathologic factors known to influence immunotherapy response.
We also assessed the relationship of probiotic use and response in the setting of our
microbiome signature (4) via joint effects analysis, demonstrating that the proportion of
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responders was the highest among patients with a Type-1 signature who reported no OTC
probiotic use (70% R) followed by those with a Type-1 signature who reported probiotic use
(56% R) and those with a Type-2 signature and no probiotic use (45% R). Strikingly, no
patients with a Type-2 signature who reported probiotic use responded to anti-PD-1 therapy
(0% R), though cohort size was limited (Cochran-Armitage P trend=0.005; n=46; Figure 12F).
Comparison of progression-free survival rates also supported that probiotic use was
associated with poorer outcomes, as patients who reported OTC probiotic use prior to antiPD-1 therapy were at a significantly greater risk of progression compared to non-users
(p=0.04; n=46; Figure 12G; HR= 2.40, 95% CI: 1.03-5.40). Importantly, the magnitude and
direction of the effect of probiotic use and PFS remained consistent after adjustment for
important clinical variables (TMB and PD-L1 adjusted HR= 1.91, 95% CI=0.80-4.50; Table
S4.12).
We then examined the effects of OTC probiotic use on response to immune checkpoint
blockade in preclinical mouse models, after first confirming the viability and composition of the
bacterial strains reportedly in the OTC probiotics via culture and sequencing (Fig. S4.24). To
do this, germ- free mice first received fecal microbiota transplant (FMT) using donor stool from
a complete responder (CR) patient to anti-PD-1 blockade. Following FMT, mice were orally
gavaged with OTC probiotics or sterile water control. Mice were challenged with murine
melanoma tumors and treated with anti-PD-L1 therapy (Figure 12H). In these studies, mice
receiving OTC probiotics demonstrated increased tumor growth on treatment with anti-PD-L1
compared to control mice (p=0.04 and p=0.01, respectively; Figure 12I, Fig S4.25). Similar
findings were observed in additional tumor models and in specific pathogen-free mice (Figure
S4.26). This is consistent with results indicating the impact of OTC probiotics in pre-clinical
models of colorectal cancer, demonstrating that mice receiving OTC probiotics had
accelerated growth of adenomas (29).
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Furthermore, consistent with findings in the human cohort, microbiome alpha diversity
was lower in the OTC probiotic-treated groups compared to control (Probiotic 1, p=0.15,
Probiotic 2, p=0.03; Figure 12J). Additionally, the overall structure of the microbiome by beta
diversity was distinct (p=0.006; Figure 12K) and pathway analysis indicated differences in
functional patterns (Fig S4.27). Analysis of tumor-infiltrating immune subsets from anti-PDL1
treated mice revealed a significantly reduced frequency of IFN-gamma positive CD8+ T cells
(p=0.03; Figure 12L) and a trend toward fewer IFN-gamma CD4+ T (Th1) cells (Figure 12M)
in tumors from mice receiving OTC probiotics versus control. These tumor-infiltrating T cell
responses correlated with altered amounts of macrophages in the colon lamina propria, which
may play a role in antigen presentation, of mice that received OTC probiotics versus control
(p=0.02; Figure 12N).
Unsupervised analyses of the flow cytometry data corroborated the findings in immune
subsets between OTC probiotic treatment versus control (Figures 12L-O, S4.28). These data,
together with published studies demonstrating delayed reconstitution of gut microbes in the
setting of probiotic use after antibiotics (9) and increased tumorigenesis in murine models of
colorectal carcinoma in probiotic-treated mice (29) suggest that the impact of probiotic
formulations on immunity and other host functions needs to be more carefully studied, and
that indiscriminate use of OTC probiotics in patients with cancer on immunotherapy should be
discouraged.
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Figure 12 Associations of OTC probiotic use with features of the gut microbiome and
response to melanoma therapy
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Figure 12 Associations of OTC probiotic use with features of the gut microbiome and
response to melanoma therapy. (A) Pie chart showing proportion of melanoma patients who
reported probiotics use prior to starting therapy. (B) Alpha diversity differences in melanoma
patients by probiotics status by the Inverse Simpson scale (n=105, p=0.05 by MW test). (C) Pie
chart showing proportion of healthy AGP subjects who took probiotics at the time of sample
submission. (D) Alpha diversity differences in healthy AGP subjects by probiotics status by the
Inverse Simpson scale (n=282, p=0.002 by MW test). (E) Stacked bar plot showing proportion of
patients who responded by probiotic group and corresponding Fisher’s exact p-value (p=0.05)
(n=46, No use=31, Yes use = 15). (F) Stacked bar plot showing proportions of patients who
responded by probiotic use and microbiome signature group (p= 0.005 by Cochoran-Armitage test
for trend). (G) Kaplan-Meier plot comparing progression-free survival intervals of patients who
received anti-PD-1 by probiotics status (n=46, p=0.04 by Log-Rank). (H) Experimental design of
studies in germ-free (GF) mice that received FMT from a complete responder (CR) donor
combined with OTC probiotic 1, OTC probiotic 2 or water control prior to tumor injection (2.5 × 105
to 8 × 105 BP tumor cells) and treatment with anti-PD-L1. Time in days relative to tumor injection
I) Mouse tumor growth curve comparing volume of tumors of mice who received probiotics or water
control (n=4-5/group). OTC probiotic 1, OTC probiotic 2 vs water control. p-values from linear
mixed-effects model (p=0.04 OTC probiotic 1 vs control, p=0.01 OTC probiotic 2 vs control) *p<
0.05. (J) PCoA comparing functional profiles of gut microbiomes by PICRUSt in mice treated with
probiotics (experimental Day 0) vs control using Bray-Curtis dissimilarity (p=0.04 by ANOISM).
Immune profiling studies comparing (K) frequency of IFN-gamma positive CD8+ T cells in tumors
as well as (L) DCs as percent of CD45+ cells and (M) number of CD4+Tregs in the mesenteric
lymph nodes of mice receiving OTC probiotics versus control at the time of sacrifice (p=0.006,
p=0.03, and p=0.009 respectively by KW test).
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Summary
There is evidence that gut microbes can modulate immunotherapy response, however the
impact of diet and supplements isn’t well-studied. In a large cohort of melanoma patients, we
assessed fecal microbiota profiles (n=312), dietary habits, and over-the-counter (OTC)
probiotic use (n=105); with parallel pre-clinical studies. We observed substantial differences
in gut microbiota between responders (R) and non-responders (NR) to systemic therapy,
as previously reported. Notably, patients with low dietary fiber were less likely to respond to
anti-PD-1

immunotherapy

(adjusted-OR=0.15,

95%

CI=0.02-0.80)

with

shortened

progression-free survival (PFS) (adjusted- HR=3.29, 95% CI=1.03-10.40; n=38).
Additionally, patients reporting OTC-probiotic use had lower microbiome diversity
(p=0.05), and shortened PFS on immunotherapy (adjusted-HR=1.90, 95% CI=0.80-4.50;
n=46). Findings were validated in pre-clinical models, revealing further mechanistic insight.
Together, these data have important implications for immunotherapy patients.
This is the first report to investigate differences in the gut microbiome between healthy
individuals and patients with melanoma, as well as to examine the role of dietary factors and
OTC probiotic use in patients on cancer immunotherapy. Together, our results have several
potentially important implications. Here, we consistently show that patients with a more
diverse gut microbiome and more “favorable” gut microbiome profiles demonstrate enhanced
responses to therapy (though the definition of a truly “favorable” gut microbiome is
incompletely understood). Additionally, we demonstrate that patients with melanoma exhibit
a different community structure of the gut microbiome compared to healthy individuals, though
limitations exist in comparing these datasets given differences in collection and sequencing,
among other variables.
Importantly we show that other factors that impact the gut microbiome, namely dietary
fiber and OTC probiotic use, are associated with differential response to immune checkpoint
blockade. Though causality cannot be addressed from the observational human cohort where
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unmeasured confounders may exist, our preclinical models support that anti-tumor immunity
is impaired in mice receiving a low fiber diet and in those who are administered OTC probiotics
with suppression of intra-tumoral IFN-gamma+ T cell responses.
However, limitations in these cohorts also exist, and further validation of hypotheses
generated in this report should be tested in larger cohorts with more in-depth assessment of
dietary intake and other health determinants, in parallel with further mechanistic studies in
preclinical models. Nonetheless given these results, we need to strongly consider the effects
of diet and OTC probiotic use in patients on immunotherapy, monitoring and perhaps even
modulating these factors to improve cancer outcomes.
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CHAPTER 5: DISCUSSION
In the context of anti-cancer therapeutics, the microbiome remains a complex and diverse
consortium that has been shown to influence on response to various cancer therapeutics.
However, how the microbiota shapes host immunity has yet to be fully elucidated. Ongoing
work has allowed us to begin to see how the complex milieu of the tumor microenvironment
is shaped by the gut microbiome. To that end, this body of work has highlighted three
unique points of discussion: (A) The composition of gut microbiome shapes host immunity,
(B) Health determinants, such as lifestyle and diet, promote key inflammatory pathways and
unique gut microbiota composition, and (C) The composition of the gut microbiome can
shape patient response to immune checkpoint blockade. It is important to examine these
three points within the context of the field and to understand how this work could potentially
influence oncology and adjacent fields of study concerned with chronic inflammation. Lastly,
we pose a number of outstanding questions that if answered will have a broad impact on
global health and disease.

The Composition of the Gut Microbiome Shapes Host Immunity
To the first point, in order to appreciate the dynamic relationship of host immunity and the
gut microbiome it is important to understand that the gastrointestinal (GI) tract is the major
mucosal surface of the human body and the most densely colonized organ. The overall
bacterial load of the GI tract has been described to contain between 1013-1014; nearly
equaling the number of the mammalian cells in the body (117) (118). Moreover, the GI tract
is also home to the largest concentration of immune cells in the human body. This sets the
foundation for a uniquely symbiotic relationship between the gut microbiome and the
associated local immune system which is central for the maintenance of the systemic
immune tonus.
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The lamina propria and gut-associated lymphoid tissues (GALT) contain the largest
pool of cells mediating innate and cognate immune responses. Moreover, there is marked
regional variation in immune cells along the GI tract, with TH17 decreasing in number from
the duodenum to the colon, and with regulatory CD4+ FOXP3+ T cell (Treg) being most
abundant in the colon (119). Pioneering mouse studies demonstrated that distinct bacterial
species can fine-tune intestinal immune responses, such as TH17 (120, 121), Treg (122) or
TH1 (123, 124), TFH (123) and B cell activation (125). There are numerous cell types in
the lamina propria and mesenteric lymph nodes- follicular and memory B cells, IgA+ and
IgG+ plasma cells, effector and memory CD4+ T cells, Treg cells, CD8+ T cells, γδ T cells,
innate lymphoid cells, natural killer cells (NK), mast cells and myeloid cells (cDC1, cDC2,
pDC, LYVE1+ or CD16+ macrophages, monocytes). Interestingly these cell types follow a
region- specific transcriptional distribution linked to activation (126) (127). While unique
bacterial species have been associated with specific cancer types, for example
Fusobacterium nucleatum is frequently associated with colorectal tumors and has been
shown to modulate the immune environment and promote tumor growth through
proinflammatory signaling cytokines IL-8 and CXCL1 and the suppression of T and NK cells.
Amplification and interaction of specific bacteria may also induce distinct immunologic,
metabolic, and transcriptional expression converging to play a key role in health and
disease. Altogether these studies show that the links between the gut microbiome and the
host immune system are severely intertwined. While this dissertation work touches on the
influence of the gut microbiome on immunity a more comprehensive characterization of this
relationship is needed. This detailed characterization would not only help us understand how
the gut microbiome shapes immunity but also allow us to explore the health determinants
that shape this remarkable relationship upstream.
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Health Determinants Alter the Gut Microbiota
Concerning our second point, how health determinants alter the microbiome, we first look to
first recognize how the microbiome is colonized. Colonization by the intestinal microbiome
occurs rapidly during and after birth (128, 129). A successful colonization is determined by
microbial selection and competition that begins in the first hours of life (130). Throughout our
lifetimes, the microbial population in the human GI tract is affected by a multitude of
environmental factors such as age (128, 131), geography (131), dietary habits (102, 132),
use of antibiotics (133, 134), host genetics (135, 136) and the pressure of the immune
system (137).
Additionally, the intestinal microbiota promotes post-natal maturation of physiological
gut functions such as the integrity of the epithelial barrier, the expression of essential
enzymes (138), the development of the intestinal vascularization (139), and of the enteric
nervous system; all essential for motility (140). Most importantly, the gut microbiota
participates in the maturation of the local and systemic immune system to ensure tolerance
vis-à-vis of food antigens and the elimination of pathogens, maintaining a mutual symbiosis
between commensals and self-tissues for the homeostasis of the meta-organism (141)
(142).
While the microbiome can be shaped by a number of factors, diet is one that has
been closely studied. Interestingly, Western style diets (high fat, high sugar) and meat
consumption may in fact be major risk factors in diseases such as cancer (143). The diet
displays a dominating role in shaping the structure of gut microbiota, occasionally leading to
a detrimental alteration of microbiota ecology and functionality. Indeed, increasing dietary
fiber can lead to the establishment of a favorable microbiota regulating the production of the
anti-inflammatory short chain fatty acids (SCFA) (144). An unbalanced microbiota, known as
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dysbiosis, has also been associated with many maladaptive states such as cancer,
autoimmunity, and type I diabetes (145-149).
As it relates to cancer, this work was the first report to investigate differences in the
gut microbiome between healthy individuals and patients with melanoma; as well as to
examine the role of dietary factors and over the counter probiotic use in patients on cancer
immunotherapy. While a small piece of the pie, our results have several potentially important
implications. We consistently show that patients with a more diverse gut microbiome and more
“favorable” gut microbiome profile demonstrate enhanced responses to therapy. Additionally,
we establish that patients with melanoma exhibit a different community structure of the gut
microbiome compared to healthy individuals. Perhaps most exciting, we show that other
factors that impact the gut microbiome, namely dietary fiber and OTC probiotic use, are
associated with differential response to immune checkpoint blockade. Though causality
cannot be addressed from our human cohort where unmeasured confounders may exist, our
preclinical models support that anti-tumor immunity is impaired in mice receiving a low fiber
diet and in those who are administered OTC probiotics.
While this work continues, the impact of various determinants of health on the gut
microbiome are beginning to come to light (150-153). Additionally, it is evident that is about
more than what we eat, but about the health determinants that are within and beyond our
individual control; often classified as social and biological in nature. Social determinants
range from community support to education where biological determinants range from
genetics to environment. While we cannot control where we are born and grow up, we are
often involved in decision making around our diet, how many hours we sleep, and how we
vote to shape public policy. Deeper discussions and focused studies on these determinants
influence human health remain ongoing (Appendix A1).
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The Composition of the Gut Microbiome Can Shape Patient Response
to Immune Checkpoint Blockade
Accumulating evidence points to the critical role of the gut microbiota in the efficacy of ICB.
Early work revealed that antibiotics taken within the month preceding start of anti-CTLA-4 or
anti-PD-1 antibodies, markedly attenuated the clinical benefit, reducing both progressionfree and overall survival across many metastatic and stage III malignancies amenable to
therapies based on immune checkpoint inhibition (42, 109). Additional work showed that
fecal microbial transplantation of stools from patients prone to respond to ICB or doomed to
fail first- or second-line ICB-based therapy confer sensitivity or resistance to tumor bearing
mice treated with anti-PD-1 antibodies respectively (154). While shotgun metagenomics
sequencing of patients’ stools at diagnosis are thought to be predictive of primary resistance
to PD-1 blockade in metastatic melanoma (54) , kidney (109) and lung cancers (42). Parallel
work examining the oral compensation of antibiotic-treated tumor bearers, or dysbiotic hosts,
with monoclonal anticancer probiotics (such as Akkermansia muciniphila, or Bifidobacterium
pseudolongum (47) restored full blown immunostimulatory activity of anti-PD-1 antibodies.
Conversely, ICB also has an impact on the gut composition. Vetizou et al. reported that antiCTLA-4 antibody modulated the ileal bacteria composition, increasing the relative
abundance in Bacteroides spp. (namely B. fragilis) and Burkolderiaceae family members,
involved in the IL-12-dependent priming of TH1 cells as well as the immunostimulatory and
anti-cancer effects of CTLA-4 blockade (40). In line with these preclinical data, six months of
therapy with nivolumab ameliorated the alpha diversity of metastatic kidney cancer bearing
patients in those individuals benefiting from the antibodies. Such studies are awaited in
MSIhigh CRC amenable to PD-1 blockade. Finally, memory TH1 and Tc1 immune responses
directed against immunogenic bacteria E. hirae, A. muciniphila, and B. fragilis dictated
progression free survival in cancer patients treated with anti-PD-1 or anti-CTLA-4 Abs (42,
52, 154).
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Summary
It is reasonable to hypothesize that microbial translocation, due to disruptions in gut
homeostasis, leads to an augmented function in CD8+ T cells. Moreover, if true, it is
reasonable to suggest that microbial translocation from the gut results in a large release of
TLR ligands triggering tumor regression (155-157). This is in line with long standing
research demonstrating that activation of the innate immune system can trigger tumor
regression with bacterially derived products (158, 159). These studies, and others, also
suggest that the intestinal microbiota modulates the immune effects of chemotherapy,
radiation, and other forms of cancer treatment via bacterial translocation of selected species
into secondary lymphoid organs (160). While the immune mechanisms of specific bacterial
species may vary, total bacterial stimulation via microbiome disturbance likely drives an
immediate innate response of innate pathogenic like T helper cells and the induction of
memory Th1 immune responsiveness. This was immune mechanism has been found to be
constant across multiple studies suggesting these immune cell subtypes play a uniquely
distinct role in medicating tumor regression (161-170). Interestingly, similar chronic
inflammatory disease states such as arthritis, encephalomyelitis, type I diabetes, and
neurodegenerative disorders have been closely tied to unique changes in the gut
microbiome and pathogenetic Th17 cells and innate immunity activation (171-174);
advocating for the theory that chronic inflammatory disease settings may share common
immunological and microbiome dysfunction.
Collectively, this dissertation has helped better define the mutualistic role of the gut
microbiome and host immunity in the context of immune checkpoint blockade and has
provided new clinical insights as to how the gut microbiome, across a variety of influences,
shape patient outcomes. Lastly, this work has helped the research community better
understand how modulation of the gut microbiome, intrinsically or extrinsically, may enhance
the patient response to immunotherapy. Taken together these data can be leveraged to
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allow for the utilization of host immunity and the gut microbiome to predict, prevent and
produce better treatments for cancer patients. Moreover, given the “immune” similarities
cancer shares with a number of other chronic inflammatory diseases this research looks to
also have an impact on arthritis, type II diabetes, neurodegenerative disorders, and
infectious diseases such as COVID-19.

.
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CHAPTER 6: FUTURE DIRECTIONS &
OUTSTANDING QUESTIONS
Future Directions
As the study of the microbiome is expanding, different attempts are being made to tip the
scale on the ‘favorable’ microbiome side. Targeting the gut microbiome may provide
previously unexplored means to improve systemic therapy for multiple types of cancer. These
may range from simple dietary modifications to novel phage-based therapies (Table 2). The
relative ease with which the microbiota can be targeted makes it particularly attractive, as
microbial modulators could prove to be a feasible therapeutic adjunct for existing anticancer
regimen, especially given their profound influence on the effector arm of the immune system.
However, complexities exist with such approaches, as we do not yet know the composition of
an ‘optimal’ gut microbiome in the setting of cancer treatment, nor do we know if this will apply
across treatments as well as across cancer types. Additionally, the choice of a particular
approach would be secondary to comprehensive and careful testing its effectiveness in a
clinical trial.
It is evident that a significant amount of work remains to be done to further elucidate
the impact and targetability of the gut microbiota in influencing cancer responses, and to fully
comprehend its entire potential as it pertains to our health and wellness (see ‘Outstanding
Questions’). Nevertheless, current efforts will undoubtedly prove to be invaluable.

Outstanding Questions
As a result of this work, and in light of parallel efforts bring done by the scientific and medical
communities globally the following are a list of outstanding questions yet to be fully realized.
Here we have broken them down by focus area:
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ON TECHNOLOGICAL APPROACHS OF MICROBIOME ANALYSIS
•

Why is the 16S gene used as a bacterial genomic marker? Is it sufficient to use in
studying the gut microbiome?

•

How have we come to compare and exploit the advantages of the different
methodologies used to taxonomically and functionally characterize the microbiome?

•

What technology would allow us to better understand the ‘unseen’ players in the
microbiome?

•

How do we more efficiently layer the complex data that acquired in microbiome studies
(genetic, taxonomic, immune, epigenetic, human metadata, etc.)?

•

Can we move beyond studies that assess correlation on the basis of presence or
absence of a microbe?

•

We often focus on the bacterial microbes in the gut but how much can we now assess
the role of the fungi or viruses that are also part of the gut microbiome?

ON THE HEALTH OF THE GUT MICROBIOME
•

What does a ‘healthy’ gut microbiome phenotype look like on average? More
specifically, what constitutes microbial function and dysfunction?

•

What forces shape the human gut microbiome? Which of these are the most powerful?

•

How do specific species interact with the host immune system?

•

Can we deliver interventional nutrition, lifestyle changes, or medicines to improve
health via the gut microbiome?

•

Can short term changes to determinants of health influence the gut microbiome and
patient health? (FIGURE Determinants of health)

•

Can we better understand why the microbiome plateau during childhood? After this
point is the microbiome mutable?

106

ON KEY PLAYERS IN THE GUT MICROBIOME
•

What are the unique roles played by bacterial metabolites to drive and navigate the
outcome to cancer therapies?

•

Which components of the gut microbiome are essential to our well-being?

•

Can we look for mutations that potentially affect the dietary and metabolic activity of
the microbes in the gut, skin, mouth, etc.?

ON THE GUT MICROBIOME AND CANCER
•

Responses to anticancer therapy have been shown to be dependent on increased gut
microbial diversity and differential abundance of specific bacterial taxa. Ongoing
testing is underway in preclinical models and clinical trials to identify optimal microbial
modulators (fecal microbiota transplantation, defined bacterial consortia, diet, etc.) that
can help shape a ‘favorable microbiome’, each of which has their own set of
advantages. Is there a rationale for choosing one method over the other?

•

Can specific cluster of microbes or a particular composition of the microbiome predict,
prevent, and/ or stop the potentiation of cancer?

•

Does the gut microbiome effect toxicity to immune checkpoint blockade?

ON THE RELATIONSHIP BETWEEN HOST IMMUNITY AND THE GUT MICROBIOME
•

There is ongoing crosstalk between microbial and tumor antigens in shaping T cell
repertoires. A growing body of evidence suggests that these associations are contextspecific. Is it possible to compare and contrast the influence of microbiota on our
immune response following treatment with various anticancer therapeutics?

•

Is there a better mouse model to assess the microbiome and its role in immunity?

•

Do specific bacterial species shape the cellular phenotype of the immune response?
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•

We believe that the immune system is closely aligned with the functionality of the gut
microbiome but we don’t yet have a sense for directionality. Would the immune system
benefit from interventional treatment of the gut microbiome or vice versa?
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SUPPLEMENTAL FIGURES

Supplementary Figure S3.1: Microbiome sample acquisition schema. Oral and gut
microbiome sample collection in melanoma patients initiating treatment with PD-1
blockade. Oral microbiome samples were collected at the time of clinic visits, whereas
fecal microbiome samples were collected on an outpatient basis.
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Supplementary figure S3.2: Sample collection timeline. Median time and range
(parentheses) in days between important clinical events associated with patients that
contributed (A) oral and (B) fecal microbiome samples. *Longitudinal oral microbiome
samples were collected from only one patient.
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Supplementary figure S3.3: Responders to anti PD-1 immunotherapy present an
enriched tumor immune infiltrate at baseline. Immunohistochemical quantification and
representative images at 40x3 magnification of (A) CD3, (B) PD-1 (p=0.13), (C) FoxP3
(p=0.13), (D) GzmB (p=0.11), (E) PD-L1 (p=0.13) and (F) RORγT (p=0.14) as counts/mm2
or H-Score in R (blue) and NR (red) to anti PD-1 immunotherapy by one-sided MW test. *
p<0.05.
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Supplementary figure S3.4: Patients with a high abundance of Faecalibacterium
present a favorable anti- tumor immune infiltrate prior to anti PD-1 immunotherapy.
Spearman rank correlation heatmap of GzmB, CD3, CD8, PD-1, FoxP3, PD-L1 by HScore, RORγT by counts/mm2 by IHC and abundance of all genera within the
Ruminococcaceae family in the fecal microbiome (n=15). Red=positive correlation,
blue=negative correlation, white=no correlation.
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Supplementary figure S3.5: Faecalibacterium and Bacteroidales abundance in
the fecal microbiome have distinct associations with the tumor immune
infiltrate prior to anti PD-1 immunotherapy. Univariate linear regression between
Faecalibacterium abundance (blue), Bacteroidales abundance (red), and density by
counts/mm2 or H-score of (A) CD3, (B) GzmB, (C) PD-1, (D) PD-L1, (E) FoxP3, and
(F) RORγT by IHC in tumors at baseline of patients treated with anti-PD-1. Lines
show regression for Faecalibacterium (blue) and Bacteroidales (red) with the
associated r2 and p-values by Slope test.
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Supplementary figure S3.6: No association between CD8+ T cell density and alpha
diversity or crOTU community type. (A) Pairwise Spearman correlation between CD8+
T-cell density and Inverse Simpson score (n=15; r= 0.01, p=0.96). (B) MW test of CD8+
T-cell density between patients in crOTU community type 1 (n=5) vs crOTU community
type 2 (n=11), (p= 0.58).
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Supplementary figure S3.7: Gating strategy for flow cytometric analysis of
peripheral blood in patients treated with anti PD-1 immunotherapy. PBMC at baseline
in patients treated with anti PD-1 immunotherapy were analyzed by gating for CD19+ B
cells, CD3+CD8+ T cells, CD3+CD4+ T cells (CD3+CD4+FoxP3+ regulatory and
CD3+CD4+FoxP3- effector), monocytes (based on CD14/HLA-DR), and MDSC (CD3CD19- HLADR- CD33+CD11b+).
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Supplementary figure S3.8 Patients with high Faecalibacterium abundance display
a peripheral cytokine profile favorable for response to anti PD-1 immunotherapy at
baseline and enhanced cytokine responses over the course of therapy. (A)
Spearman rank correlation heatmap between Clostridiales, Faecalibacterium,
Ruminococcaceae, and Bacteroidales abundance and peripheral concentration of
cytokines in pg/mL at baseline by multiplex bead assay. Red=positive correlation,
blue=negative correlation, white=no correlation. Change in production of cytokines in
serum of responders (n=2, blue) and non-responders (n=2, red) to anti PD-1
immunotherapy for (B) IP-10 (p=0.04 and p=0.34, respectively), (C) MIP-1β (p=0.04 and
p=0.90, respectively), and (D) IL-17A (p=0.07 and p=0.86, respectively) in fold-change
from baseline by ratio paired t-test.
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Supplementary figure S3.8: Gating strategy for myeloid multiplex IHC in the tumors
of patients treated with anti PD-1 immunotherapy at baseline. Myeloid multiplex
immunohistochemistry gating strategy showing immune cells (CD45+), lymphoid cells
(CD45+CD3+CD20+CD56+), myeloid cells (CD45+CD3-CD20-CD56-), mast cells
(CD45+CD3-CD20-CD56-HLADR-Tryptase+), granulocytes (CD45+CD3-CD20-CD56HLADR- CD66b+), M1 tumor-associated macrophages (CD45+CD3-CD20-CD56HLADR+CSF1R+CD163-), M2 tumor- associated macrophages (CD45+CD3-CD20CD56-HLADR+CSF1R+CD163+), mature dendritic cells (CD45+CD3-CD20-CD56HLADR+CSF1R-DCSIGN-) and immature dendritic cells (CD45+CD3-CD20- CD56HLADR+CSF1R-DCSIGN+).
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Supplementary figure S3.9: High Faecalibacterium abundance at baseline is
associated with an increased immune infiltrate prior to anti PD-1 immunotherapy.
(A) Multiplex immunohistochemistry showing representative myeloid immune cell staining
at 40 magnification. (B) Quantification of CD45, CD3/CD20/CD56, CD68, CD66b,
Tryptase, HLA-DR, CD163, and DC-SIGN as counts/mm2. (C) Quantification of myeloid
cells, lymphoid cells, mast cells, granulocytes, M1 and M2 tumor-associated
macrophages, immature dendritic cells, and mature dendritic cells as a percentage of total
CD45+ immune cells in patients with a high Faecalibacterium (n=2, blue) or high
Bacteroidales (n=2, red) abundance.
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Supplementary figure S3.10: A favorable gut microbiome is associated with systemic anti-tumor
immunity. (A, top) Snapshot of explanted xenograft tumors from FMT exp2, showing differences in
tumor size between the indicated experimental groups. (A, bottom) Difference in size of tumors
implanted in R-FMT (blue) and NR-FMT mice (red), or control mice (black). Tumor volumes on day 14
post-tumor implantation are plotted, each value representing a single mouse. Data from two
independent experiments. Also reported in Figure 4H as fold change. (B) Representative
immunofluorescent staining of tumors (top) and gut (bottom) from Control (left), NR-FMT (middle), and
R-FMT (right) in GF mice post-FMT for CD45 (purple), CD8 (yellow), and nuclei (DAPI, blue). (C) Flow
cytometry quantification showing the frequency of CD45+ immune cells in R-FMT (blue), NR-FMT (red),
and control mice (black) in blood and tumor. (D) t-SNE plot of total live cells (top) isolated from tumors
derived from control (n=2, Blue), NR (n=3, Red), and R- (n=2,Green) colonized mice by mass cytometry.
t-SNE plot of total live cells (top) overlaid with the expression of CD45 (middle) and PD-L1 (bottom).
Equal numbers of cells are displayed from each group. (E) Flow cytometry quantification showing the
frequency of CD45+CD11b+Ly6G+ innate effector cells in R-FMT (n=2, blue), NR-FMT (n=3, red), and
control mice (n=2, black) in blood and tumor. (F) Flow cytometry quantification showing the frequency
of CD45+CD11b+CD11c+ suppressive cells in R-FMT (blue, n=2), NR-FMT (red, n=3), and control mice
(black, n=2) in blood and tumor (n=3). (G) IHC quantification showing the number of RORγT+ Th17 cells
in R-FMT (n=2, blue), NR-FMT (n=3, red), and control mice (n=2, black) in tumor as counts/mm2. (H)
Flow cytometry quantification showing the frequency of CD4+FoxP3+ regulatory T cells in R-FMT (blue,
n=2), NR-FMT (red, n=3), and control mice (black, n=2) in spleen. (I) Flow cytometry quantification
showing the frequency of CD4+IL17+ Th17 cells in R-FMT (blue), NR-FMT (red), and control mice (black)
in spleen.
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Supplementary figure S3.11: 16S analysis of fecal samples from R and NR donors
and germ-free recipient mice. Relative abundance comparisons of (A)
Faecalibacterium, (B) Ruminococcaceae and (C) Bacteroidales by MW test on day 14
post tumor injection. Data from 2 independent experiments are presented. ** p<0.01.
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Supplementary figure S3.12: Schematic representation of crOTUs compared to
traditional taxonomy. 5 hypothetical OTUs are represented as black dots in the middle
of the panel. Traditional taxonomy is depicted on the right and the crOTU methodology is
depicted on the left. In this figure, crOTU4 recapitulates species level classification by
grouping the two OTUs that both belonged to species A. However, crOTU5 is made up of
OTUs from species C and species D. Higher up in the tree, crOTU2 and crOTU3
recapitulate genus level classification. crOTU3 recapitulates genus F, whereas crOTU2
contains OTUs from genus G as well as species C. Such de novo clusters also occur at
higher taxonomic levels and provide more systematic bacterial groupings when compared
to standard taxonomy.
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Fig. S4.1 Differences in alpha diversity and response by Chao1, Shannon in patients
treated with systemic therapy. Alpha diversity by A) Shannon and B) Chao1 indices and
response to any systemic therapy (n=202, R=74, NR=128), p-values from 2-sided Wilcoxon
rank sum test.
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Fig. S4.2 The gut microbiome and response to common systemic therapies in metastatic
melanoma. A) Alpha diversity by Inverse Simpson B) Beta diversity by Bray-Curtis distances and C)
LFfSe analysis of differentially abundant bacterial taxa in melanoma patients treated with targeted
therapy (n=19, R=16, NR=3). D) Alpha diversity by Inverse Simpson E) Beta diversity by Bray-Curtis
distances and F) LFfSe analysis of differentially abundant bacterial taxa in melanoma patients treated
with anti-CTLA4 based immunotherapy (n=16, R=7, NR=9). G) Alpha diversity by Inverse Simpson H)
Beta diversity by Bray-Curtis distances and (I) LFfSe analysis of differentially abundant bacterial taxa
in melanoma patients treated with anti-PD-1 based immunotherapy (n=108, R=66, NR=42). J) Alpha
diversity by Inverse Simpson K) Beta diversity by Bray-Curtis distances and L) LFfSe analysis of
differentially abundant bacterial taxa in melanoma patients treated with immune checkpoint blockade
(n=170, R=64, NR=106). Pvalues from 2-sided Wilcoxon rank sum test and ANOSIM with 999
permutations.
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Fig. S4.3 Abundance comparison of candidate taxa by response in anti-PD1 treated
melanoma patients. Confirmation of previously identified (cite Gopalakrishnan Science 2018) proresponse bacterial taxa by pairwise comparison using Mann-Whitney tests. (A) Firmicutes (R=66;
NR=42), (B) Clostridiales (R66=;NR=42) (C) Ruminococcaceae (R=66;NR=42), (D) Faecalibacterium
(R=66;NR=42). p-values from 2-sided Wilcoxon rank sum test. Results confirmed with DADA2
denosied ASVs. Firmicutes (p=0.03), (B) Clostridiales (p=0.02) (C) Ruminococcaceae (p=0.003), (D)
Faecalibacterium (p=0.03) Fig. S4. The gut microbiome in late-stage melanoma patients by age, sex,
and body mass index (BMI)(n=273) (A), (C), (E), Alpha diversity by Inverse Simpson by age, sex and
BMI respectively (B),(D),(F), p values from 2-sided Wilcoxon rank sum test. Beta diversity by BrayCurtis dissimilarity by age, sex and BMI respectively, p-values by ANOSIM with 999
permutations.
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Fig. S4. The gut microbiome in late-stage melanoma patients by age, sex, and body
mass index (BMI)(n=273) (A), (C), (E), Alpha diversity by Inverse Simpson by age, sex and
BMI respectively (B),(D),(F), p values from 2-sided Wilcoxon rank sum test. Beta diversity by
Bray- Curtis dissimilarity by age, sex and BMI respectively, p-values by ANOSIM with 999
permutations.
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Fig. S4.5. Differences in microbiome community structure between healthy individuals
from the American Gut Project (AGP) (n=194) and melanoma patients (n=312) by A)
unweighted (p=0.001) and B) weighted UniFrac (p=0.001), p-values by ANOSIM with 999
permutations.
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Fig. S4.6. Differences in alpha diversity by Shannon, Chao1 between healthy individuals
from the American Gut Project (n=194) and melanoma patients (n=312), p-values from 2sided Wilcoxon rank sum test.
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Fig. S4.7. Differences in microbiome community structure by melanoma stage
Ordination of beta diversity between early (n=39) and late-stage melanoma patients (n=273)
by A) unweighted and B) weighted UniFrac, p-values by ANOSIM with 999 permutations.
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Fig. S4.8. Differences in alpha diversity by stage of melanoma. Comparison of alpha
diversity by A) Shannon and B) Chao1 indices between early (n=39) and late-stage
melanoma patients (n=273), p-values from 2-sided Wilcoxon rank sum test.
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Fig. S4.9. Differential taxonomic abundance by melanoma stage. Volcano plot depicting
pairwise comparisons of relative abundances of bacterial taxa between early (n=39) and late
stage melanoma patients (n=273), p-values from 2-sided Wilcoxon rank sum test.
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Fig. S4.10. Distribution of estimated dietary fiber intake in the late-stage melanoma
lifestyle cohort. Histogram of dietary fiber intake in primary analytic cohort of 38 patients
initiating anti-PD1 therapy establishing threshold of 20 grams of fiber per day. Intake
assessed via the 26-item NCI dietary screener questionnaire and reflects the month prior to
therapy.
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Fig. S4.11. Differences in microbiome community structure by dietary fiber status in
late stage melanoma patients Comparison of beta diversity by A) Unweighted UniFrac and
B) Weighted UniFrac between patients with low (n=50) vs. high dietary fiber intake (n=14), p
values by ANOSIM with 999 permutations.
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Fig. S4.12. Differences in alpha diversity by dietary fiber status in the late-stage
melanoma lifestyle cohort Comparison of alpha diversity by A) Inverse Simpson B)
Shannon and C) Chao1 indices between patients with low (n=50) vs. high dietary fiber
intake (n=14), p-values from 2-sided Wilcoxon rank sum test.
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Fig. S4.13. Melanoma growth kinetics from additional mouse fiber study (B2905, M4).
Mice receiving sufficiently high fiber diet (circles) or low fiber diet (squares) treated four
times with intraperitoneal injection of anti-PD-1 antibody or the isotype control in (A) SPF
mice and (B) germ-free mice. Data points are means +/- 95% CIs tumor volume from one
representative experiment (n=2-5/group).
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Fig. S4.14. Melanoma growth kinetics from additional mouse fiber studies (MC38 and
BRAF/PTEN). A) Growth kinetics in mice injected with MC38 receiving sufficiently high fiber
diet (circles) or low fiber diet (squares) treated four times with intraperitoneal injection of
anti-PD-1 antibody or the isotype control. Data points are means + SEM tumor volume from
one experiment (n=4-5/group). B) Bar plot of % tumor rejection at Day 21 of anti-PD1
treated MC38 tumor bearing mice. C) Growth kinetics in mice injected with BRAF/PTEN
melanoma receiving sufficiently high fiber diet (circles) or low fiber diet (squares) treated four
times with intraperitoneal injection of anti-PDL-1 antibody or the isotype control. Data points
are means +SEM tumor volume from one experiment (n=4-5/group). D) Bar plot of % tumor
rejection at Day 40 of anti-PDL1 treated BRAF/PTEN tumor bearing mice E) Survival curves
of anti-PDL1 treated BRAF/PTEN tumor bearing mice.
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Fig. S4.15. Effect of dietary fibers on response to anti-PD1 and microbiome composition using mice from
two different vendors (Jackson Laboratories and Taconic Biosciences). (A) HMel melanoma growth kinetics of
control (high fiber) diet (left) or low fiber 675 (fiber free) diet (right) treated four times with intraperitoneal injection
of anti-PD-1 antibody (solid symbols) or the isotype control left untreated (open symbols). Data are means +/SEM tumor volume from one representative experiment (n=5/group) with mice from Jackson laboratory
performed at the same time as the experiment with Taconic mice shown in Figure 2.G. (B) and (C) Relative
abundance heatmaps of Taxa (B) and genes with Gene Ontology (GO) terms (B) which are significantly
differentially abundant between mice groups having been fed either a Fiber Free or Fiber Rich diet. Difference in
abundance was assessed for each feature using the Mann-Whitney-Wilcoxon (MWW) test and adjusted using
the False Discovery Rate (FDR) adjustment. Only features with FDR-adjusted p-values lower than 0.05 are
shown and whose log2 fold change of the medians were larger than 1.5 and 2 for taxa or GO terms, respectively.
Before MWW testing, taxa in relative abundances lower than 50 parts per million (PPM) in at least 5% of
samples and/or whose genome completeness was predicted to be smaller than 5% of the expected size in at
least 5% of samples, were discarded. GO terms with relative abundances lower than 70 parts per million (PPM)
in at least 5% of samples were also discarded before MWW testing. Heatmap column ordering is unsupervised
and based on the relative abundances of all features in each sample.

139

Fig S4.16. Abundance comparison of Akkermansia muciniphila and Enterococcus
hirae in mouse fiber experiments. Pairwise comparison between mice fed fiber-poor and
fiber-rich diet from 2 independent experiments (n=10/group) of (A) Akkermansia muciniphila
and (B) Enterococcus hirae. p-values from 2-sided Wilcoxon rank sum test.
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Fig S4.17. The abundance of all genes encoding Hydroxylamine reductase (E.C. number
1.7.99.1) is increased by high fiber diet both in patients and in mice, although different bacterial
species account for its expression. (A) Relative abundances in parts per million (PPM) of all genes
encoding Hydroxylamine reductase (E.C. number 1.7.99.1) in each diet group in each host species.
Significance of difference between groups was calculated using the Mann- Whitney-Wilcoxon (MWW)
test. (B) Stratification by Last Known Taxon (LKT) of the relative abundances in parts per million
(PPM) of all genes encoding Hydroxylamine reductase (E.C. number 1.7.99.1) found in contigs
classified as each taxon shown.
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Fig. S4.18 Metabolomic profiling of SCFAs in mouse fiber experiments. Levels of fecal
SCFAs by mass spectrometry in sufficiently high vs low fiber diet mice at (A) Day 5 in the feces
and (B) Day 14 in the caecum following initiation of anti-PD1 treatment.
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Fig. S4.19 Flow cytometry and Transkingdom network analysis to identify key players that mediate effect of dietary
fibers on anti-PD1 response in mice. (A) CD4+ and (B) PD-1-expressing CD4+ tumoral immune populations in 2
experiments of mice on fiber-rich diet vs fiber-poor diet at time of sacrifice by Flow Cytometry (p=0.03, 0.04, respectively by
Wilcoxon rank sum test). (C) Transkingdom network, integrating host’s gene expression, tumor and FACS measurements with
microbial genes and taxa, provides a statistical model to investigate the effects of high fiber diet on tumor. The red and green
colors indicate increased and decreased abundance, respectively, by high fiber diet. (D) Functional enrichment of up-and
down-regulated genes by high fiber vs low fiber diet within PD1 treated mice from the host gene expression subnetworks. (E),
(F), (H) ranking of top candidates [(E)genes, (F) 16 rRNA amplicon sequence variants (ASVs), (H) tumor and FACS
easurements] based on network property of Bipartite betweenness centrality (BiBC). (G) abundance of the top two ASV
candidates increased by high fiber vs low fiber diet in mice receiving anti-PD1 (Mann-Whitney U test, two-tailed p-value <
0.05). One outlier was removed using Graphpad Prism’s default ROUT (Q=1%). (I) Abundance of ICOS+CD8+T cells in mice
fed high or low fiber diet, with or without anti-PD1 treatment (Mann-Whitney U test, two-tailed p-value < 5%).
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Fig. S4.20 Antibiotics use among late-stage melanoma patients who did and did not
use OTC probiotics. Pie chart displaying proportion of antibiotic uses among a) patients
who a) took and b) did not take OTC probiotics.
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Fig. S4.21 Differences in alpha diversity and OTC probiotics use by Chao1, Shannon
among late-stage melanoma patients. Comparison of alpha diversity by A) Shannon and B)
Chao1 indices between patients who used (n=34) vs. did not use (n=44) OTC probiotics
prior to therapy start, p-values from 2-sided Wilcoxon rank sum test.
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Fig. S4.22. Differences in alpha diversity and OTC probiotics use by Chao1, Shannon
among healthy American Gut (AGP) cohort. Comparison of alpha diversity by A) Shannon
and B) Chao1 indices between people who used (n=94) vs. did not use (n=79) OTC
probiotics, p-values from 2-sided Wilcoxon rank sum test.
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Fig. S4.23. Differences in microbiome community structure by OTC probiotic use
among melanoma patients. Comparison of beta diversity between patients who used
(n=34) vs. did not use (n=44) OTC probiotics by (A) unweighted and (B) weighted UniFrac,
p-values calculated by ANOSIM with 999 permutations.
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Fig. S4.24. Composition of OTC probiotics used in mouse experiments by 16S rRNA
gene sequencing and culture. (A) 16S sequencing of probiotic Bifidobacterium longum
35624 (left) and Lactobacillus GG (right) and (B) colony count of cultured probiotic capsule
contents by serial dilution
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Fig. S4.25. Comparison of fold change (to control) of tumor sizes from replicate
probiotic experiments (1-4) (A) depicting measurements from mice in 5 replicate
experiments before start of anti-PDL1 therapy and (B) depicting measurements of tumor
size at the time of best response from mice in 4 replicate experiments. Differences by
Kruskal-Wallis and Wilcoxon rank sum tests, (n=4-5/group).
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Fig. S4.26. BP and MC38 growth kinetics from replicate probiotic experiments (A)Experimental design of
studies in germ-free (GF) mice that received FMT from a completer esponder (CR) donor combined with
Probiotic 1, Probiotic 2 or water control prior to tumor injection (2.5 Å~ 105 to 8 Å~ 105 BP tumor cells) and
treatment with anti-PD-L1. Time in days relative to tumor injection. (B) Tumor growth curves for individual GF
mice in Experiment 2 treated with anti–PD-L1 and Probiotic 1 (lavender, n=1), Probiotic 2 (purple, n=2), or
control (black n=2). (C) Tumor growth curves for individual GF mice in Experiment 3 treated with anti– PD-L1 and
Probiotic 1 (lavender, n=5), Probiotic 2 (purple, n=4), or control (black n=5). (D) Tumor growth curves for
individual GF mice in Experiment 4 treated with anti–PD-L1 and Probiotic 1 (lavender, n=4), Probiotic 2 (purple,
n=5), NR-FMT (NR) (grey, n=5) or control (black n=6). (E) Tumor growth curves for individual GF mice in
Experiment 5 treated with anti– PD-L1 and Probiotic 1 (lavender, n=8), Probiotic 2 (purple, n=7), or control (black
n=7). (F) Experimental design of studies in GF mice that received FMT from a complete responder (CR) donor
combined with Probiotic 1, Probiotic 2, or water control prior to tumor injection (3 Å~ 105 MC38 tumor cells) and
treatment with anti-PD-L1. Time in days relative to tumor injection. (G) Tumor growth curves for individual GF
mice in Experiment 6 treated with anti–PD-L1 and Probiotic 1 (lavender, n=6), Probiotic 2 (purple, n=6), or
control (black n=6). (H) Experimental design of studies in SPF BL6 mice that received FMT from a complete
responder (CR) donor combined with Probiotic 1, Probiotic 2, or water control prior to tumor injection (3 Å~ 105
MC38 tumor cells) and treatment with anti-PD-L1. Time in days relative to tumor injection. (I)Tumor growth
curves for individual SPF BL6 mice in Experiment 7 treated with anti–PD-L1 and Probiotic 1 (lavender, n=8),
Probiotic 2 (purple, n=8), or control (black n=7).
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Fig. S4.27. WGS of post-treatment fecal samples in humanized GF-mice (FMT from
complete responder) gavaged orally with either OTC probiotics or water followed by
tumor inoculation and treatment with anti-PDL1. A) Ordination by PCoA of Bray-Curtis
beta-diversity distances based on GO counts by group. p-values by ANOSIM B)
Unsupervised hierarchical clustering of the most differentially abundant GO terms by group.
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Fig. S4.28. Correlative immune data from mice treated with probiotics (A) Frequency of
tumor lymphoid cells as % live, displayed on a per-mouse basis (B) Frequency of tumor myeloid and
dendritic cells as % CD45+, displayed on a per-mouse basis (C) Frequency of mLN myeloid and
dendritic cells as % CD45+, displayed on a per-mouse basis (D)Frequency of mLN lymphoid cells as
% live, displayed on a per-mouse basis, (E) Number colon myeloid cells, displayed on a per-mouse
basis (F) Number of colon lymphoid cells, displayed on a per-mouse basis (G) Heatmap showing
normalized marker expression of each lymphocyte cluster in (Fig 12O)
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Fig. S4.29. Comparison of results using VSEARCH-OTUs and denoising with DADA2.
Pairwise Spearman correlation comparing (A) alpha diversity scores and (B)
Ruminococcaceae abundance. (C) Procrustes analyses comparing both methodologies (p
< 0.001 and goodness of fit (M2) values of 0.327). All samples are represented by red dots.
The black ends of each edge represent output from the DADA2 pipeline, whereas the blue
end represent VSEARCH-OTUs. The length of the connector lines is inversely proportional
to the overall concordance between the two pipelines.
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Fig S4.30. Compositional differences in the microbiome validated using DADA2
denoised ASV. Volcano plot analogous to Fig. 1D depicting pairwise comparisons of relative
abundances of bacterial taxa using DADA2 denoised ASVs between R (n=128) and non-NR
(n=74) to systemic therapy, crude p-values from Wilcoxon rank sum test. Analogous pvalues using DADA2 denoised ASVs; Firmicutes (p=0.008), Clostridiales (p=0.002),
Ruminococcaceae (p=0.001), Faecalibacterium (p=0.06).
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Supplemental Table S3.1: Availability of biospecimens (oral and gut microbiome
samples, tumor biopsies, blood draws) by analyses.
Subset Corresponding
n (R/NR)
Sample
Inclusion Criteria*
figures
Type
A

Fig. 1B, S4B

109**

Oral

B

Fig. 1B

53

Fecal

C

S4A

48

D

Fig. 1C, S5, S9A,
Fig. 2A-E, S13A,
Fig. 3A,B, S14
Fig. 1D,E, S7, Fig.
3C,D

43 (30/13)

Fecal,
Oral
Fecal

39

Fecal

F

Fig. 2F, Fig. 3E, S16

25 (14/11)

Fecal

G
H

Fig. 4A, S17
Fig. 4B,C, S18, S19

21 (15/6)
15 (11/4)

I

Fig 4E-F, S24

4 (2/2)

K

S3

10 (7/3)

Tissue
Tissu
e,
Feca
l
Tissu
e,
Feca
l
Tissue

L

S6, S8, S10A, B,
S13B, S15A,B

86 (54/32)

Oral

M

S3

3 (3/0)

Fecal

N

Fig. 4D, S22A

11 (8/3)

Blood

O

S22

4 (2/2 )

Blood

E
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Banked baseline oral sample
available
Banked baseline fecal sample
available
Matched fecal and oral samples
Banked baseline fecal
sample available, clinical
response information known
Banked baseline fecal
sample available, sufficient
follow up time
Banked baseline fecal
sample available, clinical
response information known
Banked baseline FFPE tissue
Banked baseline FFPE tissue
and fecal sample available,
clinical response information
known
Multiplex IHC

Banked baseline tumor sample
available, passed QC for WES,
matched fecal sample available
Banked baseline oral
sample available, clinical
response information known
Banked baseline and on
treatment fecal samples
available (all 4 patients included
in subset D)
Banked baseline PBMC and
fecal samples available, clinical
response information known
Banked baseline serum and
fecal samples available,
clinical response information
known

Supplemental Table S3.2 Baseline characteristics of patients fecal and oral microbiome
analyses cohorts
Oral Microbiome
R

Age
Median
Range
Gender
Male
Female
Ethnicity
White
Other
Primary Type
Cutaneous
b

Other
Prior Targeted Therapy
Yes
No
Prior Checkpoint
Therapy
Yes
No
Disease Stage
III
IV
Lactate
Dehydrogenasec
Normal
Elevatedd
Treatment Type
PD-1 Monotherapy
PD-1 Combinatione

Pa

NR

n=52
(%)

n=34
(%)

66.5

64.5

21-88

32-87

Fecal Microbiome
R
NR
n=30 (%)

n=13
(%)

0.57

0.60
64

70

21-88

42-80

20 (67)
10 (33)

8 (62)
5 (38)

28 (94)
2 (6)

11 (85)
2 (15)

0.14
41 (79)
11 (21)

22 (65)
12 (35)

48 (92)
4 (6)

29 (85)
5 (6)

0.74

0.47

0.57

0.032
44 (85)

22 (65)

8 (15)

12 (35)

0.68
25 (83)

10 (77)

5 (17)

3 (23)

5 (17)
25 (83)

6 (46)
7 (54)

0.76
8 (15)
44 (85)

4 (12)
30 (88)

0.76

0.81
17 (33)
35 (67)

12 (35)
22 (65)

14 (27)
38 (73)

3 (9)
31 (91)

0.46
9 (30)
21 (70)

2 (15)
11 (85)

20 (67)
10 (33)

1 (8)
12 (92)

0.05

<0.01

0.21

0.11
44 (85)

23 (68)

8 (15)

10 (30)

25 (86)

9 (69)

4 (14)

4 (31)

0.05
50 (96)
2 (4)

28 (82)
6 (18)

Pa

0.22
29 (97)
1 (3)

11 (85)
2 (15)

a p-values calculated by Wilcoxon rank sum (age), Chi-squared (gender, prior checkpoint) and
Fisher's exact (all others)
b other category includes acral, mucosal and unknown primaries
c LDH not available on one (R) patient in the fecal cohort and one (NR) patient in the oral cohort.
d elevated LDH: exceeding the upper limit of normal (618 IU/mL), all samples assayed in a
common laboratory.
e combinations included: Abraxane, Urelumab, Aldara cream
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GLOSSARY
Adoptive cell transfer: type of anti-infectious or antitumor therapy which involves the transfer
of cells in a patient. These cells can be derived from the patient itself (autologous transfer) or
from different individuals (allogeneic transfer).
Adoptive immunotherapy: a cancer treatment uses cells originated from a patient or
individual and generates tumor-specific immune cells infused into cancer patients with the
goal of recognizing, targeting, and killing tumor cells.
Alpha-diversity: mean species diversity within a single microbiota sample. Anti-PD-1
immunotherapy: monoclonal antibody, mainly used as cancer immunotherapy. It blocks the
programmed death-1 (PD-1) immune checkpoint expressed on the surface of immune CD8+
T cells, thus rejuvenating them from exhaustion to sustain an antitumor response.
Assembled or unassembled reads: a read refers to the sequence of a cluster that is
obtained after the sequencing process is complete. Users receive sequencing data as
unassembled reads. Sequence assemble refers to the aligning and merging of fragments from
long DNA sequencing in order to reconstruct the original genome.
Bacille Calmette-Guerin (BCG): a live attenuated strain of Mycobacterium bovis; FDA
approved for primary therapy of in situ bladder carcinoma. Beta-diversity: mean species
diversity across different microbiota samples.
Checkpoint inhibitors: generally, antibodies that inhibit key checkpoint receptors such as
PD-1. When these proteins are blocked, the ‘brakes’ on the immune system are released and
cytotoxic T cells can kill certain cancer cells more effectively.
Copy number variations (CNV): an important component of genomic diversity; it is a type of
structural variation, defined as a type of duplication or deletion event, of one kilobase (kb) or
larger, in which sections of the genome are present in comparison with a reference genome.
Digital-PCR assays: a precise method of PCR; can be used for
direct quantification and clonally amplified nucleic acid strands such as DNA, cDNA, or RNA;
target applications include mutation detection and copy number variations.
Dysbiotic gut: also referred to as dysbacteriosis of the gut, in contrast to the eubiotic gut,
wherein a microbial imbalance or maladaptation takes place. Dysbiosis can be caused by
changes in diet, antibiotics, and/or chronic inflammation.
Eubiotic gut: characterized by a dominance of potentially beneficial microbial species, mainly
belonging to two bacterial phyla, Firmicutes and Bacteroides. A healthy, or eubiotic gut, is a
balanced but flexible ecosystem that tolerates pathogens from flora.
‘Favorable’ microbiome: significantly higher alpha-diversity and relative abundance of
Ruminococcaceae bacteria relative to an ‘unfavorable’ microbiome. Gemcitabine: cytotoxic
agent used in the treatment of multiple solid and hematological tumors.
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Gut associated lymphoid tissues (GALT): key component of the mucosa associated
lymphoid tissue; works in tandem with the immune system to protect against infection in the
gut.
High-throughput culture: a series of protocols and techniques for the efficient screening of
a large number of extinction culture attempts for growth and subsequent identification.
Human Microbiome Project: United States National Institutes of Health research initiative to
improve the understanding of the microbial flora involved in human health and disease.
Immune checkpoints: molecules which regulate the activity of the immune system and selftolerance. These checkpoints can be stimulatory (e.g., CD28, CD40) or inhibitory (e.g., CTLA4, PD-1). Indoleamine2,3-dioxygenase (IDO): catalyzes the first and rate limiting step in the
oxidation of L tryptophan to N-formylkynurenine.
Inflammasome: cytosolic protein complexes which activate inflammatory responses through
the maturation and secretion of
cytokines such as interleukin-1b (IL1b) and interleukin-18 (IL-18).
Irinotecan: cytotoxic agent mostly used to treat colon cancer and small cell lung cancer.
MALDI-TOF: matrix-assisted laser desorption ionization time-of-flight mass spectrometry is a
rapid, accurate, and cost-effective method of microbial characterization and identification.
Molecular mimicry: refers to sequence similarities between foreign and self-peptides, which
can lead to the cross activation of autoreactive T or B cells by peptides derived from
pathogens.
Next-generation sequencing techniques: a catch-all term to describe multiple modern high
throughput sequencing techniques (Illumnia Solexa, Roche 454, Proton/ PGM, and SOLiD
sequencing) and applies to genome sequencing, genome resequencing, transcriptome
profiling (RNA-Seq), DNA–protein interactions (ChIP-sequencing), and epigenome
characterization. All of these methods allow for sequencing of DNA and RNA quickly and
accurately.
Operational taxonomic units (OTUs): used to classify groups of closely related species, a
pragmatic proxy for microbial species at different taxonomic levels, often grouped by DNA
sequence similarity of a specific taxonomic marker gene. Oxaliplatin: cytotoxic agent mostly
used to treat colon cancer.
Pattern recognition receptors (PRRs): mainly expressed by innate immune cells; germlineencoded host receptors, which are specialized in the detection of pathogen-associated
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).
PCR primer and amplification bias: a type of artifact common in whole-genome
amplification; results when the end product of the amplification method does not dependably
recapitulate the starting DNA.
16S rRNA gene: gene coding for a component of the 30S small subunit of a prokaryotic
ribosome; used to reconstruct phylogenies. ab+ T cell: T cells with a TCR composed of two
glycoprotein chains, alpha and beta TCR chains (95% of T cells).
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gd+ T cells: T cells with a T cell receptor on their surface made of one gamma chain and one
delta chain. In high abundance in the gut and other mucosae.
T regulatory cells (Tregs): a subpopulation of T cells that modulate the immune system,
maintaining self-tolerance and homeostasis. Generally, Tregs are immunosuppressive and
downregulate induction and growth of effector CD8+ T cells.
Th1 effector cells: induced in parallel to Th17 cells and, like Th17, these polarized cells are
proinflammatory; they produce INFg and TNF-b.
Th17 CD4+ lymphocytes: transforming growth factor b, interleukin 6 (IL6), IL21, and IL23
can differentiate naïve CD4+ T lymphocytes into the Th17 subtype. Can contribute to local
and chronic inflammation through proinflammatory cytokines (e.g., IL-17, IL-21, IL-22), which
mainly recruit neutrophils.
TIGIT: T cell immunoreceptor with Ig and ITIM domains; immune receptor found on T cells
and natural killer (NK) cells.
Toll-like receptors: Toll-like receptors are single, membrane spanning, noncatalytic
receptors which are expressed on innate immune cells such as macrophages and dendritic
cells. They recognize structurally conserved molecules derived from microbial pathogens.
Whole metagenomic sequencing (WMS): or shotgun metagenomics, allows for the
comprehensive sampling of all genes in all organisms present in a given complex sample.
Excellent tool to evaluate bacterial diversity and detect the abundance of microbes in various
environments.
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APPENDIX
APPENDIX A1: DETERMINANTS OF HEALTH THAT IMPACT THE GUT
MICROBIOME
In this dissertation we discuss at length the role of the gut microbiome and host immunity in
how cancer patients respond to immune checkpoint blockade. Moreover, we only briefly
discuss a few factors, diet and probiotic use, within our patient cohort. While the connections
of the gut microbiome to general health and disease are beginning to come to light, it is also
important to discuss not just what we eat but the large number of health determinants that are
both within and beyond our individual control (Figure_: Determinants of Health). To that end
this brief discussion provides additional insight as to the complexities surrounding what
shapes health and disease as well as the opportunity to leverage the gut microbiome.

“You Are What You Eat”
“In food excellent medicine can be found (Hippocrates, “De Alimento”, 300 BC),” “Tell me
what you eat and I will tell you what you are (Brillat-Savarin, 1792),” “Man is what he eats
(Feuerbach, 1825),”; while all of these quotes were grounded in the philosophical teaching
that food influenced one’s state of mind today we can appreciate the literal meaning of the
words, “you are what you eat.” Interestingly, while nutritional and medical advice continues
to be shaped by our understanding of health, there is now an increased appreciation for not
only what we eat but for the way in which our body processes, manages, and promotes our
health through the intestinal microbiome.
Your gut microbiome is as unique as your fingerprint, weighs ~3kg (6 lbs.), and is
composed of both good and bad bacteria, fungi, and viruses. Together it shapes both health
and maladaptive states such as heart disease, cancer, neurodegenerative disorders, and
diabetes; as well as infectious disease states such as COVID-19. As we continue to learn
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more about the role of the microbiome in health and disease, we are also beginning to
understand how our microbiome shapes our well-being and how our microbiome is impacted
by multitude of factors and forces; some we can control, some we cannot.
These factors and forces are often referred to as determinants of health. They can
be both social, and biological. While some we can individually control (lifestyle habits),
others we cannot (where we are born, grow up, live, work and age). Collectively, these
determinants are often collaboratively defined, researched, and influenced by scientific and
health governance services worldwide such as the European Center for Disease Control
(ECDC), European Research Council (ERC), and the World Health Organization (WHO).
Together these efforts look to improve health outcomes worldwide. While this ongoing work
is massive in its scope (Figure 1 Determinants of Health), this commentary will focus on 1)
how the gut microbiome influences disease, 2) how social and biological determinants
shape the gut microbiome.

The Impact of the Gut Microbiome on Disease
The term microbiome refers to the community of commensal bacteria, fungi and viruses and
their genomes that shares our body space. The microbiome is often further defined by its
location such as the skin, oral, lung, cervical, or gut microbiome. In total, there are 10x the
number of microbial cells in the human gut than in the whole human body, totaling roughly
100 trillion microbes representing as many as 5,000 different species and 300x more DNA
than the human genome (113). Interestingly, the role this diverse and abundant flora play in
our daily lives varies from metabolic to immunologic to neurologic and back again. Exciting
work is being conducted worldwide on how best to leverage the gut microbiome to improve
health and to prevent maladaptive states such as cancer, neurodegeneration, obesity, and
SARS-CoV-2, among others (Figure 2 The Gut Microbiome Influences Disease).
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Cancer
Recent work has demonstrated that key bacteria present in tumors and in the gut may
shape how patients respond to their various treatment plans (41). Additionally, it is
increasingly more evident that the commensal bacteria present in the gut microbiome may
also be closely involved in how the immune system fights cancer (43, 54, 61). Moreover, a
recent study showed, in both preclinical and clinical settings, that bacteria present within the
gut modulates how a patient might respond to anti-cancer therapy such as chemotherapy,
radiation, and immunotherapy; a powerful precision medicine that leverages the human
immune system to fight off cancer (175). Furthermore, work has also shown that there are
bacteria present in tumors themselves and that is bacteria can vary across tumor types (62,
176). With these new advances in our understanding about the role bacteria in the gut and
within tumors we can begin to investigate ways to target, track, and prevent cancer (177).

Mental Health and Neurodegeneration
The interface between the central nervous system and the enteric nervous system,
termed the gut-brain axis (GBA), is an emerging field of microbiome research. The central
nervous system (CNS) is the main mammalian cognitive center, while the enteric nervous
system (ENS, the “little brain”), is a division of the autonomic nervous system that governs
the gastrointestinal tract. While research into the GBA is fairly new it is an exciting topic for
many cross functional fields to study because of the interesting role of the gut microbiome in
the function of the ENS and, therefore, the CNS. Basic research into the GBA has resulted
in several key findings on how the CNS and the ENS are regulated by the composition of
the gut microbiome. Importantly, the GBA exists in an equilibrium and small changes to the
gut microbiome can elicit behavioral changes and vice versa (178). Studies in germ-free
(GF, lacking a gut microbiome) and specific-pathogen-free (SPF, healthy gut microbiome)
mice have shown that the presence of anxiety-like behaviors in mice with no microbiome
across multiple murine anxiety tests (179, 180). Interestingly, subsequent treatment with
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probiotics was shown to decrease depressive behaviors (181). In studies of
neurodegeneration and the microbiome, it is hypothesized that an impaired gut microbiome
contributes to chronic systemic inflammation potentiating diseases such as Alzheimer’s and
Parkinson’s (182-184). Diet, genetics and other health metrics also contribute to high
variability in these conclusions, but research into the gut microbiome and the GBA has
suggested a dynamic equilibrium exists between the gut microbiome, mental well-being, and
brain health.

Obesity and Diabetes
The prevalence of obesity is an increasing public health issue in developed and developing
countries. A recent study predicted that, by 2030, there will be a ~30% increase in obesity
prevalence and a 130% increase in severe obesity prevalence worldwide (185). This is
thought to increase alongside non-communicable comorbidities, such as cardiovascular
disease, hypertension and diabetes. While obesity is known to be influenced by a number of
factors, including diet, genetics and environment, there is increasing evidence that the gut
microbiome plays a key role in shaping metabolism and the progression of both type 1
(T1D) and type 2 diabetes (T2D) (186). Additionally, there is evidence that specific microbial
populations have a direct link to obesity (187) and that perturbation of gut microbial diversity
can lead to increases in inflammation, pathogenic bacteria populations and, subsequently,
the onset of diabetes (188). Lastly, the strong connection between commensal bacteria and
obesity, as well as diabetes, warrants investigation as a source and a candidate for
precision therapeutic targeting.

COVID-19
An inflammatory response is a hallmark of many viral and bacterial infections, from the
common cold to infectious disease states such as COVID-19, and in each of these disease
states the gut microbiome plays a key role in mediating the development and onset of
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systemic inflammation and immune activation. As discussed above, the regulation of
systemic inflammation is an important contributor to disease progression; especially as it
relates to varying levels of infectivity. While much of the research on the role of the
microbiome in infection is in the context of HIV/AIDS (189), it has been shown that
dysbiosis, or the perturbation of the gut microbiome composition, contributes and
potentiates inflammation and precedes childhood maladaptation of autoimmune diseases
such as Celiac disease as well as the immune response to viral respiratory infection (190192). The gastrointestinal tract is the largest immune center in the human body and, as
such, plays both a direct or indirect role in negative inflammatory disease states such as
chemokine storms and immune adverse related events.
Recently, a study of COVID-19, demonstrated that the presence of gastrointestinal
disorders appears before or follow the onset of respiratory symptoms brought on by COVID19. Further research has shown that the gut microbiota influences respiratory viral infections
and the gut-lung axis (GLA); sharing both namesake and conceptual framework with the
GBA (193-195). If in fact the dysbiosis of the gut microbiome can be resolved, it is thought
we could control pathogenesis of infectious disease states like COVID-19. While research
in this area is ongoing, the ability to connect the gut microbiome with these inflammatory
disease states, past research on gut microbiome suggests that the GLA is a key player.
Current research seeks to explore these disease states and biological mechanisms
in greater detail using both mouse models and human correlates. Seeking to address the
provocative question of how microbiota may affect health and disease. If we are able to
understand this complex relationship more deeply, new approaches can be used to prevent
disease and improve general health.

Physical and Social Determinants Which Shape the Microbiome
While the connection of the gut microbiome to general health and disease are beginning to
come to light, it is also important to discuss not just what we eat but the large number of
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health determinants that are within and beyond our individual control (Figure 2). For
example, social determinants such as social support, education, genetics, and
environmental factors and physical determinants such as genetics and environmental
factors. While we are not able to control where we are born and grow up, we can be
involved in decision making around our diet, sleep, and stress. Additionally, we have the
ability to shape governmental policy around public health. Herein we discuss some thoughtprovoking influences on health and the microbiome; specifically, diet, physical environment,
education, social support, and wealth inequality.

Physical Environment
Physical environment encompasses city setting, pollution, water quality, noise and more.
Collectively, they all play a vital role in shaping the health of the gut microbiome and health
outcomes globally. Among major social and physical determinants of health, the physical
environment is one of the most important indicators of long-term health. Factors like chronic
exposure to unsafe drinking water, airborne pollutants and other environmental toxins are
known precursors to developmental defects and disease. Other anthropogenic factors play
an important role in health, such as urbanization and city structure, which contribute to the
health of an area by supporting or impeding general mobility and activity. Exposure to
harmful physical environments, and the adverse implications, is observed largely in
communities of lower socioeconomic status, and is seen especially in areas with pervasive
racial segregation.
One common example that has been quantified both in larger health outcomes as
well as its importance in health relates to water quality and air pollution. In general,
European countries have exceptionally water quality (as defined by quality standards related
to physical and chemical properties) and low air pollution (as defined by emissions,
chemicals, dust, ozone, etc.) as compared to other G20 countries (196, 197), contributing to
the overall health of the continent through a number of suspected mechanisms. Water
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quality has been an increasing concern in the past decade as global agriculture has required
the use of greater nutrients resulting in increased runoff. Moreover, increased nitrate levels
have been associated with various cancer subtypes such as colorectal cancer thought to be
due to how readily absorbed into the upper GI and systemically distributed (198).

Education
Education, is a unique social determinant of health in that it theoretically can afford upward
social mobility to those who are afforded the opportunity. The advantages that education
creates are undeniable, and there is a strong, well documented link between education and
health(199) that is likely related to the inherent connection between education, occupation,
and income. While this is the most intuitive explanation, research has suggested that the
process of learning instills important skills of reasoning as well as emotional and social
knowledge that support healthy lifestyles (200). European educational policy emphasizes
accessible primary, secondary and tertiary education and, by doing so, this affords
Europeans the increased economic mobility, greater occupational choice and the skills
needed to form healthy lifestyle choices. College tuition in many European states is free for
European citizens, and is otherwise far cheaper than a college education in the United
States, Japan or Australia. Accessibility to education throughout Europe plays a vital role in
the economy and health of the region. Moreover, research performed by social
epidemiologists suggest that the microbiome is shaped by this type of educational
environment and through the experience of psychosocial stress which in turn shapes host
immune function and the microbiome (201).

Social Support
Strong social support networks, a hallmark of European welfare policy, have been shown to
have a large impact in disparate areas of a person’s life, health and well-being. An
overwhelming body of literature has determined that poverty/low socioeconomic status has
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a strong effect on physical and mental health (202), which have both been shown to
coordinate with the composition of the gut microbiome. Warding off widespread poverty with
a robust social safety net could help mitigate the health factors associated with poverty,
thereby promoting healthier lifestyles for those in lower socioeconomic statuses and altering
commensal bacteria in turn. Moreover, social support networks that provide financial and
behavioral support around health influences such as nutrition, smoking cessation series,
and social relationship programs have demonstrated a positive effect on the microbiome.
For example, one study showed families that share homes and interact more regularly,
compared to isolated individuals, share more of their microbiome diversity (132). Further
studies revealed that the community composition of the microbiome influenced airborne
bacteria prompting researchers to consider how these factors shape inflammatory disease
states like allergies (203). While work in this particular area is ongoing, there is great
confidence in the knowledge that social support systems, or lack thereof, have an effect on
public health (204).

Income Inequality
The link between income and health outcomes is well established in the literature (205); as
income rises, a person’s general health improves. Research has also suggested that
income inequality, the distribution of wealth across income groups, is linked with the health
outcomes of a country (206). The exact mechanisms for these phenomena are under
debate, but established theory states that countries with higher income equality likely do not
invest as heavily into social support services, education and healthcare as countries with
more equal distributions of wealth. Compared with developed countries, the European
states have relatively low levels of income inequality, which may be attributed to the
investment that European countries make in social systems. Considering the connections
between income inequality in health, education and social support, the levels of income
inequality maintained in Europe may also be associated with a unique European gut
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microbiome. This has been further studied utilizing a UK twin study and Chicago based
cohort demonstrated lower area-level socioeconomic status was associated with reduced
alpha-diversity and greater abundance Bacteroides and lower abundance of Prevotella in
the colon; often associated with diet and lifestyle, and disease states (207).

Conclusion
While microbiome research continues to address biological and clinical questions related to
improving health and disease; such as cancer, neurodegeneration, and infectious disease. It
is increasingly important to recognize there are a number of health determinants that
influence shape the human microbiome; such as diet, social support, and income inequality.
Taken together, perhaps the famous mantra, “You are what you eat,” needs a revamp: “You
are the consequence of your lived experience.”
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Figure 1 Determinants of Health shaping health outcomes
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Figure 2 The microbiome influences multiple disease states
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